OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT

Proposition 65

Reconsideration of a Chemical Listed under Proposition 65 as Known to Cause Reproductive Toxicity

Chemical Listed via the Labor Code Mechanism:

Chloroform

August 2016



Reproductive and Cancer Hazard Assessment Branch

Office of Environmental Health Hazard Assessment California Environmental Protection Agency

AUTHORS AND REVIEWERS

The Office of Environmental Health Hazard Assessment's (OEHHA) Reproductive and Cancer Hazard Assessment Branch was responsible for the preparation of this document.

Primary Authors

Farla L. Kaufman Ph.D.Marlissa Campbell, Ph.D.Staff ToxicologistStaff ToxicologistReproductive Toxicology and Epidemiology SectionReproductive and Cancer Hazard Assessment Branch

Contributing Author

Allegra N. Kim, Ph.D. Research Scientist III Reproductive Toxicology and Epidemiology Section Reproductive and Cancer Hazard Assessment Branch

OEHHA Reviewers

Allan Hirsch Chief Deputy Director

Martha Sandy, Ph.D. Chief, Reproductive and Cancer Hazard Assessment Branch

James M. Donald, Ph.D. Chief, Reproductive Toxicology and Epidemiology Section Reproductive and Cancer Hazard Assessment Branch

Technical Support

Brian Rodriguez, MPH Melissa T. Ibarra, MPH Jamie L. Larson BS Reproductive and Cancer Hazard Assessment Branch

Acting Director

Lauren Zeise, Ph.D.

Contents

| Contents |
|--|
| Acronyms and abbreviations7 |
| Background9 |
| 1. Introduction |
| 1.1. Compound identification, physical properties and uses |
| 1.2. Use and exposure information12 |
| 2. Human Studies of Reproductive and Developmental Toxicity of Chloroform |
| 2.1. Notes on Exposure Assessment in Epidemiologic Studies of Chloroform13 |
| 2.2. Notes on the Tables and Figures Presenting Human Studies of Reproductive Outcomes |
| 3. Animal Studies of Reproductive and Developmental Toxicity of Chloroform |
| 4. Summary |
| References |
| Appendix A. Tables of Associations between Chloroform and Other Disinfection By- Products Exposure and Reproductive Outcomes in Human Studies |
| Appendix B. Tables of Exposure Measures, Uptake Factors Used In Estimating Internal Dose, and Windows of Exposure in Human Studies |
| Appendix C. OEHHA (2005) Re-analysis of Data from Two Chloroform Epidemiological Studies: Wennborg et al. (2000) and Infante-Rivard (2004) |
| Appendix D. Parameters for Literature Searches on the Reproductive Toxicity of Chloroform |
| Attachment 1: OEHHA (2004) Evidence of Developmental and Reproductive Toxicity of Chloroform |

List of Tables

Table 1. Reproductive Outcomes Assessed in Human Studies of Chloroform (CHL) Exposure, Grouped by Exposure Measure.

Table 2. Summary of Selected Study Design Elements and Measured or Estimated Chloroform (CHL) Levels in Human Reproductive Studies.

Table 3a. Detailed Summaries for Human Studies of Chloroform (CHL) Exposure and Reproductive Outcomes: Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW).

Table 3b. Associations between Chloroform (CHL) Exposure and Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW) in Human Studies.

Table 4a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Reproductive Outcomes: Spontaneous Abortion (SAB), Stillbirth (SB), Birth Defects (BD), Fertility and Menstrual Cycle Function.

Table 4b. Associations between Chloroform (CHL) Exposure and Spontaneous Abortion (SAB), Stillbirth, Birth Defects and Fertility in Human Studies.

Table 5a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Male Reproductive Outcomes.

Table 5b. Associations between Chloroform (CHL) Exposure and Sperm Parameters in Human Studies.

Table 6. Studies of Developmental Toxicity of Chloroform in the Rat, Inhalation Route.

Table 7. Study of Developmental Toxicity of Chloroform in the Mouse, Inhalation Route.

Table 8. Studies of Developmental Toxicity of Chloroform in the Rat, Oral Route.

Table 9. Study of Developmental Toxicity of Chloroform in the Mouse, Oral Route.

Table 10. Study of Developmental Toxicity of Chloroform in the Rabbit, Oral Route.

Table 11. Study of Developmental Toxicity of Chloroform in Zebrafish, in vitro.

Table 12. Studies of Female Reproductive Toxicity of Chloroform in Rats, Inhalation Route.

Table 13. Study of Female Reproductive Toxicity of Chloroform in Mice, Inhalation Route.

Table 14. Studies of Female Reproductive Toxicity of Chloroform in Rats, Oral Route.

Table 15. Studies of Female Reproductive Toxicity of Chloroform in Mice, Oral Route.

Table 16. Study of Female Reproductive Toxicity of Chloroform in Rabbits, Oral Route.

Table 17. Study of Female Reproductive Toxicity of Chloroform in Beagle Dogs, Oral Route.

Table 18. Study of Male Reproductive Toxicity of Chloroform in Mice, Inhalation Route.

Table 19. Study of Male Reproductive Toxicity of Chloroform in Rats, Oral Route.

Table 20. Study of Male Reproductive Toxicity of Chloroform in Mice, Oral Route.

Table 21. Study of Male Reproductive Toxicity of Chloroform in Beagle Dogs, Oral Route.

Table 22. Study of Multigeneration Reproductive Toxicity of Chloroform in Mice, Oral Route.

Appendix A. Tables of Associations between Chloroform and Other Disinfection By-Products Exposure and Reproductive Outcomes in Human Studies.

Table A3c. Associations between Chloroform (CHL) and Other Disinfection By-Products Exposure and Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW) in Human Studies.

Table A4c. Associations between Chloroform (CHL) and Other Disinfection By-Products Exposure and Spontaneous Abortion (SAB), Stillbirth, Birth Defects, Fertility and Menstrual Cycle Function in Human Studies.

Table A5c. Associations between Chloroform (CHL) and Other Disinfection By-Products Exposure and Sperm Parameters in Human Studies.

Appendix B. Tables of Exposure Measures, Uptake Factors Used In Estimating Internal Dose, and Windows of Exposure in Human Studies.

Table B1. Exposure Measures for Chloroform (CHL), Total Trihalomethane (TTHM), Bromodichloromethane (BDCM), and Dibromochloromethane (DBCM) in Human Studies of Reproductive Outcomes: (A) Water Concentration, (B) Water Concentration and Estimated Internal Dose.

Table B2. Uptake Factors and Percent Reductions Used in Calculations of Estimated Internal Dose in Human Studies of Chloroform (CHL) Exposure.

Table B3. Windows of Exposure Assessed in Human Studies of Chloroform Exposure and Reproductive Outcomes.

List of Figures

Figure 1. Preterm Birth (PTB). Forest plot of the association between chloroform (CHL) exposure [water concentration] and PTB.

Figure 2. Preterm Birth (PTB). Forest plot of the association between chloroform (CHL) exposure [estimated internal dose] and PTB.

Figure 3. Small for Gestational Age (SGA). Forest plot of the association between chloroform (CHL) exposure [water concentration] and SGA.

Figure 4. Small for Gestation Age (SGA). Forest plot of the association between chloroform (CHL) exposure [estimated internal dose] and SGA.

Figure 5. Low Birth Weight (LBW) and Very Low Birth Weight (VLBW). Forest plot of the association between chloroform (CHL) exposure [water concentration] and LBW and VLBW.

Figure 6. Low Birth Weight (LBW) and Very Low Birth Weight (VLBW). Forest plot of the association between the change in chloroform (CHL) exposure [water concentration] and LBW and VLBW.

Figure 7. Low Birth Weight (LBW). Forest plot of the association between chloroform (CHL) exposure [estimated internal dose] and LBW.

Figure 8. Birth Weight (BW). Forest plot of the association between chloroform (CHL) exposure [water concentration] and BW.

Figure 8. Birth Weight (BW). Forest plot of the association between chloroform (CHL) exposure [water concentration] and BW (cont'd).

Figure 9. Birth Weight (BW). Forest plot of the association between chloroform (CHL) exposure [estimated internal dose] and BW.

Figure 10. Schematic of Protocol for Multigeneration Reproductive Toxicity Study with Satellite Components Used by Borzelleca and Carchman, 1982.

Acronyms and abbreviations

| adj ass BCAA BD BDCAA BDCM BrTHM btwn BW CHL conc DBAA DBCAA DBCAA DBCAA DBCAA d diff dist e.g. exp | adjusted association bromochloroacetic acid birth defects bromodichloroacetic acid bromodichloromethane - CHCl ₂ Br total brominated trihalomethanes (BDCM+DBCM+TBM) between birth weight chloroform (trichloromethane) - CHCl ₃ concentration dibromoacetic acid dibromochloroacetic acid dibromochloroacetic acid dibromochloromethane - CHClBr ₂ disinfection by-product dichloroacetic acid day difference distribution for example exposure |
|---|--|
| freq GA GSTM1 | frequency gestational age glutathione S-transferase Mu 1 |
| GSTT1 HAA | glutathione S-transferase theta-1 haloacetic acid |
| HAA5 HAA9 | sum of 5 HAAs = MCAA + DCAA + TCAA + MBAA + DBAA 9 species of HAA - MCAA, DCAA, TCAA, MBAA, DBAA, TBAA, BCAA, DBCAA, BDCAA |
| HR incl info IQR LBW LGA MBAA MCAA MX N N N N N N N N D OR PTB RR | hazard ratio included information interquartile range low birth weight large for gestation age monobromoacetic acid monochloroacetic acid halogenated furanone population size sample size neural tube defect odds ratio preterm birth (preterm delivery) relative risk |

| SAB SB | spontaneous abortion still birth |
|-----------|---|
| SGA | small for gestational age – also referred to as intrauterine growth restriction (IGR, IUGR), fetal growth restriction (FGR) |
| STD | sexually transmitted diseases |
| suppl | supplement |
| TBAA | tribromoacetic acid |
| ТВМ | bromoform (tribromoform) - CHBr ₃ |
| TCAA | trichloroacetic acid |
| THM | trihalomethane |
| TTHM | total trihalomethanes (sum of the 4 THM = CHL + BDCM + DBCM + TBM) |
| VLBW | very low birth weight |
| w/ | with |
| w/in | within |
| | |

Background

Proposition 65¹ requires the State of California to publish a list of chemicals known to cause cancer or reproductive toxicity. This list must be updated at least once a year. Reproductive toxicity includes developmental toxicity, and female and male reproductive toxicity. Chemicals added to the list as known to cause reproductive toxicity affect one or more of these endpoints.

Chloroform was added to the list as known to cause reproductive toxicity in 2009 because it was identified by reference as such in the California Labor Code. Proposition 65 thus required its inclusion on the list, as discussed in greater detail below. There are three additional ways for a chemical to be added to the Proposition 65 list:

- 1. The Developmental and Reproductive Toxicant Identification Committee (DARTIC) finds that the chemical has been clearly shown to cause reproductive toxicity.
- 2. An organization designated as an "authoritative body" by the DARTIC has identified it as causing reproductive toxicity².
- 3. An agency of the state or federal government requires that it be labeled or identified as causing reproductive toxicity.

Reason for Reconsideration of Listing

Because of changes in federal regulations, chloroform no longer meets the criteria for inclusion on the list on the basis of the Labor Code mechanism. Following the process for the first of the three listing mechanisms cited above, OEHHA is presenting chloroform to the DARTIC for a decision as to whether it has been clearly shown through scientifically valid testing according to generally accepted principles to cause reproductive toxicity. If the Committee makes that determination, the chemical will remain on the list.

Chloroform was added to the list on the basis of a Threshold Limit Value (TLV) developed by the American Conference of Governmental Industrial Hygienists (ACGIH)

¹ The Safe Drinking Water and Toxic Enforcement Act of 1986: Health and Safety Code section 25249.5 *et seq.,* passed by voter initiative.

² Title 27, California Code of Regulations, section 25306(I). The authoritative bodies are: U.S. Environmental Protection Agency, U.S. Food and Drug Administration, National Institute for Occupational Safety and Health, National Toxicology Program solely as to final reports of the National Toxicology Program's Center for Evaluation of Risks to Human Reproduction, and International Agency for Research on Cancer solely as to transplacental carcinogenicity.

that was based in part on developmental toxicity. The TLV provided a basis for listing via the Labor Code at the time because:

- Proposition 65 provides that the list of chemicals known to the state to cause reproductive toxicity "shall include at a minimum those substances identified by reference in Labor Code Section 6382(b)(1) and those substances identified additionally by reference in Labor Code Section 6382(d)³".
- California Labor Code Section 6382(d) further provides that "...any substance within the scope of the federal Hazard Communication Standard (29 C.F.R. Section 1910.1200) is a hazardous substance subject to this chapter".
- Until 2012, the federal Hazard Communication Standard (HCS) incorporated TLVs as a definitive source for establishing that a chemical is hazardous.

In March 2012, the federal Occupational Safety and Health Administration amended the HCS to remove reference to ACGIH TLVs as a mandatory basis for establishing that chemicals are hazardous. Consequently, a TLV based on reproductive or developmental toxicity no longer provides the basis for listing a chemical as known to the state to cause reproductive toxicity under Proposition 65.

Reconsideration Procedure

Chloroform is being brought to the DARTIC because it does not meet the criteria for inclusion on the list by any of the other listing mechanisms contained in the statute.

The Office of Environmental Health Hazard Assessment (OEHHA) has, through a contract with the Sheldon Margen Public Health Library at the University of California, Berkeley, conducted literature searches to identify studies that potentially provide information on the reproductive toxicity of chloroform. The searches covered the three major reproductive toxicity endpoints, namely developmental toxicity and male and female reproductive toxicity. The databases searched and parameters used in these searches are described in Appendix D.

The results of these searches were reviewed by OEHHA staff and all studies that provided data on reproductive toxicity were identified. The design parameters and results of these studies on male reproductive, female reproductive and developmental toxicity are summarized in tables as described below. The complete study reports for


³ Health and Safety Code section 25249.8(a)

chloroform have been provided to the DARTIC and are available to the public upon request.

For completeness, the original ACGIH document that specifically supported development of the chloroform TLV has also been provided to the DARTIC in electronic form. This document was not used in the process that resulted in the 2009 listing of chloroform under Proposition 65. Rather, the inclusion of the chloroform TLV based in part on a reproductive toxicity endpoint in the document, "Threshold Limit Values for Chemical Substances and Physical Agents in the Environment, American Conference of Governmental Industrial Hygienists (ACGIH)" (latest edition) resulted in the listing. The relevant entry from that document also has been provided in electronic form to the committee. In addition, chloroform was previously considered for listing by the DARTIC in 2004 and again in 2005 after additional information and analysis of data were provided at the DARTIC's request. Chloroform was not identified by the DARTIC at that time as causing reproductive toxicity. The hazard identification materials provided to the DARTIC in 2004 and 2005 are also being provided to the current Committee members (see Attachment 1 and Appendix C, respectively).

1. Introduction

1.1. Compound identification, physical properties and uses



Chloroform (1,1,1-Trichloromethane) Molecular Formula: CHCl₃, CAS Number 67-66-3

Chloroform (CHL) is a colorless liquid with a pleasant odor. Its physical properties are as follows (NIOSH Pocket Guide to Chemical Hazards <u>http://www.cdc.gov/niosh/npg/npgd0127.html</u>):

| Molecular Weight | Boiling Point | Freezing Point | Solubility |
|------------------|-----------------------------|------------------|--------------|
| 119.4 | 143°F | -82°F | (77°F): 0.5% |
| Vapor Pressure | Ionization Potential | Specific Gravity | |
| 160 mmHg | 11.42 eV | 1.48 | |

1.2. Use and exposure information

The major use of chloroform is in production of chlorodifluoromethane, in turn a major precursor of tetrafluoroethylene. It is a common laboratory solvent and reagent, a byproduct of chlorine water disinfection, and was formerly used as a surgical anesthetic.

2. Human Studies of Reproductive and Developmental Toxicity of Chloroform

2.1. Notes on Exposure Assessment in Epidemiologic Studies of Chloroform

Information on exposures to chloroform is discussed in Sections B.2 and C.4.1 of the 2004 OEHHA Hazard Identification Document, "Evidence on the Developmental and Reproductive Toxicity of Chloroform" (Attachment 1). Additional more recent relevant exposure information is briefly summarized here.

In 2002, U.S. EPA lowered the total trihalomethane drinking water standard from 0.10 mg/L to 0.08 mg/L for large surface water systems and in 2004 for smaller systems ("Stage 1 and Stage 2 Disinfectants and Disinfection Byproducts Rules", available at https://www.epa.gov/dwreginfo/stage-1-and-stage-2-disinfectants-and-disinfection-byproducts-rules). Analysis of the National Health and Nutrition Examination Survey (NHANES) data showed a significant decline (76%) in blood chloroform levels between 1999-2004; however, a similar decrease was not seen in the other trihalomethanes levels (LaKind et al., 2010; Riederer et al., 2014).

Well-controlled exposure studies have identified many factors that affect blood chloroform levels in humans, including showering and bathing, washing dishes by hand, and ingestion of hot beverages made with tap water, etc., with showering and bathing shown to be a strong if not the strongest predictor of blood chloroform levels (Lynberg et al., 2001; Nuckols et al., 2005; Backer et al., 2008). Additionally, genetic participants with GSTT1-null (inactive enzyme) have been shown to have higher post-shower blood chloroform concentrations than GSTT1-positive participants (Backer et al., 2008). GSTT1-1 is polymorphic in humans, with approximately 20-25% of Caucasian and 50% of Asians having a homozygous deletion of this gene, resulting in the null genotype (Landi et al., 1999).

Recent studies have used blood chloroform levels as measures of exposure. Although blood chloroform decreases within a relatively short timeframe (minutes to hours), a steady-state concentration is thought to exist due to frequency of exposure throughout the day, from activities such as showering and bathing, and slow partitioning out of adipose tissue (Blount et al., 2011).

Few epidemiologic studies have measured chloroform at the tap water in each participant's residence. Chloroform levels can change with distance from the municipal water treatment plant. With an increased amount of organic matter in the system, chloroform levels will likely increase by the time the water is delivered to a residence at increasing distance from the treatment plant. The amount of organic matter can vary depending on season. Therefore, relying on chloroform measurements taken at the treatment plant would likely introduce exposure misclassification. However, this misclassification should be non-differential in that the probability of being misclassified should not differ across groups of study participants. Products containing triclosan have been shown to react with free chlorine in drinking water to increase the formation of chloroform (Rule et al. 2005). Fiss et al. (2007) found that reactions between triclosan in household consumer products (such as antimicrobial soaps) and free chlorine at the tap leads to exposure to reaction products such as chloroform, chlorinated phenols and chlorinated phenoxy-phenols. In model simulations for formation of chloroform from tap water (at the maximum contaminant level of 80 μ g/L for trihalomethanes) and triclosan-containing products, Fiss et al. (2007) calculated that exposure from inhalation and dermal routes could lead to exposures of 6.8–28 mg/year, or an increase in an individual's overall exposure by 15-40%. Since the use of many triclosan-containing products is widespread, this could conceivably lead to considerable misclassification of exposure.

Imprecise exposure assessment resulting in non-differential misclassification of exposure would likely bias the estimate of any association of risk towards the null (i.e., to not detecting an effect even if one were present).

2.2. Notes on the Tables and Figures Presenting Human Studies of Reproductive Outcomes

The tables and figures in this document include almost all the studies presented in the 2004 HID, as well as studies published from 2004 into 2015. Two studies in the 2004 HID which are not included here are Tylleskar-Jensen (1967), a case study of eclampsia published in Danish and cited in Reprotext 2004 but not translated by OEHHA, and a study of semen quality (Fenster et al., 2003) that presented results for total trihalomethanes only, in which chloroform was not the dominant trihalomethane in the water.

Three studies in which chloroform was not included in the statistical analysis assessing risk of exposure were included in these tables. In the studies of Lewis et al. (2006, 2007) chloroform accounted for ~90 percent of total trihalomethane concentration but the statistical analysis was conducted only for total trihalomethane concentration. In the study by Patelarou et al. (2011), a very well-conducted study, chloroform concentrations were very low and thus were not included in the statistical analysis. Hence, this study does not appear in Tables 3a, 3b or A3a.

To facilitate consideration of this complex data set, the tables and figures for the human studies of reproductive outcomes are presented in order of increasing detail. Thus, Table 1 is a list of the studies and outcomes, organized by the measure of exposure, which provides a high level overview of the scope of the dataset.

Table 2 provides more detailed information of each study concerning study design and exposure, organized chronologically. This table, however, is still intended as an overall reference for the dataset.

Figures 1-9 are forest plots of specific reproductive outcomes organized by outcome and by measure of exposure:

- Figure 1 Preterm birth by water concentration;
- Figure 2 Preterm birth by estimated internal dose;
- Figure 3 Small for gestational age by water concentration;
- Figure 4 Small for gestational age by estimated internal dose;
- Figure 5 Low birth weight and very low birth weight by water concentration;
- Figure 6 Low birth weight and very low birth weight by change in water concentration;
- Figure 7 Low birth weight and VLBW by estimated internal dose;
- Figure 8 Birth weight by water concentration;
- Figure 9 Birth weight by estimated internal dose.

The studies in each figure are organized by increasing chloroform exposure based on the lowest value for each study's highest exposure category.

Table 3a provides a detailed summary of each of the studies examining preterm birth, small for gestational age, low birth weight or birth weight, ordered chronologically. Similarly, Table 4a provides summaries for the studies of spontaneous abortion, stillbirth, birth defects, fertility and menstrual cycle function, with Table 5a providing the summaries for studies of sperm quality.

Tables 3b, 4b, and 5b provide the findings of associations between chloroform exposure levels and risk estimates for the studies in Tables 3a, 4a, and 5a. These tables are organized by increasing water chloroform concentration exposure, based on the lowest value for each study's highest exposure category. If the study did not present risk estimates for water chloroform concentration, then ranking was based on the next most relevant measure (e.g., integrated uptake values). Companion tables presented in Appendix A as Tables A3c, A4c and A5c correspond to Tables 3c, 4c and 5c,with the addition of the risk estimates for other trihalomethanes, in addition to those for chloroform.

Additionally, Table B1 in Appendix B presents measured concentrations for chloroform exposures as well as those for total trihalomethanes, bromodichloromethane, and dibromochloromethane.

The complete list of Tables included in Appendices presenting information from these human studies is as follows:

Appendix A:

Table A3c. Associations between Chloroform (CHL) and Other Disinfection By-Products Exposure and Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW) in Human Studies.

Table A4c. Associations between Chloroform (CHL) and Other Disinfection By-Products Exposure and Spontaneous Abortion (SAB), Stillbirth, Birth Defects, Fertility and Menstrual Cycle Function in Human Studies.

Table A5c. Associations between Chloroform (CHL) and Other Disinfection By-Products Exposure and Sperm Parameters in Human Studies.

Appendix B:

Table B1. Exposure Measures for Chloroform (CHL), Total Trihalomethane (TTHM), Bromodichloromethane (BDCM), and Dibromochloromethane (DBCM) in Human Studies of Reproductive Outcomes: (A) Water Concentration, (B) Water Concentration and Estimated Internal Dose.

Table B2. Uptake Factors and Percent Reductions Used in Calculations of Estimated Internal Dose in Human Studies of Chloroform (CHL) Exposure.

Table B3. Windows of Exposure Assessed in Human Studies of Chloroform Exposure and Reproductive Outcomes.

Studies that examined uptake of chloroform (or other trihalomethanes) through various routes of exposure used different terminology to represent estimated internal dose (e.g. internal uptake, total integrated uptake, etc.). In most of the figures and tables presented in this HID, for ease of reading and comparison across studies, this document generally used the term "estimated internal dose" to indicate uptake. The exception is the detailed summary tables (Tables 3a, 4a, and 5a) in which the terms used in the studies were retained in order for the reader to more easily read the table in conjunction with the study publications.

Unless otherwise noted, low birth weight was defined as birth weight less than 2,500 grams, small for gestational age was the lowest 10th centile of birth weight for each gestational week, and preterm birth was <37 weeks gestation.

The sample sizes are presented using the abbreviation N for the initial study population and n for the resulting sample population after any exclusion or loss to follow-up, etc. All odds ratios and risk ratios where the confidence interval does not include 1, or analyses where the p value is < 0.05 are shown in bold.

All results are presented as adjusted for covariates/confounders unless otherwise noted.

Under the column "Covariates/Confounders" (Tables 3a, 4a, and 5a) the variables adjusted for in the analysis are noted. Other variables considered but not adjusted for in the models are noted at the bottom of that column.

In most studies, covariates were retained in the models if they were statistically significant or if they changed the effect estimate (odds ratio or β -coefficient) by greater than 10%. If a study used different criteria for the inclusion of covariates it was noted in the table.

Most studies assessed maternal residence from birth records and did not account for maternal residential mobility during pregnancy. Therefore, it is only noted in the comments section of the detailed summary tables (Tables 3a, 4a, and 5a) when a study did take this into account.

Some studies collected information concerning exposure to trihalomethanes at work. However, few studies that collected this information quantified it and included it in the statistical analysis. Therefore, as with residential mobility, work exposure is only noted in the comments section of the detailed summary tables when the study did take this exposure into account.

None of the studies adjusted for multiple comparisons.

Unless otherwise noted, estimated internal dose (including total uptakes, etc.) incorporated estimated uptake from ingestion, inhalation and dermal exposure.

Findings for other disinfection by-products were only presented if results were statistically significant. However, significant associations for total trihalomethanes were not routinely presented in the tables since in almost all the studies chloroform accounted for the majority of the total trihalomethane concentration and the results were similar.

The studies were reviewed for their disclosure statements with respect to any declared conflict of interest. Almost all the studies included a statement in which the authors declared "no conflict of interest or "no competing interests" and/or "no competing financial interests". One of the older studies (Dahl et al., 1999) and the study by Zhou et al. (2010) translated from Chinese did not include such a statement.

The following groups of studies, noted by different symbols, were conducted using the same participants or a subset of the same participants. These symbols are used throughout the tables to indicate these related studies.

 * Botton et al., 2015; Villanueva et al., 2011, Patelarou et al., 2011
 Botton et al. used a subset of the participants from a mother-child cohort study in Spain (Infancia y Medio Ambiente (INMA)) (Villanueva et al.).
 Although Botton et al. also included participants from another cohort in Greece (RHEA) (Patelarou et al., 2011), the chloroform levels for the Greek cohort were mostly undetectable and thus were excluded from the analyses. † Hoffman et al., 2008; Savitz et al., 2005

Hoffman et al. included a subset of the cohort enrolled in Savitz et al. Savitz et al., 2006 is a peer-reviewed article with a subset of findings published in Savitz et al., 2005, thus this HID only cites the more complete 2005 publication.

‡ Lewis et al., 2007; Lewis et al., 2006

These study populations were from the same database of vital records and were almost exactly the same participants.

* * King et al., 2000; Dodds and King, 2001

These study populations were from the same population-based perinatal database. The same environmental monitoring data was used by both studies for exposure assessment.

- † Zeng et al., 2014; Zeng et al., 2013
 Zeng et al., 2013 used a subset of study participants included in Zeng et al., 2014.
- ‡ ‡ Grazuleviciene et al., 2013; Danileviciute et al., 2012; Grazuleviciene et al., 2011 Each study used different subsets of subjects from the same prospective cohort (Kaunas HiWATE).

Table 1. Reproductive Outcomes Assessed in Human Studies of Chloroform (CHL) Exposure, Grouped by Exposure Measure.

Studies Grouped by Exposure Measure¹

| Exposure Measure ¹ | Outcome (number of studies by any exposure measure) | | | | | | | | | | | | |
|-------------------------------|---|-------------|--------------------|------------|------------|-----------|-----------|-------------------------|---------------------------------------|--|--|--|--|
| | РТВ (9) | SGA (15) | LBW (9) | BW (10) | SAB (3) | SB (4) | BD (3) | Sperm Quality (4) | Other (3) | | | | |
| Water Concentration | | | | | | | | | | | | | |
| Iszatt et al. 2014 | | | X (and VLBW) | | | Х | | | | | | | |
| Iszatt et al. 2013 | | | | | | | | Х | | | | | |
| Rivera-Nuñez and Wright 2013 | Х | Х | | Х | | | | | | | | | |
| Summerhayes et al. 2012 | | Х | | Х | | | | | | | | | |
| Patelarou et al. 2011* | Х | Х | Х | | | | | | | | | | |
| Zhou et al. 2010 | | | | Х | | | | | | | | | |
| Hoffman et al. 2008 † | | Х | | Х | | | | | | | | | |
| Lewis et al. 2007 ‡ | Х | | | | | | | | | | | | |
| Lewis et al. 2006 ‡ | | | Х | | | | | | | | | | |
| Hinckley et al. 2005 | Х | Х | Х | | | | | | | | | | |
| Porter et al. 2005 | | Х | | | | | | | | | | | |
| Toledano et al. 2005 | | | X (and VLBW) | | | X | | | | | | | |
| Dodds et al. 2004 | | | , | | | Х | | | | | | | |
| Infante-Rivard 2004 | | Х | | | | | | | | | | | |
| Wright et al. 2004 | Х | Х | | Х | | | | | | | | | |
| Windham et al. 2003 | | | | | | | | | X (Menstrual cycle function) | | | | |
| Dodds and King 2001 * * | | | | | | | X | | | | | | |
| King et al. 2000 * * | | | | | | X | | | | | | | |
| Waller et al. 1998 | | | | | X | | | | | | | | |
| Kramer et al. 1992 | X | X | X | | | | | | | | | | |

Abbreviations: BD - birth defects; BW - birth weight; CHL - chloroform; LBW - low birth weight; PTB - preterm birth; SAB - spontaneous abortion; SB - stillbirth; SGA - small for gestational age; VLBW - very low birth weight.

¹ Studies with the same symbol (e.g., *) are drawn from the same population or cohort. See "Introductory notes for tables" for an explanation of the relationship of study populations among the studies marked with a given symbol.

Table 1. Reproductive Outcomes Assessed in Human Studies of Chloroform (CHL) Exposure, Grouped by Exposure Measure

(cont'd).

| St | u | ji | es | (| G | iro | D | u | р | e | d | ł | bу | / |
|----|---|----|----|---|---|-----|---|---|---|---|---|---|----|---|
| _ | | | | | | | | | | | | | | |

| Exposure Measure | | | | | Outcome | | | | |
|--------------------------------------|------------|-----|-----|----|---------|----|----|------------------|-----------------|
| | РТВ | SGA | LBW | BW | SAB | SB | BD | Sperm Quality | Other |
| Estimated Internal Dose ² | | | | | | | | | X (Postnatal |
| Botton et al. 2015* ³ | | | | | | | | | weight gain) |
| Smith et al. 2015 | | | | Х | | | | | |
| Zeng et al. 2014 † † ^{3,4} | | | | | | | | Х | |
| Grazuleviciene et al. 2013 ± ± | | | | | | | Х | | |
| Costet et al. 2012 3,5 | Х | Х | | | | | | | |
| Danileviciute et al. 2012 ‡ ‡ | | Х | X | | | | | | |
| Levallois et al. 2012 3,5 | | Х | | | | | | | |
| Grazuleviciene et al. 2011 ‡ ‡ | | Х | Х | Х | | | | | |
| Iszatt et al. 2011 ^{3,5} | | | | | | | Х | | |
| Villanueva et al. 2011* | Х | Х | Х | Х | | | | | |
| Savitz et al. 2005 † ^{3,5} | Х | X | | X | X | | | | |
| Blood Level | | | | | | | | | |
| Zeng et al. 2013 † † | | | | | | | | Х | |
| Air Samples | | | | | | | | | |
| Chang et al. 2001 | | | | | | | | Х | |
| Questionnaire re: Occupational | l Exposure | | | | | | | | |
| Wennborg et al. 2000 | | | | Х | Х | | | | |
| Dahl et al. 1999 | | | | | | | | | Х |
| | | | | | | | | | (Fertility) |

² Generally these studies estimated the internal dose of CHL as the sum of uptakes from the dermal, inhalation, and ingestion routes of exposure.

 ³ Results for individual routes of exposure were also reported.
 ⁴ Zeng et al. (2014) did not report total dose; only results for routes of exposure through ingestion and showering/bathing were reported.

⁵ Risks were also calculated for CHL concentration in water.

| | Stud | ly | | Exposure | | | | | | |
|---|--|---|---|---|---|--|---|--|--|--|
| Author Year of Study | Design | Location | Outcomes/ Sample Size | Timing | Assessment | CHL Level ¹ | Other DBPs Measured and Analyzed ² | | | |
| Botton et al.* Prospective 2015 cohort | Spain (3 locations) | Postnatal weight growth Total n = 2,216 | Entire pregnancy | Monitoring data | Median (µg/L): Gipuzkoa = ~12, Sabadell = ~20, Valencia = ~0 | TTHM BrTHM | | | | |
| | | | | Estimated internal dose | Range (μg/d): Gipuzkoa = ~0-0.05, Sabadell = ~0-1.4, Valencia = ~0-2.1 | | | | | |
| Smith et al. Prospective 2015 cohort | England | BW n = 7,438 | Each trimester Entire pregnancy | Monitoring data | Time-weighted average conc: Mean (SD) (μg/L) = 37.8 (3.8) | THMs ³ HAAs BrTHM | | | | |
| | | | | Estimated internal dose | Mean (SD) (µg/d) = 1.61 (1.46) | | | | | |
| Iszatt et al. 2014 | Retrospective cohort Intervention - enhanced coagulation water treatment (EC) | England | Total live births n = 429,599 LBW n = 27,664 VLBW n = 4,209 SB n = 2,279 | Entire pregnancy | Monitoring data | Mean (SD) (μg/L): Before EC = 38.6 (4.2) After EC = 19.4 (1.0) | TTHM BDCM DBCM | | | |
| Zeng et al. † † 2014 | Prospective cohort | China | Sperm parameters n = 324 | Time of semen sample relative to days of abstinence | Monitoring data | Mean (µg/L) =13.71 | TTHM BrTHM | | | |
| | | | | | Estimated internal dose | Ingestion: IQR (μ g/d) = 0.005–0.019 Showering/bathing: IQR (μ g/d) = 0.064–0.246 | | | | |
| Grazuleviciene Prospective et al. ‡ ‡ cohort 2013 | Lithuania | $\frac{\text{Birth Defects}}{\text{Heart}} = 57$ $\frac{\text{Musculo-}}{\text{skeletal}} = 37$ | 1 st , 2 nd , and 3 rd month 1 st trimester | Monitoring data | Mean (SD) (μg/L): all sites = 7.8 (10.2) 3 plants = 0.9 (1.0) 1 plant = 17.7 (9.0) | THMs TTHM HAAs ⁴ MX ⁴ | | | | |
| | | | Urogenital $n = 23$ Total $n = 3,074$ | | Estimated internal dose | Range (µg/d) = 0.001–2.109 | - | | | |

Abbreviations: BDCM - bromodichloromethane; BrTHM - total brominated trihalomethanes; BW - birth weight; CHL - chloroform; conc - concentration; d – day; DBCM - dibromochloromethane; DBP - disinfection by-products; EC - enhanced coagulation; exp - exposure; HAA - haloacetic acid; IQR - interquartile range; IUGR - intrauterine growth restriction; L – liter; LBW - low birth weight; NTD neural tube defect; PTB - preterm birth; SB - stillbirth; SD - standard deviation; SGA - small for gestational age; MX - halogenated furanone (trichloromethane); TBM - bromoform; TCAA - trichloroacetic acid; THMs - trihalomethanes; TTHM - total trihalomethanes (sum of CHL, BDCM, DBCM, and TBM); VLBW - very low birth weight. Total n - number of individuals included in the final analysis.

* Studies with the same symbol (e.g. *) are drawn from the same population or cohort. See "Introductory notes for tables" for an explanation of the relationship between studies.

OEHHA August 2016

¹ CHL level measured in monitored water samples unless otherwise noted.

 $^{^{2}}$ Other DBPs which were included in the statistical analysis unless otherwise noted.

³ In every instance where THMs appears in this table, statistical analyses were conducted on each of the THMs separately.

⁴ Measured concentration occurred only at very low levels, and was therefore not included in the statistical analysis.

| | Stud | ly | | | Exposure | | | | | |
|------------------------------------|--|---------------|--|---|---|---|--|--|--|--|
| Author Year of Study | Design | Location | Outcomes/ Sample Size | Timing | Assessment | CHL Level ¹ | Other DBPs Measured and Analyzed ² | | | |
| Iszatt et al. 2013 | Case-control | England | Sperm concentration and motility cases $n = 642$ controls $n = 926$ | Sampled 3–5 days after abstinence | Monitoring data | Mean (SD) (μg/L): cases = 25.9 (19.0) controls = 27.3 (19.1) | TTHM BrTHM | | | |
| Rivera-Nuñez and Wright 2013 | Retrospective cohort (semi-ecologic) | Massachusetts | SGA n = 68,409 BW n = 651,512 PTB n = 37,136 Total n = 672,120 | Each trimester | Monitoring data | Mean (µg/L) = 30.6 | THMs TTHM BrTHM HAAs | | | |
| Zeng et al. † † 2013 | Cross-sectional | China | Sperm parameters Serum testosterone n = 401 | Time of semen sample relative to days of abstinence | Blood conc | Mean (µg/L) = 0.057 Median = 0.050 | THMs TTHM BrTHM | | | |
| Costet et al. 2012 | Prospective cohort | France | SGA n = 171 PTB n = 105 Total n = 3,226 | Each trimester | Monitoring data | Mean (SD) (µg/L) = 9.3 (7.0) | THMs TTHM Urinary TCAA | | | |
| | | | | | Estimated internal dose | IQR (µg/d) = <0.068–<0.237 | | | | |
| Danileviciute et al.‡ ‡ 2012 | Nested case- control | Lithuania | SGA n = 96 LBW n = 59 Total n = 682 | Each trimester Entire pregnancy | Monitoring data | Mean (SD) (µg/L): all sites = 7.8 (10.2) 3 plants = 0.9 (1.0) 1 plant = 17.7 (9.0) | THMs TTHM HAAs ⁴ MX ⁴ | | | |
| | | | | | Estimated internal dose Assessed GSTT1 and GSTM1 genotype | Median (µg/d) = 0.1424 Range = 0.0013–2.13 | | | | |
| Levallois et al. 2012 | Population-based case-control | Quebec City | SGA cases n = 571 controls n = 1,925 | Each trimester | Monitoring data | Mean (SD) (µg/L): cases = 43.3 (40.7) controls = 41.1 (39.2) | THMs TTHM BrTHM HAAs | | | |
| | | | | | Estimated internal dose | IQR (µg/d) = <42.24–169.81 | | | | |
| Summerhayes et al. 2012 | Retrospective cohort | Australia | SGA n = 31,813 BW n = 314,982 Total n = 314,982 | Each trimester Entire pregnancy | Monitoring data | Mean (SD) (µg/L) = 33.6 (16.0) Median = 30.9 Range = 3.4–121.5 | TTHM BDCM DBCM BrTHM HAAs ⁵ | | | |

⁵ Not included in the statistical analysis.

| | Stud | ly | | | Exposure | | | | | |
|--|--|---------------------------|--|---|--|---|---|--|--|--|
| Author Year of Study | Design | Location | Outcomes/ Sample Size | Timing | Assessment | CHL Level ¹ | Other DBPs Measured and Analyzed ² | | | |
| Grazuleviciene et al. ‡ ‡ 2011 | Prospective cohort | 5 | Monitoring data | Mean (SD) (µg/L): all sites = 7.8 (10.2) 3 plants = 0.9 (1.0) 1 plant = 17.7 (9.0) | THMs TTHM HAAs ⁴ MX ⁴ | | | | | |
| | | | | | Estimated internal dose | Range (µg/d): 0.0013–2.13 | | | | |
| Izsatt et al. 2011 | Case-control England <u>Birth Defect</u> 1 st trimester Hypospadias cases n = 354 controls n = 336 | 1 st trimester | Monitoring data | Median (μg/L) = 2.9 Range = 0.0–90 | THMs TTHM BrTHM | | | | | |
| | cont | controls n = 336 | | Estimated internal dose | IQR (µg/d) = 0–101 | | | | | |
| Patelarou et al.* ⁶ 2011 | Prospective cohort | Greece | SGA n = 73 LBW n = 76 PTB n = 156 Total n = 1,359 | Each trimester Entire pregnancy | Sampling of tap water in selected sites | Mean (SD) (µg/L) = 0.15 (0.15) | THMs BrTHM | | | |
| Villanueva et al.* 2011 | Prospective cohort | (5 locations) | SGA n = 220 BW n = 2,074 LBW n = 95 | Each trimester Entire pregnancy | Monitoring data and sampling of tap water from geographically representative areas | THM levels and percentiles were reported graphically | BrTHM | | | |
| | | | PTB n = 77 | | Estimated internal dose | Median appeared to be under 0.5 µg/d | | | | |
| Zhou et al. 2010 | Retrospective cohort | China | BW n = 1,385 | Each trimester 1 st & 2 nd trimester Entire pregnancy | Monitoring data | Range (µg/L) of mean values = 6.0– 51.2 | BrTHM HAAs | | | |
| Hoffman et al. † 2008 | Prospective cohort | US (3 locations) | SGA n = 113 BW n = 1,854 Total n = 1,958 | Each trimester | Sampling of tap water from geographically representative locations - weekly and intensive short-term sampling | Mean (SD) (µg/L) = 46.7 (13.3) at chlorinated sites 13.7 (3.3) at brominated sites | THMs TTHM HAAs | | | |
| Lewis et al. ‡ 2007 | Population-based case-control | Massachusetts | PTB n = 2,813 Total n = 37,498 | 1 st & 2 nd trimester 4 weeks before birth Entire pregnancy | Monitoring data - weekly | TTHM (μg/L): Interquartile range = 59 Min, max of range = 28–87 CHL fraction of TTHM = 83–93% | ТТНМ | | | |
| Lewis et al. ‡ 2006 | Retrospective cohort | Massachusetts | LBW n = 780 Total n = 36,529 | Each trimester Entire pregnancy | Monitoring data - weekly | TTHM (μg/L): IQR = 59 Min, max of range = 28–87 | ТТНМ | | | |
| | | | | | | CHL fraction of TTHM = 83–93% | | | | |

⁶ No separate statistical analysis was conducted for CHL as the measured concentrations were very low. Statistical analysis was conducted only for BrTHM.

| | Stud | ly | | Exposure | | | | | | |
|-----------------------------------|--|----------------------------|--|--|--|--|---|--|--|--|
| Author Year of Study | Design | Location | Outcomes/ Sample Size | Timing | Assessment | CHL Level ¹ | Other DBPs Measured and Analyzed ² | | | |
| Hinckley et al. 2005 | Retrospective cohort | Arizona | $\begin{array}{rrrr} IUGR n = & 4,396\\ LBW n = & 1,010\\ PTB n = & 4,008\\ Very PTB n = & 564\\ Total n = & 48,119 \end{array}$ | Various time windows within the 3 rd trimester | Monitoring data | Mean not reported CHL categories (µg/L) = <10, 10–16, ≥16 | THMs TTHM HAAs | | | |
| Porter et al. 2005 | Retrospective cohort | Maryland | SGA n = 1,114 Total n = 15,315 | Each trimester Entire pregnancy | Monitoring data | Mean (μg/L) (95% Cl): all sites = 34.1 (32.5, 35.7) | THMs TTHM HAAs | | | |
| Savitz et al. † 2005 | cohort (3 locations) SGA n = 102 (up to week 20) BW n = 1,738 PTB n = 196 SAB n = 258 | | Sampling of tap water from geographically representative locations – weekly and intensive short-term sampling | Mean (μg/L) = - 45.6 at chlorinated sites - Below minimum reporting level at brominated sites - 11.9 at low DBP site | THMs TTHM BrTHM HAAs | | | | | |
| | | Total n = 1,934 | | Estimated internal dose | Range (week 27-birth) (μg/d) = 0–>1.3 (in the highest quartile) | | | | | |
| Toledano et al. 2005 | Retrospective cohort | United Kingdom | LBW n = 60,641 Very LBW n = 9,167 SB n = 4,852 Total n = 920,571 | 3 rd trimester (93 days before birth) | Monitoring data | Mean levels not reported CHL tertiles (µg/L) = <20, 20–40, >40 | TTHM BDCM BrTHM | | | |
| Dodds et al. ⁷ 2004 | Population-based case-control | Nova Scotia and Ontario | SB cases n = 112 controls n = 398 Total n = 510 | 1 st & early 2 nd trimester | Residential tap water sampled for each subject | Mean levels not reported CHL categories (µg/L) = 0, 1–49, 50–79, >80 | TTHM BDCM | | | |
| Infante-Rivard 2004 | Case-control | Montreal | SGA cases n = 458 controls n = 426 Total n = 884 | Entire pregnancy | Monitoring data Assessed CYP2E1 and MTHFR C677Tgenotype | Mean (SD) (μg/L): cases = 11.84 (11.84) controls = 11.58 (16.31) | THMs TTHM | | | |
| Wright et al. 2004 | Retrospective cohort | Massachusetts | SGA n = 17,359 BW n = 3,463 PTB n = 11,580 Total n = 187,731 | 3 rd trimester | Monitoring data | Median (µg/L) = 26 Range 0–135 | THMs TTHM BDCM HAAs MX | | | |
| Windham et al. 2003 | Prospective cohort | California | Menstrual cycle function n = 403 | 90 day window | Monitoring data | Mean not reported CHL categories (μ g/L) = 1 st quartile, 2 nd -3 rd quartile, 4 th quartile (≥17) | THMs TTHM BDCM DBCM TBM | | | |

⁷ Daily exposure from ingestion, inhalation and absorption were also estimated but no values were presented. ACGIH TLV DART Chemical 24

| | Study | / | | Exposure | | | | | | |
|----------------------------|--|-------------|--|--|--|--|---|--|--|--|
| Author Year of Study | Design | Location | Outcomes/ Sample Size | Timing | Assessment | CHL Level ¹ | Other DBPs Measured and Analyzed ² | | | |
| | | | | | | | BrTHM | | | |
| Chang et al. 2001 | Case report | Taiwan | Sperm Parameters n = 1 | Sampled 4 days after abstinence | Reconstructed scenario of air exposure using passive and active sampling | Air samples = 8.5 ppm active sample 4.6 ppm passive sample | | | | |
| Dodds and King * * 2001 | Retrospective cohort | Nova Scotia | $\begin{array}{l} \underline{Birth\ Defects}\\ NTD\ n=\ 77\\ Cleft\ n=\ 82\\ Cardiovascular\\ n=\ 430\\ Chromosomal\\ abnormalities\\ n=\ 96\\ Total\ n=\ 49,842 \end{array}$ | 1 -3 months prior to pregnancy and 1 month after conception (time frames were specific to the birth defect | Monitoring data | Mean (μg/L) = 64.1 | BDCM DCBM ⁴ TBM ⁴ | | | |
| King et al. * * 2000 | Retrospective cohort | Nova Scotia | SB n = 214 Total n = 49,756 | Entire pregnancy | Monitoring data | Mean (µg/L) = 64.1 | TTHM BDCM DCBM ⁴ TBM ⁴ | | | |
| Wennborg et al. 2000 | Retrospective cohort (BW) Case control (SAB) | Sweden | $\begin{array}{ll} BW & n = 654 \\ SAB & n = 73 \\ Total & n = 869 \\ (number of \\ pregnancies) \end{array}$ | Pre-pregnancy | Interview questionnaire: work history with exp to CHL | No CHL levels measured | | | | |
| Dahl et al. 1999 | Retrospective cohort | Norway | Fertility measured as time to pregnancy n = 1408 pregnancies | 6 months pre- pregnancy | Interview questionnaire: work performed w/ dental restorative materials and chemicals (number per week) | 75% reported use of CHL-based materials | | | | |
| Waller et al. 1998 | Prospective cohort | California | SAB n = 499 Total n = 5,144 | 1 st trimester | Monitoring data Ingestion data | CHL reported as categories (µg/L): 0–3 = 13.6% 4–16 = 30.1% ≥17 = 17.6% | THMs TTHM | | | |
| Kramer et al. 1992 | Population-based case-control | Iowa | $\begin{array}{c} \text{SGA}\\ \text{cases} n= 187\\ \text{controls} n= 935\\ \text{LBW}\\ \text{cases} n= 159\\ \text{controls} n= 795\\ \text{PTB}\\ \text{cases} n= 342\\ \text{controls} n= 1,710\\ \end{array}$ | At time of birth | Monitoring data | Mean (SD) (μg/L) = 12.5 (38.7) Median = 1 Range = 0–350 | THMs Total organic halides | | | |

25

| Study (Year) | CHL Water Concentration (µg/L) | | Odds Ratio | Lower Cl | Upper Cl |
|---------------------------------|-----------------------------------|----------------|------------------|-------------|-------------|
| Kramer et al. 1992 | 1–9 Entire Pregnancy | | 1.10 | 0.80 | 1.40 |
| | ≥10 | <u>_</u> | 1.10 | 0.70 | 1.60 |
| Costet et al. 2012 | 5-<10 | | 0.70 | 0.40 | 1.20 |
| | 10-<15 | I | 0.50 | 0.30 | 0.90 |
| | ≥15 | | 0.80 | 0.40 | 1.40 |
| Savitz et al. 2005† | >0.1–≤10.9 | | 0.68 | 0.42 | 1.11 |
| | >10.9–≤30.4 | | 0.76 | 0.47 | 1.24 |
| | >30.4–≤48.2 | I | 0.52 | 0.31 | 0.90 |
| | >48.2 | | 0.54 | 0.31 | 0.92 |
| Rivera-Nuñez and Wright 2013 | >5–21 2 nd Trimester | + | 1.00 | 0.94 | 1.06 |
| | >21–35 | ¦_ → _ | 1.08 | 1.02 | 1.14 |
| | >35–52 | ¦ | 1.06 | 0.99 | 1.12 |
| | >52 | - - | 1.00 | 0.94 | 1.07 |
| Lewis et al. 2007 ^{±1} | 40–60 Entire Pregnancy | | 0.92 | 0.82 | 1.02 |
| | ≥60 | _ - | 0.85 | 0.74 | 0.97 |
| | 40–60 2 nd Trimester | | 0.87 | 0.77 | 0.99 |
| | ≥60 | _ _ | 0.82 | 0.71 | 0.94 |
| Wright et al. 2004 | >26–63 | | 0.95 | 0.91 | 0.99 |
| | >63–135 | | 0.90 | 0.84 | 0.97 |
| | | l 0.25 | I 1.75 | | |

Figure 1. Preterm Birth (PTB). Forest plot of the association between chloroform (CHL) exposure [water concentration] and PTB. Confidence intervals (95%) are denoted by "CI." Studies are ordered based on the lowest value of each study's highest exposure category. Results represent third trimester exposure unless otherwise noted.

¹ Lewis et al. 2007 measured total trihalomethanes (TTHM), of which CHL constituted ~90%. Risk estimate is a hazard ratio.

Figure 2. Preterm Birth (PTB). Forest plot of the association between chloroform (CHL) exposure [estimated internal dose] and PTB. Confidence intervals (95%) are denoted by "CI." Studies are ordered based on the lowest value of each study's highest exposure category. Results represent third trimester exposure.

| Study (Year) | CHL Estimated Internal Dose (µg/d) | | Odds Ratio | Lower Cl | Upper Cl |
|-------------------------|---|---------------------------------|---------------|-------------|-------------|
| Villanueva et al. 2011* | 10% increase in total residential uptake ¹ | • | 1.00 | 0.99 | 1.01 |
| Costet et al. 2012 | 0.068-<0.133 | | 1.80 | 0.70 | 4.80 |
| | 0.133-<0.237 | < | 0.70 | 0.20 | 2.10 |
| | ≥0.237 | | 1.00 | 0.40 | 2.90 |
| Savitz et al. 2005† | >0–≤0.2 | | 1.03 | 0.65 | 1.66 |
| | >0.2–≤0.8 | _ | 0.56 | 0.32 | 0.96 |
| | >0.8–≤1.3 | | 0.82 | 0.49 | 1.37 |
| | >1.3 | | 0.59 | 0.34 | 1.01 |
| | | I I I 0.25 1 1.75 2.5 | | | |

¹β-coefficients from the regression model were multiplied by the logarithm of 1.1 to derive an effect estimate for a 10% increase in exposure.

| Study (Year) Co | CHL Water oncentration (μg/L) | Odds Ratio | Lower Cl | Upper Cl |
|------------------------------|--|---------------|-------------|-------------|
| Kramer et al. 1992 | 1–9 Entire Pregnancy | 1.30 | 0.90 | 1.80 |
| | ≥10 | 1.80 | 1.10 | 2.90 |
| Costet et al. 2012 | 5-<10 | 0.80 | 0.50 | 1.20 |
| | 10–<15 | 1.00 | 0.60 | 1.50 |
| | ≥15 | 0.90 | 0.50 | 1.40 |
| Hinckley et al. 2005 | 10–16 | 1.02 | 0.94 | 1.11 |
| | ≥16 + | 1.01 | 0.93 | 1.10 |
| Infante-Rivard 2004 | >23.7 Entire Pregnancy | 1.06 | 0.63 | 1.79 |
| Savitz et al. 2005† | >0.2–≤19.2 | 1.45 | 0.79 | 2.64 |
| | >19.2–≤47.1 | 1.33 | 0.71 | 2.49 |
| | >47.1 | 1.05 | 0.54 | 2.01 |
| Hoffman et al. 2008†¹ | Site 1: 44.3–49.0 | 1.40 | 0.60 | 3.10 |
| | Site 1: 49.1–94.0 | 1.10 | 0.50 | 2.60 |
| | Site 2: 11.6–15.6 | • 4.90 | 1.50 | 15.80 |
| | Site 2: 15.7–22.1 | 2.40 | 0.70 | 8.40 |
| Porter et al. 2005 | | 1.02 | 0.84 | 1.24 |
| | 2 nd quintile 3 rd quintile 4 th quintile 5 th quintile 15.96–27.26 27.27–51.07 >51.07 | 0.96 | 0.79 | 1.16 |
| | 4 th quintile | 0.98 | 0.81 | 1.19 |
| | 5 th quintile <mark>-¦</mark> | 1.07 | 0.88 | 1.29 |
| Levallois et al. 2012 | 15.96–27.26 | 0.90 | 0.70 | 1.30 |
| | 27.27–51.07 | 1.00 | 0.80 | 1.40 |
| | >51.07 | 1.20 | 0.90 | 1.70 |
| Rivera-Nuñez and Wright 2013 | >5 - 21 | 1.01 | 0.96 | 1.05 |
| | >21–36 | 1.00 | 0.95 | 1.04 |
| | >36–52 | 1.04 | 1.00 | 1.10 |
| | >52 | 1.04 | 0.99 | 1.09 |
| Summerhayes et al. 2012² | 25.00–30.18 | 1.01 | 0.96 | 1.07 |
| | 56.03–148.94 | 1.12 | 1.05 | 1.18 |
| Wright et al. 2004 | >26–63 | 1.05 | 1.02 | 1.09 |
| | >63–135 | 1.11 | 1.04 | 1.17 |

Figure 3. Small for Gestational Age (SGA). Forest plot of the association between chloroform (CHL) exposure [water concentration] and SGA. Confidence intervals (95%) are denoted by "CI." Studies are ordered based on the lowest value of each study's highest exposure category. Results represent third trimester exposure unless otherwise noted.

¹ Hoffman et al. 2008 analyzed CHL exposure at two sites. Site 1 consisted predominantly of chlorinated disinfection by-products (DBPs). Site 2 consisted predominantly of brominated DBPs.

² Summerhayes et al. 2012 reported risk estimates as relative risks. Water concentration values represent 5th and 10th decile exposure values.

ACGIH TLV DART Chemical for Reconsideration: Chloroform

Figure 4. Small for Gestational Age (SGA). Forest plot of the association between chloroform (CHL) exposure [estimated internal dose] and SGA. Confidence intervals (95%) are denoted by "CI." Studies are ordered based on the lowest value of each study's highest exposure category. Results represent third trimester exposure.

| Study (Year) | CHL Estimated Internal Dose (µg/d) | | Odds Ratio | Lower Cl | Upper Cl |
|-------------------------------|---|----------------------|---------------|-------------|-------------|
| Danileviciute et al. 2012‡ ‡¹ | Above vs. Below Median Median: 0.1424 | | 1.31 | 0.82 | 2.08 |
| | Median: 0.1424 - Specific for GSTT1-1 | | 1.18 | 0.71 | 1.97 |
| | Median: 0.1424 - Specific for GSTT1-0 | | 1.75 | 0.50 | 6.10 |
| | Median: 0.1424 - Specific for GSTM1-1 | ← | 0.88 | 0.44 | 1.78 |
| | Median: 0.1424 - Specific for GSTM1-0 | | 1.74 | 0.89 | 3.41 |
| Villanueva et al. 2011* | 10% increase in total residential uptake ² | | 1.00 | 0.99 | 1.01 |
| Costet et al. 2012 | 0.068-<0.133 | _ | 1.10 | 0.50 | 2.30 |
| | 0.133-<0.237 | | 1.20 | 0.60 | 2.40 |
| | ≥0.237 | | 1.00 | 0.50 | 2.10 |
| Grazuleviciene et al. 2011‡‡ | 0.0249-0.2868 | | 1.19 | 0.87 | 1.63 |
| | 0.2868-2.1328 | _ | 1.22 | 0.89 | 1.68 |
| | Continuous (0.1 µg/d) | - | 1.03 | 1.00 | 1.09 |
| Savitz et al. 2005† | >0–≤0.5 | ` > | 1.16 | 0.63 | 2.14 |
| | >0.5–≤1.2 | | 1.26 | 0.68 | 2.33 |
| | >1.2 | | 1.14 | 0.62 | 2.09 |
| Levallois et al. 2012 | 1.72–11.88 | | 1.20 | 0.90 | 1.60 |
| | 11.89–34.30 | | 1.10 | 0.80 | 1.50 |
| | >34.30 | · | 1.30 | 1.00 | 1.80 |
| | | I I I 0.5 1 1.5 2 | 2 | | |

¹ Danileviciute et al. 2012 examined the polymorphisms of glutathione S-transferase (GST), GSTT1 and GSTM1. "GSTT1-1" represents the presence of gene activity and "GSTT1-0" represents the absence of gene activity. Similarly, "GSTM1-1" represents the presence of gene activity and "GSTM1-0" represents the absence of gene activity.

² β-coefficients from the regression model were multiplied by the logarithm of 1.1 to derive an effect estimate for a 10% increase in exposure.

Figure 5. Low Birth Weight (LBW) and Very Low Birth Weight (VLBW). Forest plot of the association between chloroform (CHL) exposure [water concentration] and LBW and VLBW. Confidence intervals (95%) are denoted by "CI." Studies are ordered based on the lowest value of each study's highest exposure category. Results represent third trimester exposure unless otherwise noted.

| Study (Year) | CHL Wate Concentration | | Outcome | | | | | Odds Ratio | Lower Cl | Upper Cl |
|--------------------------------|---------------------------|---------------------------|---------|-----|--------------|-----------------|-------------------|---------------|-------------|-------------|
| Kramer et al. 1992 | 1.0 | Entire Dreameney | LBW | _ | | | | 1.10 | 0.70 | 1.60 |
| Ridiner et al. 1992 | 1-9 | Entire Pregnancy | | | | | | | | |
| | ≥10 | | LBW | | i | | | 1.30 | 0.80 | 2.20 |
| Hinckley et al. 2005 | 10–16 | | LBW | | | • | | 1.18 | 1.00 | 1.39 |
| | ≥16 | | LBW | | i• | _ | | 1.04 | 0.88 | 1.23 |
| Toledano et al. 2005 | 20-40 | | LBW | | • | | | 1.05 | 1.03 | 1.07 |
| | >40 | | LBW | | ¦ - | | | 1.10 | 1.07 | 1.13 |
| | 20–40 | | VLBW | | - - - | | | 1.01 | 0.96 | 1.07 |
| | >40 | | VLBW | | i. | | | 1.07 | 0.99 | 1.15 |
| Lewis et al. 2006 ¹ | 40-<50 | 2 nd Trimester | LBW | | | | | 1.10 | 0.81 | 1.49 |
| | 50-<60 | | LBW | | | | | 1.08 | 0.79 | 1.49 |
| | 60-<70 | | LBW | | <u> </u> | • | | 1.24 | 0.92 | 1.67 |
| | ≥70 | | LBW | | ¦ — | • | \longrightarrow | 1.50 | 1.07 | 2.10 |
| | | | | | ł | | | | | |
| | | | | 0.5 | 1 | 1.5 | 2 | | | |

¹ Lewis et al. 2006 measured total trihalomethanes (TTHM), of which CHL constituted ~90%. This study also examined third trimester exposure; for which the odds ratios were not significant.

Figure 6. Low Birth Weight (LBW) and Very Low Birth Weight (VLBW). Forest plot of the association between the change in chloroform (CHL) exposure [water concentration] and LBW and VLBW. Confidence intervals (95%) are denoted by "CI." Rate change is the percent change calculated as the exponential of the regression coefficient (e.g. rate ratio of after/before) minus 1 and multiplied by100. The timeframe for exposure is the entire pregnancy.

| Study (Year) | Change in CHL Water Concentration (µg/L) | Outcome | | | | Cł | Rate ange (% | | Upper Cl |
|--------------------|---|---------|-----------------|-----------------|---------|---------------|-----------------|-----|-------------|
| lszatt et al. 2014 | Low: increase ≤10–decrease <10 | LBW | | | | | -5 | -9 | -1 |
| | Medium: decrease 10-<30 | LBW | | | | | -5 | -9 | -1 |
| | High: decrease 30–65 | LBW | | | | | -9 | -12 | -5 |
| | Low: increase ≤10–decrease <10 | VLBW | | | • | | -7 | -17 | 3 |
| | Medium: decrease 10-<30 | VLBW | | | | → | 4 | -7 | 16 |
| | High: decrease 30–65 | VLBW | | • | i | | -16 | -24 | -8 |
| | | | | | | | | | |
| | | | I -25 | -15 | -5 0 | I 5 | | | |

Figure 7. Low Birth Weight (LBW). Forest plot of the association between chloroform (CHL) exposure [estimated internal dose] and LBW. Confidence intervals (95%) are denoted by "CI." Studies are ordered based on the lowest value of each study's highest exposure category. Results represent third trimester exposure.

| Study (Year) | CHL Estimated Internal Dose (µg/d) | | | | | Odds Ratio | Lower Cl | Upper Cl |
|------------------------------|---|---|--------------------|---------------|-------------------|---------------|-------------|-------------|
| | Above vs. Below Median | | 1 | | | | | |
| Danileviciute et al. 2012‡‡¹ | Median: 0.1424 | | • | | | 1.45 | 0.67 | 3.13 |
| | Median: 0.1424 - Specific for GSTT1-1 | - | • | | | 1.35 | 0.57 | 3.20 |
| | Median: 0.1424 - Specific for GSTT1-0 | | 1 | | > | 7.30 | 0.14 | 391 |
| | Median: 0.1424 - Specific for GSTM1-1 | | 1 <u>1</u> 1 | | | 0.35 | 0.10 | 1.28 |
| | Median: 0.1424 - Specific for GSTM1-0 | | ¦ | • | \longrightarrow | 5.06 | 1.50 | 17.05 |
| | | | | | | | | |
| Villanueva et al. 2011* | 10% increase in total residential uptake ² | | • | | | 1.00 | 0.99 | 1.02 |
| Grazuleviciene et al. 2011‡‡ | 0.0249–0.2868 | | | | | 2.12 | 1.11 | 4.02 |
| | 0.2868–2.1328 | | | | | 2.13 | 1.15 | 3.92 |
| | Continuous (0.1 µg/d) | | • | | | 1.09 | 1.01 | 1.18 |
| | | | 1 | | | | | |
| | | 0 | 1 2.5 | I 5 | 7.5 | | | |

¹ Danileviciute et al. 2012 examined the polymorphisms of glutathione S-transferase (GST), GSTT1 and GSTM1. "GSTT1-1" represents the presence of gene activity and "GSTT1-0" represents the absence of gene activity. Similarly, "GSTM1-1" represents the presence of gene activity and "GSTM1-0" represents the absence of gene activity.

 2 β -coefficients from the regression model were multiplied by the logarithm of 1.1 to derive an effect estimate for a 10% increase in exposure.

Figure 8. Birth Weight (BW). Forest plot of the association between chloroform (CHL) exposure [water concentration] and BW. Confidence intervals (95%) are denoted by "CI." Studies are ordered based on the lowest value of each study's highest exposure category. Results represent third trimester exposure unless otherwise noted.

| Study (Year) | CHL Water Concentration (µg/L) | | | | Change in BW (g) | Lower Cl | Upper Cl |
|--------------------------------------|-------------------------------------|------------|--------------|----------------|---------------------|-------------|-------------|
| Summerhayes et al. 2012 ¹ | 20.4–43.9 Entire Pregnan | су | | | -5 | -9 | -1 |
| | 20.4–43.9 1 st Trimester | | + | | -4 | -7 | -1.1 |
| | 20.4–43.9 2 nd Trimester | | . | | -3.4 | -6.4 | -0.3 |
| | 20.4-43.9 | | - | | -2.6 | -5.8 | 0.6 |
| Savitz et al. 2005† | >0.1–≤10.9 | ← | | | -18 | -86 | 51 |
| | >10.9–≤30.4 | | • | _ | -6 | -75 | 62 |
| | >30.4–≤48.2 | _ | • | \rightarrow | 12 | -56 | 80 |
| | >48.2 | | | \rightarrow | 28 | -39 | 96 |
| Hoffman et al. 2008†² | Site 1: 44.3–49.0 | | | \rightarrow | 26 | -51 | 104 |
| | Site 1: 49.1–94.0 | - | • | \rightarrow | 24 | -56 | 103 |
| | Site 2: 11.6–15.6 | ~ • | | | -66 | -194 | 62 |
| | Site 2: 15.7–22.1 | - | i | > | 69 | -61 | 199 |
| Rivera-Nuñez and Wright 2013 | >5–21 | | + | | -1 | -7 | 5 |
| | >21–36 | | - - - | | -9 | -15 | -2 |
| | >36–52 | | - | | -13 | -19 | -7 |
| | >52 | | <u>→</u> | | -15 | -21 | -8 |
| Wright et al. 2004 | >26–63 | | - | | -14 | -19 | -9 |
| | >63–135 | | | | -18 | -26 | -10 |
| | | −75 | l 0 | 75 | | | |

¹ Summerhayes et al. 2012. Water concentration values represent inter-quartile range increase in exposure during the entire pregnancy. Exposure level values for other timeframes of exposure did not vary from these values by more than ~2 µg/L.

² Hoffman et al. 2008 analyzed CHL exposure at two sites. Site 1 consisted predominantly of chlorinated disinfection by-products (DBPs). Site 2 consisted predominantly of brominated DBPs.



Figure 8. Birth Weight (BW). Forest plot of the association between chloroform (CHL) exposure [water concentration] and BW (cont'd). Confidence intervals (95%) are denoted by "Cl."

| Study (Year) | CHL Water Concentration (µg/L | .) · | | | | | Odds Ratio ¹ | Lower Cl | Upper Cl |
|------------------|----------------------------------|---------------------------|----------|-----|----------|-----|----------------------------|-------------|-------------|
| | | | | | | | | | |
| Zhou et al. 2010 | 2 nd quartile | 3 rd trimester | | - | | | 1.37 | 0.99 | 1.88 |
| | 3 [⊯] quartile | | | | | > | 1.67 | 0.98 | 2.85 |
| | 4 th quartile | | | · · | | | 1.82 | 1.10 | 3.02 |
| | 2 nd quartile | Entire Pregnancy | · . | - | <u>_</u> | | 0.96 | 0.60 | 1.53 |
| | 3 rd quartile | | | | | | 1.45 | 0.88 | 2.40 |
| | 4 th quartile | | | | | | 1.64 | 0.90 | 3.00 |
| | | | | | | | | | |
| | | | <u> </u> | - | | | | | |
| | | | 0.25 | 1 | 1.75 | 2.5 | | | |

¹Above versus below the median.

Figure 9. Birth Weight (BW). Forest plot of the association between chloroform (CHL) exposure [estimated internal dose] and BW. Confidence intervals (95%) are denoted by "CI." Studies are ordered based on the lowest value of each study's highest exposure category. Results represent third trimester exposure.

| Study (Year) | CHL Estimated Internal Dose (μg/d) | | | | | | | Change in BW (g) | Lower Cl | Upper Cl |
|------------------------------|---|-----------------|---|---|----------|---|----------------|---------------------|-------------|-------------|
| Villanueva et al. 2011* | 10% increase in total residential uptake ¹ | | | | • | | | -0.07 | -1.00 | 0.85 |
| Grazuleviciene et al. 2011‡‡ | Continuous (0.1 µg/d) | ← | • | | | | | -57.8 | -111.6 | -4.0 |
| Savitz et al. 2005† | >0–≤0.2 | | | | ÷ • | | \rightarrow | 10 | -58 | 78 |
| | >0.2–≤0.8 | - | | | •i | | _ | -4 | -72 | 63 |
| | >0.8–≤1.3 | | | | 1 | • | \rightarrow | 37 | -31 | 105 |
| | >1.3 | | | - | ! | • | \rightarrow | 32 | -36 | 100 |
| Smith et al. 2015 | Total: ≥0.91–<1.56 | | - | • | <u>+</u> | | | -14.8 | -37.7 | 8.1 |
| | Total: ≥1.56 | | | | <u>i</u> | | | -8.7 | -31.8 | 14.3 |
| | Pakistani Origin: ≥0.91–<1.56 | | | | +• | | | 5.1 | -27.1 | 37.4 |
| | Pakistani Origin: ≥1.56 | ← | • | | 1 | | | -42.8 | -78.2 | -7.4 |
| | White British: ≥0.91–<1.56 | _ | | • | <u>+</u> | | | -27.0 | -66.1 | 12.1 |
| | White British: ≥1.56 | | | | | | | 9.5 | -26.8 | 45.8 |
| | | | | | - | | | | | |
| | | -75 | | | 0 | | 75 | | | |

¹ The β -coefficient (g) from the regression model was multiplied by the logarithm of 1.1 to derive an effect estimate for a 10% increase in exposure.

Studv/ Outcomes Covariates/ Study Desian/ Exposure Exposure Results Comments Confounders Location Sample sizes of Interest Measurement Methods Dosages Botton et al.* Prospective Postnatal Water Sampling: All the following Beta coefficients (95% CI) Models adj for: THM conc in the woman's Residential THM conc of postnatal weight gain (0cohort weight CHL values were residence during pregnancy 2015 growth were collected through approximated from 6 months) for an entire Cohort ranged from median value of 1 (from 2 mothersampling campaigns of a figure in the pregnancy IQR increase of Maternal age $\mu g/L$ in Crete to 117 $\mu g/L$ in Sabadell child cohort 4 measures tap water, and from total integrated CHL uptake Spain (3 study publication Gender sites) and studies of weight selected public buildings $(\mu q/d)$: Gestational age Greece between for all study areas and CHL water conc Parity Exp data included extensive Hospital delivery and regulatory monitoring $(\mu g/L)$: - through all routes for all Maternal predetailed water use collected sites = -9.30 (-87.3, 68.7) data in Sabadell cohort recruitment 1 vear of pregnancy prospectively (e.g. water at week 10-13 Median = weight source, filter use, exp at work, age Number of THM Gipuzkoa ~12 - through ingestion for all Paternal weight showering/bathing, swimming, of pregnancy samples: Sabedell ~20 sites = -40.3(-122, 41)Paternal height etc.) Valencia ~0 2003-2008 Gipuzkoa = 421 Maternal Sabadell = 198- through ingestion for education Data came from a large cohort Valencia = 162specific sites study providing wide variability n = 2.216 term Range = Maternal births Crete = 72Gipuzkoa ~0-20 Gipuzkoa = smoking during in exp (mother-child Sabadell ~0-40 9.63 (-174, 193) pregnancy Data collected almost Valencia ~0-50 Sabadell = Examined residential mobility pairs) -151 (-288, -15) every month in Gipuzkoa Other covariates only 5% of mothers reported a Valencia and Sabadell, 3 time Crete - CHL levels considered: change in residence during Valencia = 36.7 (-87, 160) pregnancy (between week 12 2003-2005 points in Valencia, and 4 were mostly n = 594time points in Crete undetected and Breastfeeding and week 32) excluded from CHL Respiratory Sabadell Exposure Measure: infection before Excluded population was not analysis 2004-2006 THM conc were 6 months significantly different from the n = 473determined at residence Total integrated Bathing and final population in terms of exp, for all months of CHL uptake showering in the outcome, and potential Gipuzkoa through all routes first months of confounders pregnancy 2006-2008 $(\mu g/d)$: life n = 407Interviews and Formula water Percent of women remaining after exclusion for missing data questionnaires were Range = type Crete collected at different time Gipuzkoa ~0-0.5 was Gipuzkoa (67%), Sabadell 2007-2008 Sabadell ~0-1.4 (76%), Valencia (75%) points for the different n = 742locations ranging from Valencia ~0-2.1 <12 weeks destation to Tap water consumption varied the 3rd trimester across sites, but overall few women consumed tap water Information included: during pregnancy water type (municipal/bottled/private Data collection differed for all well); home and away study sites from home water use; cooking water use: filter There was a lack of information use (assumed 90% on postnatal THM exp; reduction in THM): however, excluding infants ACGIH TLV DART Chemical 36 **OEHHA** for Reconsideration: Chloroform August 2016

Table 3a. Detailed Summaries for Human Studies of Chloroform (CHL) Exposure and Reproductive Outcomes: Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW).

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---|---------------------|---------|----------------------------|--|
| | | | frequency and duration of showering and bathing; swimming pool use; and water-based fluid consumption | | | | consuming formula with tap water, or adjusting for bathing/showering only marginally changed the results seen for Sabadell |
| | | | Residential THM conc and uptake through ingestion, showering, and | | | | Other DBP analyzed: TTHM and BrTHM |
| | | | bathing during the whole pregnancy were calculated | | | | Beta coefficients (95% CI) of postnatal weight gain (0–6 months) for an IQR increase of THM and BrTHM ingestion in |
| | | | Estimated THM blood conc was determined | | | | Sabadell (µg/d): |
| | | | using the product of residential THM conc, daily personal water use | | | | BrTHM = -146 (-280, -12.3) |
| | | | and uptake factors | | | | Results were similar for TTHMs and BrTHM |
| | | | | | | | |

| • | | | | | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | |
|---------------------------------|--|-------------------------|--|--|---|--|---|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| Smith et al. 2015 England | Prospective birth cohort 2007–2010 N = 11,928 Singleton births BW n = 7,438 term births (after exclusions including: PTB (531); missing data, including water use data (2,100); THM levels (98); covariate data) | BW | Water Sampling: Routine monitoring of THM (2006–2011) Sampling occurred 9 times per year on average, for each of the water supply zones Exposure Measure: Average individual and total THM conc were estimated by trimester as a time-weighted mean of the months for that trimester Baseline questionnaire on water consumption and activities completed via interview with study administrator included: typical daily consumption of tap water, bottled water, tea, coffee, etc. at home, work/study or elsewhere water filtering at home and work time spent showering, bathing and swimming | Time-weighted average CHL water conc (µg/L): Mean (SD) for the entire pregnancy = 37.8 (3.8) Total integrated CHL uptake (µg/d): Mean (SD) for the entire pregnancy: = 1.61 (1.46) Tertiles of total integrated CHL uptake (µg/d) for the entire pregnancy: 1) <0.91 2) \geq 0.91-<1.56 3) \geq 1.56 | Mean difference in term BW (g) (95% Cl) for total integrated CHL uptake for the entire pregnancy (μ g/d) (Supplemental material Table S4): Total population: 1) referent 2) -16.3 (-39, 6.5) 3) -20.9 (-44.6, 2.8) Pakistani origin: 1) referent 2) 10.3 (-21.2, 41.9) 3) -48.3 (-84.6, -12.1) p-value for trend = 0.025 White British: 1) referent 2) -13.3 (-52.9, 26.3) 3) 9.0 (-23.5, 46.5) p-value for interaction = 0.011 Mean difference in term BW (g) (95% Cl) for total integrated CHL uptake during the 3 rd trimester (μ g/d): | Models adj for: Caffeine intake Education Fasting and post load glucose Ethnicity Smoking Parity Age Body Mass Index (BMI) Index of Multiple Deprivation Gestational age at delivery Infant sex | Integrated uptake for CHL accounted for 86% of the integrated TTHM uptake Compared to White British women, women of Pakistaniorigin drink less water from all sources combined, spend less time bathing but more time showering, and very few went swimming (2% Pakistani-origin vs 14% White British) Longer bathing duration was associated with BW reductions for Pakistani-origin, but not White British Cold tap water consumption was associated with increased BW for Pakistani-origin infants only Exp data included extensive detailed water use collected prospectively (e.g. water source; filter use, exp at work, showering/bathing, swimming, etc.) Other DBP analyzed include: TTHM, BrTHM, BDCM, HAA3 (BDCAA, TCAA, and DCAA), BDCAA, DBP7(sum of TTHM and BDCAA, TCAA, and DCAA) TBM was not modeled individually as it had many data points below the limit of detection (LOD) HAA samples were collected quarterly from the 8 water supply zones from 2007 to |
| | fo | r Reconsider | ation: Chloroform | | | August 2016 | |
| | | | | | | | |

Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW) (cont'd). Study/ Study Design/ Outcomes Exposure Exposure Results Covariates/ Comments Sample sizes Measurement Methods Location of Interest Dosages Confounders 2010 Total population: Only 3 HAAs had sufficient 1) referent detectable data points (DCAA, 2) -14.8 (-37.7, 8.1) TCAA, BDCAA) 3)-8.7 (-31.8, 14.3) There was no evidence of an Pakistani origin: association between BW and 1) referent ingestion of HAAs alone, or combined with THMs and 2) 5.1 (-27.1, 37.4) 3) -42.8 (-78.2, -7.4) HAAs, via drinking water consumption p-value for trend = 0.035 p-value for interaction = OR (95% CI) by tertile of total 0.023 integrated BrTHM uptake $(\mu g/d)$: White British: 1) referent Entire pregnancy 2) -27.0 (-66.1, 12.1) Pakistani origin 3) 9.5 (-26.8, 45.8) 1) referent 2) -6.5 (-38.0, 25.0) 3) -56.4 (-93.1, -19.6) 1st trimester Total population 1) referent 2) -24.5 (-47.3, -1.7) 3) -21.6 (-45.7, 2.5) Pakistani origin 1) referent 2) -19.1 (-50.5, 12.3) 3) -51.7 (-88.8, -14.5) 2nd trimester Pakistani origin 1) referent 2) 0.4 (-31.3, 32.1) 3) -56.3 (-92.7, -19.9) 3rd trimester Pakistani origin 1) referent 2) -7.5 (-39.0, 24.1)

Table 3a. Detailed Summaries for Epidemiologic Studies of Chloroform (CHL) Exposure and Reproductive Outcomes: Preterm

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---------|----------------------------|---|
| | | | | | | | 3) -52.8 (-89.3, -16.3) |
| | | | | | | | OR (95% CI) by tertile of total integrated BDCM uptake (μg/d): |
| | | | | | | | Entire pregnancy Pakistani origin 1) referent 2) -11.5 (-43.3, 20.2) 3) -49.8 (-86.3, -13.4) |
| | | | | | | | <u>1st trimester</u> Pakistani origin 1) referent 2) -8.6 (-40.6, 23.4) 3) -44.1 (-80.5, -7.7) |
| | | | | | | | 2 nd trimester Pakistani origin 1) referent 2) 6.5 (-25.8, 38.8) 3) -60.8 (-96.5, -25.1) |
| | | | | | | | <u>3rd trimester</u> Pakistani origin 1) referent 2) -1.2 (-33.2, 30.9) 3) -48.7 (-84.8, -12.5) |

| • | | | | • • • | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | |
|--------------------|-------------------------------|-------------------------|---|----------------------------------|---|---|--|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| lszatt et al. | Retrospective | LBW | Water Sampling: | CHL water conc | | Unadjusted rates | TTHM change was strongly |
| | cohort | (<2,500g) | Routine THM monitoring | (µg/L): | | presented, as | correlated with CHL change (r |
| 2014 | | | of public water supply: | | | infant sex, parity, | = 0.99) |
| | Birth and SB | Very LBW | - at geographically | | | and maternal age | |
| England | records | (<1500 g) | random samples - a minimum of 4 times | Mean (SD) = | | were found not to affect the rates | The background mean TTHM conc decrease was 15.1 µg/L |
| | Two sample | (SB | per year | Before (2000–2002) | | | in non-EC water zones; with a |
| | periods: | outcomes | | 38.6 (4.2) | | | statistically significant greater |
| | 2000–2002 | reported in | Two time periods for | After (2005–2007) | | | mean decrease of 30.5 μg/L in |
| | and 2005– | Table 4a) | water sampling: 3-year | 19.4 (1.0) | | | EC water zones |
| | 2007 | | period before and 3-year period after EC | CHL distribution | | | Overall statistically significant |
| | Intervention | | intervention | change (µg/L): | | | reduction in conc of TTHM, |
| | component - | | | onango (µg/=). | | | CHL, BrTHM, DBCM |
| | enhanced | | Exposure Measure: | Mean (SD) = | | | |
| | coagulation | | Postcode of maternal | Overall | | | Change in average CHL |
| | water | | residence at birth was | -19.2 (17.6) | Percent change (95% CI) | | accounted for 94% of the |
| | treatment (EC) | | linked to water zone | No EC | for rates before and after | | change in TTHM after EC |
| | (a process that | | boundary in use during | -14.0 (17.4) | EC (calculated as the | | (calculated from Table 1 in the |
| | improves | | the year of birth | EC | exponential of the | | publication) |
| | removal of DBP | | Births in the first 6 weeks | -29.2 (13.2) | regression coefficient (i.e., rate ratio of after/before) | | Of the BrTHM, the mean |
| | precursors, | | of the year were linked to | Categories for | minus 1 and multiplied by | | change in conc with EC was |
| | reducing DBP | | the water zone boundary | changes in CHL | 100) (for the entire | | only significant for BDCM |
| | formation | | of the preceding year | water conc (based | pregnancy)): | | (borderline $p = 0.05$) |
| | potential) | | 3,55 | on TTHMs) (µg/L): | 1 - 3 | | () |
| | EC was | | Water zone boundary | | LBW | | Statistically significant |
| | introduced to 4 | | information was linked to | Low increase | 1) -5 (-9, -1) | | difference between categories |
| | water | | THM conc | increases ≤10 to | 2) -5 (-9, -1) | | of change in TTHM conc in EC |
| | treatment | | A | decreases <10 | 3) -9 (-12, -5) | | and non-EC water zones |
| | works (88 of 258 water | | A water zone is a supply area with approximately | 2) Medium decrease– | VLBW * | | No information on individual |
| | zones) in | | uniform water quality, | decreases 10 to | <u>VLBW</u> 1) -7 (-17, 3) | | water use or water |
| | 2003–2004 | | with a population | <30 | 2) 4 (-7, 16) | | consumption pattern changes |
| | 2000 2001 | | ≤100,000 | 3) High decrease- | 3) -16 (-24, -8) | | concumption patient changee |
| | N= 472,526 | | , | decreases 30 | -, - , -, | | Other DBP analyzed: TTHM, |
| | (live births) | | Two exp metrics were | to 65 | *significant interaction | | BrTHM, BDCM, DBCM, TBM |
| | | | constructed for each | | between before/after EC | | |
| | LBW | | water zone – | | and CHL change p = 0.02 | | Statistically significant changes |
| | n = 27,664 | 1) | | | | | were observed for some of the |
| | | | status | | | | BDCM and DBCM conc, |
| | VLBW n = 4,209 | 2) | conc change for THMs | | | | although there were no significant interactions between |
| | 11 = 4,209 | | | | | | before/after and changes in |
| | | | | | | | |

BW (≥2,500 g)

ACGIH TLV DART Chemical for Reconsideration: Chloroform

OEHHA August 2016 conc (Supplemental material

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---------|----------------------------|---|
| | n = 401,040 | | | | | | Data 4 and 5) |
| | | | | | | | LBW Percent change (95% Cl) for rates before and after EC: BDCM 1) -3 (-8, 2) 2) -8 (-12, -5) 3) -7 (-11, -4) DBCM 1) -7 (-10, -3) 2) -9 (-14, -5) 3) -5 (-9, -1) <u>VLBW</u> Percent change (95% Cl) for rates before and after EC: BDCM |
| | | | | | | | 1) -12 (-22, 0) 2) -10 (-18, -1) |
| | | | | | | | 3) -3 (-12, 8) |
| | | | | | | | DBCM 1) -9 (-17, -1) 2) -13 (-23, -1) 3) -2 (-12, 9) |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|----------------------------|--|-------------------------|--|--|--|------------------------------------|---|
| Rivera-Nuñez and Wright | "Retrospective cohort study with a semi- | PTB SGA | <u>Water Sampling:</u> 276 public water systems (PWS) | CHL water conc (µg/L): | <u>PTB</u> OR (95% CI) by quintile of 2 nd trimester CHL exp: | Models adj for: Maternal age | Study is an extension of Wright et al., 2004 which included births in 1995–1998 |
| 2013 | ecologic study | | Quarterly town DBP | 2 nd trimester | 1) referent | Race/ethnicity | |
| Massachusetts | design" | BW | averages were calculated from all available | Mean = 30.1, Median = 27.0 | 2) 1.00 (0.94, 1.06) 3) 1.08 (1.02, 1.14) | (except in SGA models) | The correlation between CHL and TTHM conc was high |
| | Birth certificate data | | monitoring data collected 1995–2004 | Range = 0–265.9 | 4) 1.06 (0.99, 1.12) 5) 1.00 (0.94, 1.07) | Education Prenatal care | (<i>r</i> = 0.97) |
| | 1996–2004 | | Towns with annual THM | 3 rd trimester Mean = 30.6 | Associations for PTB and | source of payment | Mean CHL was 80.3% of 2 nd and 3 rd trimester mean TTHM |
| | n = 672,120 | | measurements were assigned the same conc | Median = 27.4 Range = 0–265.9 | 1 st trimester CHL exp were comparable to those shown | ZIP code Median | levels (30.1/37.5 and 30.6/38.1 µg/L respectively; Table 2) |
| | (live singleton | | for each quarter | Range = 0-200.9 | above (Supplemental | household | |
| | births) | | Residents of towns using private wells and towns | Quintiles of CHL | material Table 3) | income Marital status | Potential misclassification where annual DBP |
| | PTB n = 37,136 | | that did not disinfect were assigned DBP exp of 0 | water exp (µg/L) 3 rd trimester: | <u>SGA</u> OR (95% CI) by quintile of | Water source Disinfection | measurements were assigned the same conc for each quarter |
| | (5.7%) | | (births n = 72,180) | 1) ≤5 | 3 rd trimester CHL exp: 1) referent | TTHM/HAA5 | in towns where only annual measurements were made |
| | SGA | | (Supplemental material) | 2) >5–21 | 2) 1.01 (0.96, 1.05) | conc | |
| | n = 68,409 (11.1%) | | <u>Exposure Measure:</u> Town level exp for 1 st , | 3) >21–36 4) >36–52 | 3) 1.00 (0.95, 1.04) 4) 1.04 (1.00, 1.10) | Other covariates | Other DBP analyzed: THM4, BDCM, BrTHM, HAAs, DBP9 |
| | BW | | 2 nd , and 3 rd trimester | 5) >52 | 5) 1.04 (0.99, 1.09) | considered: | (sum of TCM, BDCM, DBCM, TBM, TCAA, DCAA, MBAA, |
| | n = 477,101 | | Residential zip code at birth was linked to PWS | 1 st and 2 nd trimester (for PTB analyses): | Associations for 2 nd trimester exp were | Smoking Parity | MCAA, and DBAA) |
| | | | To estimate 3 rd trimester | 1) ≤5 2) >5–21 | comparable to those shown above (Supplemental | Prenatal care adequacy | After adjustment for HAA5 (sum of TCAA, DCAA, MBAA, |
| | | | exp for infants born in the 2^{nd} or 3^{rd} month of a | 3) >21–35 | material Table 2) | (Kotelchuck | MCAA, DBAA) and other |
| | | | quarter, DBP quarterly | 4) >35–52 5) >52 | BW | Index) Maternal medical | covariates: - BrTHM was associated with |
| | | | values for the town of residence were used | | Change (g) (95% CI) by quintile of 3 rd trimester CHL | and reproductive health factors | reduced BW (mean BrTHM conc was ~1/5 of mean CHL |
| | | | Births in the 1 st month of a quarter were given | | exp: 1) referent | (e.g. hydramnios | conc) - CHL was no longer |
| | | | DBP levels of the | | 2) -1 (-7, 5) | preeclampsia | associated with a decreased BW |
| | | | previous quarter (Supplemental material; | | 3) -9 (-15, -2) 4) -13 (-19, -7) | pregnancy weight gain) | - CHL association with PTB |
| | | | Wright and Rivera- Nuñez, 2011) | | 5) -15 (-21, -8) | Season | was stronger |
| | | | 2 nd trimester levels were | | | | Sensitivity analyses using unexposed as the referent |
| | | | based on the quarter prior to that used for the | | | | showed a statistically significant decrease in adj BW |
| | | | 3 rd trimester value | 40 | | | associated with TTHM exp |
| | | | ART Chemical ration: Chloroform | 43 | | OEHHA August 2016 | |

| , , | • | | | 0 (), | 0 (| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | |
|--------------------|-------------------------------|-------------------------|--|---------------------|---------|---|--|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| | | | Quarter measurements were an average across all sampling locations Births before 29 weeks were not assigned a 3rd trimester value | | | | (including adjustment for HAA5), as well as a statistically significant increased risk of PTB (Supplemental material Table 6) <u>SGA</u> OR (95% CI) by quintile of 3^{rd} trimester BrTHM exp: 1) referent 2) 1.00 (0.97, 1.04) 3) 1.06 (1.02, 1.10) 4) 1.08 (1.04, 1.12) 5) 1.05 (1.00, 1.09) OR (95% CI) by quintile of 3^{rd} trimester BDCM exp: 1) referent 2) 1.04 (1.00, 1.08) 3) 1.08 (1.03, 1.12) 4) 1.09 (1.04, 1.14) 5) 1.09 (1.04, 1.13) <u>BW</u> Change (g) (95% CI) by quintile of 3^{rd} trimester BrTHM exp: 1) referent 2) -10 (-16, -4) 3) -17 (-21, -8) 4) -19 (-26, -14) 5) -13 (-22, -10) Change (g) (95% CI) by quintile of 3^{rd} trimester BDCM exp: 1) referent 2) -11 (-17, -5) 3) -14 (-21, -8) 4) -20 (-26, -14) 5) -16 (-22, -10) |

| | | | • • • | • • • | • • | , , | |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---------|----------------------------|---|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| | | | | | | | Change (g) (95% Cl) by quintile of 3 rd trimester DBP9 exp: 1) referent 2) -39 (-62, -18) 3) -42 (-64, -19) 4) -45 (-68, -22) 5) -39 (-62, -16) Significant findings were observed for some HAAs |
| | | | | | | | |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|---------------------------------|--|--|---|---|---|--|---|
| Costet et al. 2012 France | Prospective birth cohort Medical records 2002–2006 N = 3,421 n = 3,226 (live singleton births) PTB n = 105 SGA n = 171 | PTB SGA (as Fetal Growth Restriction*) * defined as BW <5 th percentile of the cohort's expected BW distribution | Water Sampling: THM conc taken from database of water distribution networks Routine monitoring of THMs began in 2004 Sampling frequency based on population size 258 of 369 networks recorded at least 1 THM measurement in 2002– 2006 2,847 women had THM measurements: - 68.1% had at least 1 annual measurement - 41.1% had at least 2 annual measurements - 19.1% had monthly measurements Hierarchical models were used to impute missing monthly levels Separate models used for each water source (groundwater, surface, mixed) Exposure Measure: Average THM levels were estimated by trimester as a time weighted mean of the months for that trimester | CHL water conc (μ g/L): Mean (SD) All sites = 9.3 (7.0) Quartiles of CHL water conc (μ g/L): 1) <5 2) 5-<10 3) 10-<15 4) ≥15 Quartiles of total integrated CHL uptake (μ g/d): 1) <0.068 2) 0.068-<0.133 3) 0.133-<0.237 4) ≥0.237 | PTB OR (95% CI) by quartile of 3^{rd} trimester CHL water conc (µg/L): 1) referent 2) 0.7 (0.4, 1.2) 3) 0.5 (0.3, 0.9) 4) 0.8 (0.4, 1.4) OR (95% CI) by quartile of 3^{rd} trimester total integrated CHL uptake (µg/d): 1) referent 2) 1.8 (0.7, 4.8) 3) 0.7 (0.2, 2.1) 4) 1.0 (0.4, 2.9) SGA OR (95% CI) by quartile of 3^{rd} trimester CHL water conc (µg/L): 1) referent 2) 0.8 (0.5, 1.2) 3) 1.0 (0.6, 1.5) 4) 0.9 (0.5, 1.4) OR (95% CI) by quartile of 3^{rd} trimester total integrated CHL uptake (µg/d): 1) referent 2) 0.8 (0.5, 1.2) 3) 1.0 (0.6, 2.1) | Models adj for: Parity Marital status Diabetes before and during pregnancy Hypertension before or during pregnancy Tobacco use Alcohol consumption Other covariates considered: Obstetric history Educational level Dietary habits | Average composition of TTHMs (%): CHL - 22 BDCM - 25 DBCM - 33 TBM - 20 Estimated participation rate = 80% 99.4% were followed through the end of pregnancy CHL conc (µg/L): mean (SD) and % of water distribution networks in: ground water 3.8 (3.2), 19.3; surface water 12.5 (6.5), 47.9; mixed water 8.0 (6.8), 32.8 Exp data included extensive detailed water use collected prospectively (e.g. bottled water, hot beverages, showering /bathing, swimming, etc.) Ingestion levels were only measured at the beginning of pregnancy; however, sensitivity analysis simulating a 25% increase in tap water consumption between the 1 st and 2 nd trimester did not significantly affect the results Info on showering, bathing, and swimming was only available for 1,505 subjects at 2 year follow-up |
| | | | Self-administered questionnaires: Taken in early pregnancy RT Chemical ration: Chloroform | 46 | | OEHHA August 2016 | No information on exp at work was included; however, 82% of mothers reported drinking bottled water at work |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|--|---------------------|---------|----------------------------|---|
| | | | Daily water intake, percent of bottled water | | | | A large proportion of women had only 1 annual THM measurement |
| | | | Total integrated uptake: exp estimated using inhalation, ingestion, | | | | Other DBP analyzed: BDCM, TBM, DBCM, TTHM |
| | | | dermal absorption (including showering/bathing, | | | | <u>SGA</u> OR (95% CI) by quartile of 1 st trimester total integrated DBCM |
| | | | swimming) | | | | uptake (µg/d): 1) referent |
| | | | Coefficient factor of 0.3 used for hot beverages | | | | 2) 1.7 (0.8, 3.7) 3) 2.4 (1.1, 5.1) |
| | | | Length and frequency of shower/bath/swimming collected at 2 year follow- up | | | | 4) 1.3 (0.6, 3.0) |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---|---------------------|--|----------------------------|--|
| | • • | | Measurement Methods Water Sampling: 4 treatment plants: all groundwater sources, each sampled at 3 distances from each plant (near the plant, at 5 and ≥10 km), 4 times/year for 3 years (85 samples in total) Mean quarterly conc was calculated for each plant Exposure Measure: Used geocoded maternal address at birth to determine CHL exp conc Average level was calculated for entire pregnancy and each trimester Internal dose (uptake): (inhalation, ingestion and dermal absorption) was calculated from algorithms using interview data (collected prospectively for most of the women - ~76%, 24% within the 1 st month of delivery) on trimester-specific water consumption including: - size and number of glasses of tap water per day (including cold and boiled water), use of | - | ORs (95% CI) for 3^{rd} trimester CHL above vs below the median internal dose (µg/d): <u>SGA</u> 1.31 (0.82, 2.08) <u>LBW</u> 1.45 (0.67, 3.13) Maternal Polymorphisms: <u>SGA</u> Specific for GSTM1-1 0.88 (0.44, 1.78) Specific for GSTM1-0 1.74 (0.89, 3.41) Specific for GSTT1-1 1.18 (0.71, 1.97) Specific for GSTT1-0 1.75 (0.50, 6.10) <u>LBW</u> Specific for GSTM1-1 0.35 (0.10, 1.28) Specific for GSTM1-0 5.06 (1.50, 17.05) Specific for GSTT1-1 1.35 (0.57, 3.20) Specific for GSTT1-0 7.30 (0.14, 391) (ORs specific for GSTM1-0 were also significant for the entire pregnancy) GSTM1 gene interaction was significant for the | | Individual THMs were highly correlated (r = 0.91–0.99) CHL accounted for ~80% of the TTHMs Exp data included extensive detailed water use collected prospectively (included filter use, exp at work, hot beverages, showering/ bathing, swimming, etc.) Considered genotype for 2 relevant genes Accounted for residential mobility by restricting analysis to women who did not change residence during pregnancy Small sample size Low prevalence of GSTT1-0 genotype = 16.4% Prevalence of GSTM1-0 = 48.7% Authors report results are preliminary and require confirmation in a larger sample with greater contrast in THM conc and internal doses Halogenated DBPs (9 HAAs, 2 haloketones, chloropricrin, chloral hydrate and MX) were measured but not included in the analysis since they were present only in low or sub µg/L, |
| | | | glasses of tap water per day (including cold and boiled water), use of bottled water at home, at | | GSTM1 gene interaction was significant for the entire pregnancy and each | | measured but not included in the analysis since they were |
| | | | bottled water at home, at work,other - number and average length of showers and baths, swimming | | entire pregnancy and each specific trimester: <u>3rd trimester interaction</u> : 15.86 (2.75, 91.40) | | if detected at all Other DBP analyzed include: TTHM, BDCM, DBCM |
| | | | pool visits RT Chemical ation: Chloroform | 48 | | OEHHA August 2016 | |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|--|---------------------|---------|----------------------------|--|
| | | | Estimated uptake factors were used for ingestion (including heated water), inhalation and dermal exp | | | | <u>SGA</u> OR (95% CI) for 1 st trimester DBCM above vs below the median internal dose (μg/d): 2.19 (1.20, 3.99) |
| | | | Glutathione S- transferase mu 1 (GSTM1) and glutathione S-transferase theta 1 (GSTT1)-null genotypes were identified by multiplex polymerase | | | | OR (95% Cl) for 3 rd trimester DBCM above vs. below the median internal dose (µg/d): <i>Specific for GSTT1-1</i> 1.89 (1.01, 3.54) <i>Specific for GSTT1-0</i> 1.04 (0.31, 3.53) |
| | | | chair reaction (PCR) (null genotypes = GSTM1-0 and GSTT1-0) | | | | LBW ORs (95% CI) for BDCM above vs below the median internal uptake (µg/d): |
| | | | | | | | Specific for GSTM1 gene Entire pregnancy interaction: 5.16 (1.01, 26.52) |
| | | | | | | | <u>3rd trimester interaction:</u> 5.29 (1.03, 27.15) |

| Study/ Study Design/ Location Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--|--|---|--|---|---|---|
| Levallois et al. Population based case- | SGA | Water Sampling: 16 water systems: 9 | CHL water conc (µg/L): | | Models adj for: | CHL was highly correlated with TTHM ($r = 0.99$) |
| 2012 control Quebec City, Birth certificate | (births <u>></u> 37 weeks, sex-specific | surface water sources, 7 groundwater sources | Mean (SD): | | Maternal age Calendar week Highest | Using multiple routes of exp assessment and modeling did |
| Canada database | 10 th percentile | Sampled 46 sites monthly for 4 THMs and | cases = 43.3 (40.7) | | education level obtained | not result in higher ORs as compared with exp using water |
| 2006–2008 cases | as per Canadian standards of | 9 HAAs in the 9 surface water systems, and 7 sites in the 7 | controls = 41.1 (39.2) | | Annual household income | conc High participation rate (cases = |
| n = 571 (singleton | BW for gestational | groundwater systems | Quartiles of CHL water conc (µg/L): | OR (95% CI) by quartile of 3 rd trimester CHL water | Pre-pregnancy BMI | 91%, controls = 93%) |
| births - 111 of which were LBW) | age) | Systems were divided into subsystems with at least 1 sampling site in | 1) <15.96 2) 15.96–27.26 | conc (μg/L): 1) referent 2) 0.9 (0.7, 1.3) | Parity History of LBW Maternal | Exp data included extensive detailed water use (e.g. hot beverages, bottled water, filter |
| controls | | each subsystem | 3) 27.27–51.07 4) >51.07 | 3) 1.0 (0.8, 1.4) 4) 1.2 (0.9, 1.7) | smoking during | use, showering/bathing, etc.) |
| n = 1925 | | Considered spatial and temporal factors in estimation of tap water | Quartiles of CHL uptake (µg/d): | OR (95% CI) by quartile of 3 rd trimester integrated | pregnancy Passive smoking at home | Extensive monthly sampling scheme allowing consideration of spatial and temporal |
| | | exp (using closest sampling site in the subsystem and sampled | | CHL uptake by route of exp (µg/d): | Coffee consumption Alcohol | variability Validation study (n = 115) was |
| | | closest to specific trimester being studied) | Ingestion: 1) | Ingestion: 1) referent | consumption History of chronic | conducted for spatial assignmen≿of THM values to a |
| | | Exposure Measure: Internal dose: | 1.72 2) .72–11.88 | 2) 1.2 (0.9, 1.6) 3) 1.1 (0.8, 1.5) 4) 1.3 (1.0, 1.8) | disease Preeclampsia | residence Authors re p orted no significant difference was found between |
| | | ingestion, inhalation, and dermal absorption, calculated from | 3) 1.89–34.30 | p-trend = 0.10 | Other covariates considered: | measurements of TTHMs or HAA9 in the particpants' tap |
| | | interview info including: | 4) 34.30 | Total Pathway: 1) referent 2) 0.9 (0.7, 1.2) 2) 4 (0.7, 1.2) | Maternal ethnicity | water and estimated values using the study's sampling strategy |
| | | - volume and # of glasses of tap water per day, hot and cold | Total Pathway: 1) | 3) 1.0 (0.7, 1.3) 4) 1.0 (0.8, 1.4) p-trend = 0.67 | Working status Marital Status Medical problem | Pharmacokinetic models were used in expcassessment |
| | | beverages, bottled water - water handling | 42.24 2) 2.24–80.21 | Results for quartiles of CHL inhalation/dermal exp were | during pregnancy Risky | Interviews 4 vere conducted a median of \sim 9 weeks after birth |
| | | (filtering, boiling, storage in fridge) -frequency and duration of showering and | 3) 0.22–169.81 4) 169.81 | reported but had no significant results | occupational exp | 8 Other DBP analyzed: BDCM, BrTHM, TTHM, DCAA, TCAA, THAA |
| Λ/ | | bathing) | 50 | | ОЕННА | Significant findings were observed for some HAAs |



| | | | 5 ()/ | 5 ()/ | 5 (| ,, , | |
|--|--|-------------------------|---|--|--|---|--|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| Summerhayes et al. | Retrospective cohort | SGA | <u>Water sampling:</u> Sydney/Illawarra water | CHL water conc (µg/L): | <u>SGA</u> | Models adj for: | 68% of zone/month values were missing |
| 2012 New South Wales, Australia | Birth records linked to birth defects registry 1998–2004 N = 362,013 (live singleton births) | BW | utility has a 3-level hierarchical structure with 14 delivery systems containing 33 distribution systems and 180 water supply zones Monthly THM monitoring rotated through 3–6 sites in each distribution | Mean (SD) = 33.6 (16.0) Median = 30.9 Range = 3.4 – 121.5 (Supplemental material) | RR (95% CI) for an IQR increase in 3 rd trimester CHL exp in water (25 μg/L): 1.04 (1.02, 1.06) Similar associations were reported for the entire pregnancy RR (95% CI) for the 5 th and | Maternal age Indigenous status Maternal country of birth Infant's gender Smoking anytime during pregnancy Parity | CHL was correlated with BDCM ($r = 0.90$) DBCM ($r = 0.27$) Calculation of distribution- system-level exp used average w/in zones (68% of zone/month were missing), then average across zones, etc. |
| | n = 314,982 (excluded infants with BD, SB, multiple births, data, | | system on a 3–6 month cycle THM exp was assigned at the distribution system level | Analyzed by each trimester and entire pregnancy | 10 th deciles of CHL water exp in the 3 rd trimester (μ g/L): 5 th decile = 1.01 (0.96, 1.07) 10 th decile = | Hypertension Maternal diabetes Preeclampsia Gestational diabetes Antenatal visit | THM exp was higher in women living in areas supplied by chlorinated water vs chloraminated water (86% of women) |
| | gestational age <22 or > 43 weeks, births with a BW >5 SDs of the average for | | THM data were averaged w/in each zone (68% of values were missing), then across zones w/in a distribution system (13% of values were missing) | | 1.12 (1.05, 1.18) Larger associations were seen for SGA <3 rd percentile | Year of birth Season of birth Area-based measure of mother's socioeconomic | The association between CHL and SGA was larger for nonsmokers Large sample size |
| | gestational age, or with missing BW or gestational age data, etc.) | | for a distribution/month THM conc During the study period, 5,341 THM observations were available | | Interaction between THMs and smoking In stratified analysis the association between SGA and 3 rd trimester exp | status (SES) | A two-pollutant model was examined with DBCM (as a dichotomous variable due to the small range of exp conc) and found that the effects of CHL on SGA were independent |
| | SGA n = 31,813 | | Exposure measure: Maternal residence at time of delivery was | | increased slightly in nonsmokers and was protective in smokers | | of DBCM Sensitivity analyses were conducted to test robustness of |
| | | | geocoded and mapped to distribution systems | | <u>BW</u> (Supplemental material) Linear regression model of change in mean BW (g) | | the results (including influence of disinfection type and potential threshold effects) for the association between THMs and SGA |
| | | | | | (95% CI) with an IQR increase in CHL exp for entire pregnancy (25 μg/L): -5.0 g (-8.6, -1.4) | | Possible misclassification of SES, assigned using an area- based measure at the census |

level (approximately 80-200

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---------|----------------------------|---|
| | | | | | | | households) |
| | | | | | | | Higher proportions of SGA births were seen in mothers from lower SES (13.2%) |
| | | | | | | | Other DBP analyzed, include: TTHM, BDCM, DBCM |
| | | | | | | | Significant association observed for BDCM and SGA |
| | | | | | | | A significant increase in mean BW (g) was seen with an IQR increase in DBCM for the entire pregnancy (2 µg/L): 4 (2, 5) |
| | | | | | | | RR (95% CI) for the 5 th and 10 th deciles of BDCM water exp in the 3 rd trimester (μ g/L): |
| | | | | | | | 5 th decile = 1.04 (0.99, 1.09) |
| | | | | | | | 10 th decile = 1.10 (1.04, 1.16) |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| 0.1. | | • | - | - | | 0 | 0 |
|------------------------------|-------------------------------|-------------------------|--|--------------------------------------|--|-----------------------------|---|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| Grazuleviciene et al. ‡ ‡ | Prospective cohort | SGA | Water Sampling: 4 treatment plants: all | CHL water conc (µg/L) | | Models adj for: | CHL accounted for ~80% of the TTHM |
| | | LBW | groundwater sources, | Mean (SD): | | <u>SGA</u> | |
| 2011 | All pregnant | | each sampled at 3 | | | | Individual THM conc were |
| | women in | BW | distances from each | All sites $= 7.8$ | | Previous preterm | highly correlated ($r = 0.91 -$ |
| Lithuania | Kaunas city | | plant (near the plant, at 5 and ≥10 km), 4 | (10.2) | | delivery Maternal | 0.99) |
| | 2007–2009 | | times/year for 3 years (85 samples in total) | At 3 plants with low THM levels = | | education Marital status | Participation rate = 79% |
| | N = 5,405 | | | 0.9 (1.0) | OR (95% CI) by tertile of | Smoking | Median gestational age at |
| | 0.044 | | Mean quarterly conc was | | 3 rd trimester total integrated | Alcohol | interview = 8 weeks |
| | n = 3,341 | | calculated for each plant | At 1 plant with | CHL uptake: | consumption | Fur data included automative |
| | (excluded multiple | | Exposure Measure: | high THM levels = 17.7 (9.0) | <u>SGA</u> | BMI Maternal age | Exp data included extensive detailed water use collected |
| | pregnancies, | | Used geocoded maternal | = 17.7 (9.0) | 1) Referent | Maternal age Parity | prospectively (included filter |
| | invalid data for | | address at birth to | Internal dose for | 2) 1.19 (0.87, 1.63) | Birth year | use, exp at work, hot |
| | THM exp, | | determine CHL exp conc | CHL (µg/d): | 3) 1.22 (0.89, 1.68) | , <u>,</u> | beverages, showering/ |
| | newborn | | | | | LBW | bathing, swimming, etc.) |
| | >4,500 g, etc.) | | Average level was | Range = 0.0013- | Continuous (0.1 µg/d) | | |
| | 001 | | calculated for entire | 2.1328 | 1.04 (1.00, 1.09) | Gestational age* | Dose response association with |
| | SGA n = 270 | | pregnancy and each | Tertiles: | LBW | (squared) Marital status | significant effect measures |
| | n = 270 | | trimester | 1) 0.0013– | 1) Referent | Maternal | Outcomes also stratified by |
| | LBW | | Internal dose (uptake): | 0.0249 | 2) 2.12 (1.11, 4.02) | education | gender and maternal ethnicity |
| | n = 156 term | | (inhalation, ingestion and | 2) 0.0249– | 3) 2.13 (1.15, 3.92) | Chronic | genuer and material en meny |
| | births | | dermal absorption) was | 0.2868 | , , , , | diseases | 54.9% of the subjects received |
| | | | calculated from | 3) 0.2868– | Continuous (0.1 µg/d): | BMI | water from the plant with |
| | | | algorithms using interview data (collected | 2.1328 | 1.09 (1.01, 1.18) | Blood pressure Smoking | highest THM levels |
| | | | prospectively | | Similar findings were seen | Alcohol | Questionnaire and birth |
| | | | for most of the women - | | for each trimester and the | consumption | certificate data were compared |
| | | | ~76%, 24% within the 1 st month of delivery) on | | entire pregnancy | Previous preterm | for participants and non- participants |
| | | | trimester-specific water | | Change in BW (g) (95%CI) | delivery | Approximated for residential |
| | | | consumption including: - size and number of | | for every 1 µg/d increase in total integrated CHL uptake | Infant gender Birth year | Accounted for residential mobility by restricting analysis |
| | | | glasses of tap water per | | for the 3 rd trimester: | Diffit year | to women who did not change |
| | | | day (including cold and | | -57.8 (-111.6, -4.0) | * Gestational age | residence during pregnancy |
| | | | boiled water), use of | | | was determined | 31 3 3 3 |
| | | | bottled water at home, at | | This was also significant for | by ultrasound | Collected questionnaire info |
| | | | work, other | | the 1 st trimester and the | | repeatedly on 10% of subjects |
| | | | - number and average | | entire pregnancy | | finding no sign difference in |
| | | | length of showers, baths, swimming | | | | water use habits or other covariates |
| | | | pool visits | | | | oovanales |
| | A | | ART Chemical | 53 | | OEHHA | |
| | | | ration: Chloroform | | | August 2016 | |

| | | | U (<i>1</i> | 0 () | | ,, , | |
|--------------------|-------------------------------|-------------------------|---|---------------------|---------|----------------------------|---|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| | | | Estimated uptake factors were used for ingestion (including heated water), inhalation and dermal | | | | Incorporated individual water use info in estimating personal exp and internal dose |
| | | | exp | | | | Low spatial variability of THM levels in all treatment plants |
| | | | | | | | Other DBP analyzed: BDCM, DBCM, TTHM |
| | | | | | | | Significant association between 3 rd trimester DBCM exp and LBW |
| | | | | | | | LBW OR (95% CI) by tertile of 3 rd trimester total integrated DBCM uptake (µg/d): |
| | | | | | | | 1) referent 2) 2.44 (1.05, 5.70) 3) 2.42 (1.03, 5.66) |
| | | | | | | | |

| • | • | | | | | | |
|-----------------------|---|-------------------------|---|----------------------------------|---|---|---|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| Patelarou et al. * | Prospective cohort | PTB | <u>Water Sampling</u> : 18 sampling points (2 | CHL water conc (µg/L): | Exp calculations were limited to the use of 3 | Models adjusted for: | Brominated THMs accounted for >80% of TTHM |
| 2011 | "Rhea" cohort | SGA | points randomly selected from each of 6 urban | Mean (SD): | brominated THMs because CHL levels were very low; | Maternal age | Very low levels of CHL and other THMs |
| Greece | 2007–2008 | LBW | water zones and 1 point in 6 rural areas) | All sampling sites = 0.15 (0.15) | therefore, no results were reported for CHL | at delivery Maternal education | Particpation rate = ~91% |
| | N = 1,760 | | Home tap water was also sampled 4 times (72 | Urban = 0.14 (0.11) | No association was seen between residential and | Smoking Marital status | Estimated exp through multiple routes |
| | n = 1,359 (pregnant women after | | samples in total) Exposure Measure: | Rural = 0.17 (0.20) | total uptake exp with reproductive outcomes for either trimester or average | Greek ethnicity Parity Infant sex | Exp data included extensive water use collected |
| | excluding multiple births, SB, women | | Women assigned a water supply zone by reported address at time of interview | | total pregnancy | Gestational age was included in | prospectively (e.g. filter use, exp at home and work, bottled water use, showering/bathing, |
| | with incomplete questionnaire data, etc.) | | Exp level per month based on individual | | | linear regression models with infant size metrics (weight, | swimming, dishwashing, etc.) Main water source was ground water |
| | PTB n = 156 | | levels of TTHM and BrTHM modeled using generalized additive | | | length, head circumference) | Sampled tap water from individual homes over time |
| | SGA n = 73 LBW | | models of water plant zone and spline of the month of sampling | | | | Assessed temporal variation- THM conc did not differ over 3 years |
| | n = 76 | | Face-to-face, computer- aided questionnaire, collected prospectively, per trimester: - drinking water source; | | | | Assessed spatial variation – THM conc differed significantly by water supply zones and by season |
| | | | tap/bottled/spring water at home and other places - average daily consumption | | | | Prospective study with follow- up data after birth |
| | | | average frequency and duration for showering and bathing swimming pool | | | | Other DBP analyzed: levels of specific THMs were too low to analyze individually |
| | | | attendance - type of water used to cook - use of filter both for | | | | |
| | | | drinking and cooking water | | | | |
| | | | ART Chemical ration: Chloroform | 55 | | OEHHA August 2016 | |

| • | | | 5 ()/ | 5 (| | U (| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | |
|--------------------|-------------------------------|-------------------------|---|---------------------|---------|------------|---|----------|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | | Covariates/ Confounders | Comments |
| | | | - usual method of | | | | | |
| | | | dishwashing (by hand/dishwashing | | | | | |
| | | | machine/both) | | | | | |
| | | | - use of gloves for | | | | | |
| | | | dishwashing by hand - frequency and duration | | | | | |
| | | | of dishwashing per day | | | | | |
| | | | Fluid consumption was | | | | | |
| | | | assessed from interviews | | | | | |
| | | | - during the 3 rd month of | | | | | |
| | | | pregnancy - during the 2 nd trimester | | | | | |
| | | | (food frequency | | | | | |
| | | | questionnaire) | | | | | |
| | | | during the 3rd trimester questions on average | | | | | |
| | | | daily consumption | | | | | |
| | | | Internal dose: | | | | | |
| | | | - exp through ingestion, | | | | | |
| | | | dermal, and inhalation | | | | | |
| | | | by sum of residential THM conc and self- | | | | | |
| | | | reported water use | | | | | |
| | | | from interview | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| | ıdy/ cation | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|----------------|----------------|-------------------------------|-------------------------|--|---|--|--|--|
| Villa al. ' | anueva et * | Prospective cohort | PTB | <u>Water Sampling:</u> THM levels were | Not reported for overall cohort, but | No significant associations between any THM and | Models adj for: | Residential ingestion uptake was very low (11% of total |
| 201 | 1 | 2000–2008 | SGA | sampled from locations determined to be | graphically represented for | PTB, SGA, LBW or BW | <u>PTB</u> SGA covariates | uptake) with most uptake resulting from |
| Spa (5 a | ain areas) | Hospital data | LBW BW | geographically representative of study areas | each area by different uses (e.g. ingestion, | Effect estimates for a 10% increase in 3 rd trimester total integrated CHL uptake | Sex BW | showering/bathing In Granada, 132 women's |
| (| , | N = 5,621 | | THM conc were | showering/bathing) | (µg/d): | <u>SGA</u> Parity | water use during pregnancy was collected retrospectively, |
| | | n = 2,074 live births | | determined from sampling campaigns of tap water and regulatory | Figure 1 in the article indicates median and 75 th | <u>PTB</u> OR (95% CI) = 1.00 (0.99, 1.01) | Maternal height and weight Weight gain | 6–8 years after delivery (final number of women included in the analysis = 84) |
| | | PTB - 3.7% | | monitoring data | percentile of total residential uptake | SGA | Smoking during pregnancy | Exp data included extensive |
| | | SGA - 10.6% LBW - 4.6% | | Number of samples varied between areas (128–421) | of CHL (ingestion + showering/bathing) were well below | OR (95% CI) = 1.00 (0.99, 1.01) | Cohort BW and LBW | detailed water use collected prospectively (e.g. sources of drinking water, filter use, exp at |
| | | LDVV - 4.0 % | | Samples were collected | 1 µg/d for each area | <u>LBW</u> OR (95% CI) = | SGA covariates, Sex | work, showering/bathing, swimming, etc.) |
| | | | | to represent the period between the minimum | Area median THM | 1.00 (0.99, 1.02) | Weeks of gestation (linear | Women who changed |
| | | | | and maximum conception dates of study subjects for each area | levels ranged from 5.9 (Valencia) to 114.7 μg/L | <u>BW</u> β-coefficient (g) (95% CI) = -0.07 (-1.00, 0.85) | and quadratic) Various area | residence between weeks 12 and 32 were excluded from the analyses (5% overall) to |
| | | | | Swimming pools were | (Sabadell, of which >30% was CHL | Results varied by area but | specific results were adj for | minimize exp misclassification |
| | | | | sampled in the municipalities that accounted for ≥70% of | [estimates based on Figure 1]) | none were significant | some of the following variables: | Analyses included models that adj simultaneously for all trimesters with no significant |
| | | | | each cohort | | | Maternal education | results |
| | | | | Exposure Measure: THM conc was assigned to the distribution system | | | Marital status Paternal weight Social class | Misclassification was likely higher for estimated exp from swimming pools as a reduced |
| | | | | of each woman's residence | | | Season of conception | number of samples were measured from selected pools |
| | | | | Interview at 32 weeks - water use during | | | Temporal and geographic variation | and were taken a few years after the pregnancies |
| | | | | pregnancy including: - sources of drinking | | | Variables also | Included extensive questionnaire data on water |
| | | | | water inside and outside the home - use of a home water | | | considered: Maternal age | consumption, however, calculated consumption seems fairly low |
| | | AC | CGIH TLV DA | filter | 57 | | Country of origin (Supplemental OEHHA | |
| | | fo | r Reconsider | ation: Chloroform | | | August 2016 | |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|--|---------------------|---------|---------------------------------|--|
| Location | Sample sizes | of Interest | Measurement Methods - changes in water ingestion in pregnancy - frequency and duration of showering, bathing, and swimming pool use (indoor, outdoor, winter, summer) - tap water ingestion was also ascertained at 12 weeks Integrated Uptake: 12- and 32-week tap water intakes were averaged to compute ingested THMs Estimated daily THM blood conc determined by the product of residential THM levels, daily personal use and uptake factors | Dosages | | Confounders material) | Participation rate was 45%– 98% Other DBP analyzed: BrTHM (BDCM, DBCM, and TBM were measured but not included separately in the analysis) |
| | | | | | | | |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|------------------------------|---|-------------------------|---------------------------------|---|--|---|--|
| Zhou et al. 2010 China | Retrospective cohort Birth records 2008–2009 N =1,385 (Women living in a water supply area of a single large scale water plant, and their term singleton infants) | BW | 2) 3) | CHL water conc (μg/L) Range of mean values (SD) = 6.0 (2.5)–51.2 (36.1) highest levels occurred during the summer Each trimester, 1 st + 2 nd trimester, and the entire pregnancy were analyzed Quartiles of average daily CHL exp: P1–P25 P26–P50 P51–P75 P76–P100 Actual values for quartiles were not presented; however, the study reported CHL exp ranged from 6.53– 41.98 (μg/L) BW exp was categorized as above/below the median | OR (95% Cl) by quartile of CHL exp during the 3^{rd} trimester: 1) referent 2) 1.37 (0.99, 1.88) 3) 1.67 (0.98, 2.85) 4) 1.82 (1.10, 3.02) OR (95% Cl) by quartile of CHL exp during the entire pregnancy: 1) referent 2) 0.96 (0.60, 1.53) 3) 1.45 (0.88, 2.40) 4)1.64 (0.90, 3.00) Other significant findings included OR (95% Cl): - CHL exp during the 1 st trimester in the 2 nd quartile: 1.74 (1.10, 2.77) - CHL exp during the 1 st and 2 nd trimester in the 3 rd quartile: 1.62 (1.05, 2.50) | Models adj for: Total gestation days Gender Mother's age Gravidity Education # of prenatal examinations Birth season Other covariates considered: Occupation Prenatal residence Postpartum residence Time of last menstrual period Parity Illness during pregnancy Term-infant gender Body weight Body length Presence of malformations | Article was translated from Chinese Accounted for residential mobility by limiting participants to those who lived in the area during pregnancy Small sample size Other DBP analyzed include: DBCM, BDCM, TBM, BrTHM, DCAA, TCAA OR (95% CI) by quartile of BrTHM exp during the 3 rd trimester: 1) referent 2) 1.40 (0.99, 1.98) 3) 1.21 (0.81, 1.81) 4) 1.51 (1.05, 2.17) Significant findings were observed for some HAAs |

| Study/ | Study Design/ | Outcomes | Exposure | Exposure | Results | Covariates/ | Comments |
|--------------|------------------------------|-------------|--|---------------------------------------|--|-------------------------|--|
| Location | Sample sizes | of Interest | Measurement Methods | Dosages | | Confounders | |
| Hoffman et | Prospective | SGA | Water sampling | CHL water conc | | Models adj for: | CHL and BDCM were highly |
| al.† | cohort | | 3 sites represented: | (µg/L) | | | correlated at the brominated |
| | | BW | 1- moderate chlorinated | Mean (SD) in 2 nd | | ML models | site $(r = 0.9)$ |
| 2008 | Community | | DBPs (CHL was the | trimester, by site: | | Maternal age | |
| | outreach and | | dominant species) | 1) 46 7 (12 2) | ODe (05% CI) by tertile of | (site 1 only) | CHL conc in the 1 st tertile at |
| US (3 | prenatal clinics | | 2- moderate brominated DBPs | 1) 46.7 (13.3) | ORs (95% CI) by tertile of the 3 rd trimester average | Race/ethnicity | site 1 was similar to or greater than the 3 rd tertile conc at site 2 |
| communities) | 2000–2004 | | 3- low levels of all DBPs | 2) 13.7 (3.3) 3) < reporting limit | residential CHL exp by site: | Income (site 1 only) | than the 3 rd tertile conc at site 2 |
| | 2000-2004 | | 5-10W levels of all DBF 3 | | residential of L exp by site. | Education (site | SGA proportion was higher at |
| | N = 2,766 | | Sites 1 and 2 used | Tertiles of | <u>SGA</u> | 1 only) | the brominated site and mean |
| | (singleton | | chloramination rather | residential CHL | <u></u> | Employment | BW was higher at the |
| | births) | | than free chlorine for | exp (µg/L) in 3 rd | Site 1 | status (site 1 | chlorinated site |
| | , | | termination disinfection | trimester, by site: | Maximum likelihood (ML) | only) | |
| | n = 1,958 | | | - | models (Supplemental | Marital status | Water sampling was done at |
| | (excluded | | Water samples collected | Site 1 | material): | Pre-pregnancy | multiple areas in the distribution |
| | pregnancies: | | weekly from sites 1 and | 1) 19.9–44.2 | 1) referent | BMI (site 1 | system and confirmed to be |
| | incomplete | | 2, and biweekly from site | 2) 44.3–49.0 | 2) 1.4 (0.6, 3.1) | _only) | uniform throughout |
| | interview data; | | 3 at a representative | 3) 49.1–94.0 | 3) 1.1 (0.5, 2.6) | Parity | |
| | lost to follow up | | location within the | Cite 0 | Bayesian models: | Caffeine intake | Used weekly or biweekly |
| | that ended in a loss; <25 or | | distribution system | Site 2 1) 6.4–11.5 | 1) referent 2) 1.9 (0.5, 8.1) | Bayesian models | samples so temporal variability is more likely to be represented |
| | >42 weeks | | DBP conc below the | 2) 11.6–15.6 | 3) 1.7 (0.4, 7.1) | Other DBP | is more likely to be represented |
| | gestation, etc.) | | minimum reporting level | 3) 15.7–22.1 | 0) 111 (011, 111) | species | Use of chloramination results in |
| | geolation, etc.) | | for each analytic method | 0, 1011 | Site 2 | Maternal age, | minimal additional DBP |
| | <u>SGA</u> | | were set to 0 | | ML models: | Race/ethnicity | formation within the distribution |
| | n = 113 | | | | 1) referent | Income | system (sites 1 and 2) thus |
| | | | Exposure measure: | | 2) 4.9 (1.5, 15.8) | Education | minimizing spatial variability |
| | <u>BW</u> | | 2 exp metrics were | | 3) 2.4 (0.7, 8.4) | Employment | |
| | n = 1,854 (term | | considered for TTHM: | | Bayesian models: | status | Exp data included detailed |
| | birth) | | 1) Estimated residential | | 1) referent | Marital status | water use collected |
| | Additional | | tap water conc 2) Estimated integrated | | 2) 4.2 (0.6, 33.7) 3) 3.6 (0.5, 30.1) | Pre-pregnancy BMI | prospectively (included sources of drinking water, filter use, exp |
| | analyses were | | uptake for TTHMs: | | 3) 3.0 (0.3, 30.1) | Parity | at work, showering/bathing, |
| | reported in | | - tap water conc | | BW | Caffeine intake | etc.); however, estimates were |
| | Savitz et al. | | combined with detailed | | | | only presented for TTHM |
| | 2005 | | exp information collected | | Site 1 | | |
| | | | at baseline by phone | | ML models: | | Bayesian models were used to |
| | | | interview (at 16 weeks | | 1) referent | | allow for simultaneous |
| | | | gestation and at follow- | | 2) 26 (-51, 104) | | modeling of highly correlated |
| | | | up between 20–25 | | 3) 24 (-56, 103) | | exp such as other DBPs |
| | | | weeks) | | Bayesian models: | | Authors state that estimates of personal exp did not show |
| | | | ingestion, showering, and bathing were | | 1) referent 2) 58 (-51, 165) | | stronger associations than |
| | | | included | | 3) 49 (-62, 156) | | residential conc |
| | | | - · · · · · · · | | -, (, , | | |
| | AC | GIH TLV DA | RT Chemical | 60 | | OEHHA | |
| | f | . D | attan. Oblansfams | | | A | |

OEHHA August 2016

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|--|----------------------------|--|
| | · | | | | Site 2 ML models: 1) referent 2) -66 (-194, 62) 3) 69 (-61, 199) Bayesian models: 1) referent 2) 64 (-146, 278) 3) 70 (-146, 294) | | Small sample size Research was supported by the American Water Works Association Research Foundation and US EPA Other DBP analyzed include: BDCM, DBCM, TTHM, and |
| | | | | | "Estimates of personal exp to individual DBP species were also examined, and results were similar to those for residential concentrations (results not shown)" | | CAA, DCAA, TCAA, BCAA, BDCAA, DBCAA, BAA, DBAA, TBAA, and HAA5 A significant association was seen between 3rd trimester average residential TTHM exp ≥80 vs < 80 and SGA: RR (95% CI) = 2.0 (1.1, 3.6) Significant findings were observed for some HAAs |

| Study/ | Study Design/ | Outcomes | Exposure | Exposure | Results | Covariates/ | Comments |
|----------------|--------------------------------|-------------|--|---|--|--|---|
| Location | Sample sizes | of Interest | Measurement Methods | Dosages | | Confounders | |
| Lewis et al. ‡ | Population- based case- | PTB | Water Sampling: Abstracted THM data | TTHM water conc (µg/L): | | Models adj for: | CHL contributed 83–93% (average = 89%) of TTHM |
| 2007 | control | | from Massachusetts Department of | Interquartile range= | | Infant sex Marital status | monthly averages |
| Massachusett | data | | Environmental Protection 2003 records for 27 communities receiving | 59 Min–max of range = 28–87 | | Kessner Index (prenatal care adequacy) | CHL was measured; however, effects of exp were only analyzed for TTHM |
| | 1999–2001 N = 39,593 | | water from a single supplier (894 samples) | CHL fraction of TTHM = 83–93% | HR (95% CI) by tertile of | Maternal age Maternal | Exp measures were based on weekly THM samples |
| | (singleton | | Weekly TTHM monitoring | | entire pregnancy TTHM exp: | race/ethnicity Maternal | |
| | births) n = 37,498 | | data from 4 sites based on maternal residence at birth applied | Tertiles of TTHM exp (µg/L): 1) <40 | 1) referent 2) 0.92 (0.82, 1.02) 3) 0.85 (0.74, 0.97) | education Parity Birth interval | Controls were matched to cases by gestational age |
| | (births: excluding | | to 24 out of 27 communities | 2) 40–60 3) <u>></u> 60 | per 10 µg/L: | Maternal | Collected data on multiple covariates |
| | births <35 or >45 weeks | | Exposure Measure: | -, | 0.95 (0.92, 0.99) | Previous PTB or SGA child | Study was able to examine exp |
| | gestation; <500 or >5000 g; | | Exp measures averaged over 1 week to 1 month | | HR (95% CI) by tertile of 2 nd trimester TTHM exp: | Prenatal care source of | over time |
| | missing information; | | TTHM exp consisted of: | | 1) referent 2) 0.87 (0.77, 0.99) | payment Conception | Multiple exp time intervals were used for assessments |
| | etc.) | | maternal residence gestational age | | 3) 0.82 (0.71, 0.94) | season Birth season | Very large and diverse study |
| | <u>PTB</u> n = 2,813 | | environmental sample per gestational period (each trimester and 4, | | Per 10 µg/L: 0.95 (0.92, 0.99) | Community per capita income Previous | population |
| | | | 2, 1 weeks before birth) | | During the last 4 weeks before birth for women with | diseases Previous | |
| | | | Calculated trimester specific and pregnancy average exp | | a government source of payment for prenatal care | trimester TTHM exp | |
| | | | | | 1) referent 2) 1.07 (0.85, 1.34) 3) 1.39 (1.06, 1.81) | | |
| | | | | | Per 10μg/L: 1.03 (0.96, 1.11) | | |
| | | | | | High exp in 2 nd trimester was associated with PTB when stratified by race (African American: HR (95% CI) = 0.62 (0.46 , | | |
| | | | ART Chemical | 62 | 0.84). | OEHHA | |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|------------------------|---|--|--|---|--|---|---|
| Lewis et al. ‡ 2006 | Population- based case- control | LBW (defined as term LBW - | <u>Water Sampling</u> Abstracted data from Massachusetts | TTHM water conc (µg/L): | | Models adj for: Gestational age | CHL contributed to 83–93% of (average = 89%) TTHM monthly average |
| Massachusetts | Birth certificate data | <2500 g and >36 weeks gestation) | Department of Environmental Protection records for 27 | Interquartile range= 59 | | Infant sex Marital status Kessner Index | Seasonal variation with peaks in May–Aug |
| | 1999–2001 | | communities from a single supplier (894 samples) | Min, max of range = 28–87 | | Maternal age race/ethnicity | Exp measures were based on weekly THM samples |
| | N = 40,514 (singleton births) | | 3 communities conducted their own chloramination, | CHL fraction of TTHM = 83–93% | | education Parity Maternal | Unique conditions of water system for exp classification |
| | n = 36,529 (excluding | | 24 received chloramination from a single facility | Quintiles of 2 nd trimester TTHM exp (µg/L): | OR (95% CI) by quintile of 2 nd trimester TTHM exp: | smoking Prenatal care source of | that may reduce non-differential misclassification |
| | births <32 or >45 weeks gestation; <500 | | Weekly average of 4 sampling sites that | 1) <40 2) 40–<50 | 1) referent 2) 1.10 (0.81, 1.49) | payment Conception season | Multiple exp time intervals were used for assessments |
| | or >5000 g; missing information; | | captured nearly all individual site values was used for the single | 3) 50–<60 4) 60–<70 5) <u>></u> 70 | 3) 1.08 (0.79, 1.49) 4) 1.24 (0.92, 1.67) 5) 1.50 (1.07, 2.10) | Birth season Per capita income | Study was able to examine exp over time |
| | etc.) LBW | | average for the 24 communities supplied by the same facility | | Per 10 µg/L increase: 1.08 (1.00, 1.17) | Previous preterm or SGA infant Previous | Did not distinguish between various pathways of exp |
| | n = 780 | | Exposure Measure: Exp measures were | | OR (95% CI) by quintile and race of 2 nd trimester | trimester TTHM exp Maternal disease | |
| | | | averaged over 1 week to 1 month | | TTHM exp: <u>Caucasian:</u> | factors (anemia cardiac disease | |
| | | | TTHM exp estimates were based on: - maternal residence at | | 1) referent 2) 1.11 (0.69, 1.78) 3) 1.10 (0.67, 1.79) | diabetes hydramnios chronic | |
| | | | birth - gestational age - environmental | | 4) 1.22 (0.76, 1.97) 5) 1.37 (0.80, 2.36) | hypertension pregnancy- related | |
| | | | sampling data Exp estimates were | | Per 10 µg/L increase: 1.06 (0.95, 1.20) | hypertension Rh sensitivity sickle cell | |
| | | | calculated for each trimester and pregnancy average | | <u>Non-Caucasian:</u> 1) referent 2) 1.08 (0.73, 1.61) 3) 1.09 (0.72, 1.66) | anemia uterine bleeding) | |
| | A | CGIH TLV DA | RT Chemical | 63 | 4) 1.27 (0.86, 1.87) 5) 1.60 (1.03, 2.47) | Other covariates considered: OEHHA | |
| | | | ation: Chloroform | | | August 2016 | |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|--|--|----------|
| | | | | | Per 10 μg/L increase: 1.10 (1.00, 1.22) | Interval since the previous live birth Previous infant who weighed >4000g Previous SGA infant | |

Studv/ Study Desian/ Outcomes Exposure Covariates/ Comments Exposure Results Location Sample sizes of Interest Measurement Methods Dosages Confounders Retrospective PTB Water Sampling: Mean CHL water PTB and Very PTB Models adj for: Hinckley et al. Large sample size Data from 3 community cohort conc was not 2005 Verv PTB water treatment facilities Authors reported that no SGA By comparing subjects within reported Birth records (<32 weeks) were used to calculate associations were the same community with 3rd trimester exp respect to exp levels, may have Arizona observed: no ORs were Paritv 1998-2002 SGA (as Education reduced potential residual presented intrauterine Total and individual Smoking confounding N = 48.119growth THMs were measured SGA Kessner index (live births and retardation quarterly for each facility, Tertiles of CHL exp Considered multiple time fetal deaths) (IUGR*) and monthly at some OR (95% CI) by tertile for LBW periods of exp $(\mu g/L)$: facilities for certain years 3rd trimester CHL exp: SGA LBW (at > 1) <10 1) referent Maternal age The community studied was n = 4.346Other DBP 37 weeks) 2) 10–16 2) 1.02 (0.94, 1.11) Race selected in order to minimize 3) ≥16 3) 1.01 (0.93, 1.10) Ethnicity misclassification due to spatial measurements were also Education variability within the distribution (exclusions: *term or taken at varving because frequencies, depending Continuous -Parity systems preterm values for the babies that on the facility 1.00 (1.00, 1.01) Smoking lowest 10th fell below Kessner index Large temporal variability and DBPs were measured at low spatial variability for DBPs percentile were the LBW 2-4 locations within the within water distribution not available published for extreme value for the distribution system of OR (95% CI) by tertile for systems gestational lowest 10th each facility 3rd trimester CHL exp: ages, births percentile of 1) referent Other DBP analyzed: BDCM, <23 weeks birth weight Procedures were used to DBCM, TTHM, HAA5, DBAA, 2) 1.18 (1.00, 1.39) gestation were by race, impute missing exp data 3) 1.04 (0.88, 1.23) DCAA. TCAA excluded; for ethnicity, Native Exposure Measure: Continuous -Significant findings were and American gestation Subjects were matched 1.00 (1.00, 1.01) observed for some HAAs births <29 to a water treatment age weeks were facility by zip code of mother's residence at excluded) birth PTB n = 4.008

Table 3a. Detailed Summaries for Epidemiologic Studies of Chloroform (CHL) Exposure and Reproductive Outcomes: Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW) (cont'd).

Very PTB

n = 564

LBW

n = 1010

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|-----------------------------------|--|--|---|---|---|--|---|
| Porter et al. 2005 Maryland | Retrospective cohort Birth certificate data 1998-2002 N = 18,087 (singleton births) n = 15,315 (restricted to African American, Caucasian, and Hispanic American infants; excluded infants born <25 or >42 weeks gestation) <u>SGA</u> n = 1,114 | SGA (as IUGR*) * defined as affecting an infant whose birth weight was below the 10 th percentile for gestational age (adjusted for sex and race) using standards from the US Census data" | Water Sampling: Monthly conc of TTHM and individual THMs (including CHL) at 4 sampling points in study obtained from the water utility company for 1997– 2002Sampling points represented varying distances from the water treatment facilityExposure Measure: Women whose residences were in zip codes corresponding to the water utility's point measurements were included in the analysis.Measurements were averaged biweekly TTHM levels based on estimated gestational periodTTHM measurements from 1997 were used for infants born in the 1 st 3 quarters of 1998 | CHL water conc (µg/L): Mean (95% Cl) = 34.1 (32.5, 35.7) Quintiles of CHL exp (µg/L): (specific quintile ranges not mentioned) | OR (95% CI) by quintile of CHL exp for the entire pregnancy: 1) Referent 2) 1.24 (1.02, 1.50) 3) 1.08 (0.88, 1.32) 4) 1.12 (0.92, 1.36) 5) 1.04 (0.85, 1.27) OR (95% CI) by quintile of 3 rd trimester CHL exp: 1) Referent 2) 1.02 (0.84, 1.24) 3) 0.96 (0.79, 1.16) 4) 0.98 (0.81, 1.19) 5) 1.07 (0.88, 1.29) | Models adj for: Marital status Mother's age Kessner index Tobacco use Other covariates considered: Maternal weight gain Child's race/ethnicity Alcohol use Mother's residence | TTHM values fluctuated by season, summer months were higher Other DBP analyzed: BDCM, DBCM, TBM, TTHM, BAA, CAA, DBAA, DCAA, CAA, TCAA, HAA5 Significant findings were observed for some HAAs |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|---------------------|-------------------------------|-------------------------|--|---|---|------------------------------|---|
| Savitz et al. † | Prospective | PTB | Water Sampling: | CHL water conc | | Model adj for: | CHL was dominant THM |
| | cohort | | 3 sites represented: | (µg/L) by site: | | | species at chlorinated DBP site |
| 2005 | | SGA | | | | <u>SGA</u> | (range = $20-120 \ \mu g/L$) with the |
| | Prenatal clinics | | 1) moderate chlorinated | Mean (range) = | | Maternal race | highest levels in summer |
| US (3 locations) | and community outreach | BW | DBP (CHL was the dominant species); | 1) 45.6 (14.7–124) 2) below minimium | | (black) Education | Sites were chosen for their use |
| 1004110113) | outreach | (SAB | 2) moderate brominated | reporting level | | Smoking | of chloramination for terminal |
| | 2000–2004 | outcome | DBP | (maximum 2.4) | | BMI | disinfection as it results in |
| | | reported in | 3) low levels of all DBP | 3) 11.9 (3.0– | | Live birth history | minimal additional DBP |
| | N = 2,766 | Table 4a) | | 52.7) | | | formation within the distribution |
| | (women) | | Sites 1 and 3 used | | <u>SGA</u> | <u>PTB</u> | system |
| | | | chloramination rather | <u>SGA</u> | | Maternal caffeine | |
| | n = 1,934 (oxoluding | | than free chlorine for terminal disinfection | Quartiles of 3rd | OR (95% CI) by quartile of 3 rd trimester CHL water | consumption Income | Extensive water sampling was done, including at multiple |
| | (excluding multiple | | terminal disinfection | trimester CHL water | conc (µg/L): | BMI | areas in the distribution system |
| | gestations, | | For each site, water | conc (µg/L): | οθης (μβ/Ε). | Live birth history | and confirmed to be uniform |
| | missing data, | | samples were measured | ····· (··g/ =/· | | , | throughout |
| | etc.) | | weekly at a location that | 1) >0.0–≤0.2 | 1) referent | Other covariates | C C |
| | | | reflected DBP conc | 2) >0.2–≤19.2 | 2) 1.45 (0.79, 2.64) | considered: | Exp data included extensive |
| | PTB | | throughout the system | 3) >19.2–≤47.1 | 3) 1.33 (0.71, 2.49) | | detailed water use collected |
| | n = 196 | | | 4) >47.1 | 4) 1.05 (0.54, 2.01) | Maternal age | mostly prospectively (e.g. water |
| | SGA | | <u>Exposure_Measure</u> : Tap water exp was the | Quartiles of 3rd | | Age at mother's interview | source; filter use, exp at work, showering/bathing, etc.) |
| | n = 102 | | average weekly sample | trimester total | OR (95% CI) by quartile of | Parity | showering/batting, etc.) |
| | 11 - 102 | | values over time of | integrated CHL exp | 3 rd trimester total integrated | Infant gender | A biomarker study was |
| | BW | | pregnancy | (µg/d): | CHL exp (µg/d): | Employment | conducted on a small sample of |
| | n = 1,738 | | | | | Ethnicity | women; however, a simple |
| | | | Daily exp, collected | 1) 0 | 1) referent | Marital status | linear relationship between |
| | | | prospectively: | 2) >0–≤0.5 | 2) 1.16 (0.63, 2.14) | Diabetes | CHL water conc and blood |
| | | | Ingestion - residential tap water | 3) >0.5–≤1.2 4) >1.2 | 3) 1.26 (0.68, 2.33) 4) 1.14 (0.62, 2.09) | Previous | levels was not evident |
| | | | conc water x | 4) >1.2 | 4) 1.14 (0.02, 2.09) | alcohol intake | Authors note that site |
| | | | consumption (number | PTB/ BW | <u>PTB</u> | Vitamin use | characteristics (e.g. |
| | | | and cup size per day of | | | Study site | demographic) or the |
| | | | tap, filtered, hot, and | Quintiles of 3 rd | OR (95% CI) by quintile of | Season | recruitment methods across the |
| | | | cold water) x uptake | trimester CHL water | 3 rd trimester CHL water | | sites may have led to biases in |
| | | | factors | conc (µg/L): | conc (µg/L): | <u>BW (Term)</u> | the estimated effects of DBP |
| | | | Total integrated exp - Including ingestion, | 1) ≥0.0–≤0.1 | 1) referent | Maternal race (black) | Multiple comparisons |
| | | | inhalation and dermal | 2) >0.1–≤10.9 | 2) 0.68 (0.42, 1.11) | Gestational age | |
| | | | absorption (water conc | 3) >10.9–≤30.4 | 3) 0.76 (0.47, 1.24) | (included both as | Research was supported by the |
| | | | x duration x uptake | 4) >30.4–≤48.2 | 4) 0.52 (0.31, 0.90) | gestational age | American Water Works |
| | | | factors) | 5) >48.2 | 5) 0.54 (0.31, 0.92) | and gestational | Association Research |
| | | | [inhalation and dermal | | | age squared) | Foundation and US EPA |
| | | | from showering and | 67 | | Maternal caffeine | |
| | | | RT Chemical ation: Chloroform | 67 | | OEHHA | |
| | 10 | | | | | August 2016 | |

| | | . . | - | _ | | | • |
|--------------------|-------------------------------|-------------------------|---|--|--|---|--|
| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| | | CGIH TLV DA | bathing] Estimated DBP levels for hot, cold, unfiltered, and filtered water were adjusted based on empirical laboratory experiments | Quintiles of 3^{rd} trimester total integrated CHL exp (µg/d): 1) 0 2) >0-≤0.2 3) >0.2-≤0.8 4) >0.8-≤1.3 5) >1.3 | OR (95% CI) by quintile of 3^{rd} trimester total integrated CHL exp (µg/d): 1) referent 2) 1.03 (0.65, 1.66) 3) 0.56 (0.32, 0.96) 4) 0.82 (0.49, 1.37) 5) 0.59 (0.34, 1.01) <u>BW</u> Mean change (95% CI) by quintile of 3^{rd} trimester CHL water conc (µg/L): 1) referent 2) -18 (-86, 51) 3) -6 (-75, 62) 4) 12 (-56, 80) 5) 28 (-39, 96) Mean change (95% CI) by quintile of 3^{rd} trimester total integrated CHL exp (µg/d): 1) referent 2) 10 (-58, 78) 3) -4 (-72, 63) 4) 37 (-31, 105) 5) 32 (-36, 100) | consumption Education Income Smoking BMI Employment Diabetes status Live birth history | Other DBP analyzed: THM4, BDCM, HAA9, BrTHM, HAA5, BrHAA, TOX SGA OR (95% CI) by quartile of 1 st trimester BDCM water exp (μ g/L): 1) referent 2) 0.51 (0.26, 0.99) 3) 0.89 (0.50, 1.59) 4) 1.04 (0.60, 1.8) Significant elevated ORs were observed for TTHM above and below 80 μ g/L at all sites, with the highest OR observed for site 1 – 2.45 (1.09, 5.50) (Supplemental table 8.15) Significant findings were observed for some HAAs <u>PTB</u> OR (95%CI) by quintile of 1 st trimester BDCM water exp (μ g/L): 1) referent 2) 0.78 (0.48, 1.26) 3) 0.78 (0.47, 1.28) 4) 0.58 (0.34, 0.96) 5) 0.73 (0.45, 1.21) OR (95% CI) by quintile of 3 rd trimester BDCM water exp (μ g/L): 1) referent 2) 0.63 (0.38, 1.04) 3) 0.47 (0.27, 0.83) 4) 0.69 (0.41, 1.15) |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---------|----------------------------|--|
| | | | | | | | 5) 0.96 (0.60, 1.54) |
| | | | | | | | OR (95% Cl) by quintile of 1 st trimester BrTHM water exp (μg/L): 1) referent 2) 0.90 (0.56, 1.45) 3) 0.69 (0.41, 1.16) 4) 0.48 (0.27, 0.84) 5) 1.01 (0.63, 1.62) |
| | | | | | | | OR (95% Cl) by quintile of 3 rd trimester BrTHM water exp (μg/L): 1) referent 2) 0.58 (0.35, 0.97) 3) 0.45 (0.25, 0.78) 4) 0.51 (0.29, 0.88) 5) 1.03 (0.65, 1.63) |
| | | | | | | | OR (95% CI) by quintile of 1 ^s trimester BrTHM total integrated exp (μg/d): 1) referent |
| | | | | | | | 2) 0.84 (0.51, 1.38) 3) 0.49 (0.27, 0.86) 4) 0.81 (0.49, 1.34) 5) 0.92 (0.56, 1.51) |

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---|----------------------------|---|
| | | | - | - | Results ORs (95% CI) by categories of 3 rd trimester CHL exp, for all water utilities combined (µg/L) (Supplemental material Table 4.12): <u>LBW</u> 1) Referent 2) 1.05 (1.03, 1.07) 3) 1.10 (1.07, 1.13) <u>VLBW</u> 1) Referent 2) 1.01 (0.96, 1.07) 3) 1.07 (0.99, 1.15) | | CommentsLarge sample sizeHierarchical links built into the model so exp was estimated with comparable precision across zones and quartersPossibility of high exp misclassification due to weighted averagesNo data on gestation ageIf CHL affects gestation length, this relationship could either contribute to or obscure the observed relationship between CHL and BWOther DBP analyzed: TTHM, BDCM, BrTHM did not show any association with LBW or VLBW (data not shown) |
| | | | weighted average THM | | | | |
| | | | conc for last 93 days | | | - - · · · · · | |
| | | | RT Chemical | 70 | | OEHHA | |
| | foi | r Reconsider | ation: Chloroform | | | August 2016 | |
| | | | | | | | |

Study/ Study Design/ Outcomes Results Covariates/ Exposure Exposure Comments Location Sample sizes of Interest Measurement Methods Dosages Confounders before birth were categorized into 3 levels

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|------------------------------------|---|---|--|---|---|---|--|
| Infante-Rivard 2004 Montreal | Case-Control University- based medical center 1998–2000 N = 985 (singleton births >24 weeks gestation) n = 884 Cases n = 458 controls n = 426 | SGA* *(Defined as IUGR in the study - BW below 10 th percentile matched for gestational age, race, and sex) | Water Samples THM conc from regulatory data collected by municipalities189 distribution systems Average daily measuresExposure measure: TTHM exp according to place of residenceIndividual THM exp as average level from treatment plant averaged over pregnancy periodCumulative index was the cumulative level over the pregnancy period (sum of conc x duration in days at specific level)Average level at tap multiplied by # of glasses of tap water per day averaged over the pregnancy (1 version included a weight of 0.9 for filter use or refrigeration)Face to face interview: (within 2 days of delivery) - maternal residence - drinking water source - use and type of domestic water filter - # of glasses of water (average/d) at home and elsewhere - usual way of | CHL water conc (μ g/L): Mean (SD): cases = 11.84 (18.19) controls = 11.58 (16.31) 90 percentile cutoff (23.7 μ g/L) for average CHL conc for the entire pregnancy: 1) \leq 90th percentile 2) > 90th percentile 2) > 90th percentile CHL levels + categories for mother and newborn variants of <i>CYP2E</i> 1 and <i>MTHFR C677T</i> : 1) wild type 2) 1 or 2 variant alleles | OR (95% CI) of entire pregnancy CHL water conc: 1) Referent 2) 1.06 (0.63, 1.79) No increased risks were observed using other exp indices for drinking water or showering (data not shown) ORs (95% CI) for relation to entire pregnancy CHL water conc according to newborn and maternal polymorphisms – <u>Newborn:</u> CYP2E1*5(G1259C) 1) 0.99(0.57, 1.74) 2) 5.62(0.82, 38.39) <i>MTHFR</i> C677T 1) 1.78 (0.82, 3.87) 2) 0.83 (0.38, 1.54) <u>Mother:</u> CYP2E1*5(G1259C) 1) 0.88 (0.50, 1.54) 2) 4.40 (0.73, 26.42) <i>MTHFR</i> C677T 1) 1.00 (0.46, 2.18) | Models adj for: Gestational age Sex Race Pregnancy weight gain Prepregnancy BMI 3 rd trimester smoking Primiparity Preeclampsia History of IUGR Other covariates considered: Parity Preeclampsia history Smoking in pregnancy | Controls born at the same hospital were matched to cases on gestational week, sex and race Substantial number of women drank bottled water Controls reported higher use of domestic water filters Genetic data included Accounted for residential mobility Exp data included detailed water use (e.g. water source, filter use, refrigeration, showering, bottled water use, etc.) Extensive control for confounding Small sample size in exposed category using 90 th percentile Limited water contaminant measures of distribution systems, no specific location within distribution system when multiple locations within system were sampled Other DBP analyzed: BDCM, DBCM, TBM, TTHM |
| | A | | RT Chemical | 72 | | OEHHA | |

Table 3a. Detailed Summaries for Epidemiologic Studies of Chloroform (CHL) Exposure and Reproductive Outcomes: Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW) (cont'd).

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|--|---------------------|--|----------------------------|----------|
| | | | consuming water from tap - # and duration of showers/week | | 2) 1.12 (0.56, 2.32) The author reported statistical heterogeneity in the risk of SGA between newborn carriers and noncarriers of the CYP2E1 variant for exp to average levels of CHL (data not shown) | | |

Studv/ Study Desian/ Outcomes Exposure Covariates/ Comments Exposure Results Location Sample sizes of Interest Measurement Methods Dosages Confounders Kramer et al. Population-PTB Water Sampling: CHL water conc CHL conc $\geq 10 \mu g/L$ tended to Models adj for: based malation based case-controWater samples taken $(\mu q/L)$: be found in towns in the from a 1987 municipal 1992 control SGA* Maternal age extreme northern and southern water survey Mean (SD) = 12.5 Number of sections of the state, but Birth certificate LBW lowa (38.7)previous undetectable conc and conc Water samples based on children between 1 and 9 µg/L were data *defined as towns that had single widely scattered throughout Median = 1Marital status 1989-1990 weighing source for drinking water Education lowa defined by surface water less than Range = 0-350Prenatal care All live the 5th supply from a single OR (95% CI) by categories Maternal CHL conc were reported as intake or ground water of entire pregnancy water high as 350 µg/L as cities with singleton percentile Categories of CHL smoking infants born to supply of one or more exp (µq/L) (percent CHL conc: <10,000 inhabitants did not for wells of a single aquifer non-Hispanic gestational of water supplies): Stratified analysis have to conform to the TTHM white women PTB: by water source standard of 100 µg/L age, based 1) Undetectable 1) referent to control for 19 years of age on Exposure measure: or older from California Exp based on maternal 2)1.1 (0.8, 1.4) effects of When analysis was restricted to (45.7)chlorinated water only, the towns with standards residence at birth 2) Low: 1–9 3)1.1 (0.7, 1.6) pesticides in 1,000-5,000 for non-(41.7)drinking water highest level of CHL exp (≥10 Births were from 1989 3) High: ≥ 10 ug/L) had an OR (95% CI) of inhabitants that Hispanic SGA: derived all their whites and 1990 while water (12.6)1) referent 1.8 (1.03, 3.0) public drinking samples were from 1987 2)1.3 (0.9, 1.8) water from a data 3)1.8 (1.1, 2.9) When stratified by type of water source to control for pesticides single source (birth data from 1989 and LBW: in drinking water, SGA analysis PTB of CHL ≥10 µg/L still had an 1990 were used 1) referent cases n = 342as smoking questions 2)1.1 (0.7, 1.6) elevated OR in water from controls n =were included on birth 3)1.3 (0.8, 2.2) shallow and deep wells 1,710 certificates only after As the 1987 survey was 1987) IUGR* conducted during a drought, the TTHM levels in 1989 and (excluding births ≤22 1990 would be expected to be weeks or ≥46 higher due to the higher conc of weeks organic material gestation) Authors attempted to control for unmeasured factors, such as cases n = 187controls n = lifestyle differences, through restriction to towns with 1,000-935 5.000 inhabitants LBW cases n = 159Gestational age was determined from the mother's controls n =795 last menstrual period as reported on the birth certificate 74

Table 3a. Detailed Summaries for Epidemiologic Studies of Chloroform (CHL) Exposure and Reproductive Outcomes: Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW) (cont'd).

ACGIH TLV DART Chemical for Reconsideration: Chloroform

OEHHA August 2016

Table 3a. Detailed Summaries for Epidemiologic Studies of Chloroform (CHL) Exposure and Reproductive Outcomes: Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth Weight (LBW), and Birth Weight (BW) (cont'd).

| Study/ Location | Study Design/ Sample sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|---|-------------------------|---------------------------------|---------------------|---------|----------------------------|---|
| | *for the purposes of this assessment | | | | | | Cases were not mutually exclusive |
| | IUGR will be considered as SGA | | | | | | THM exp levels were based on a one-time 1987 municipal water survey Total organic halides were measured in 62% of water supplies |
| | | | | | | | OR (95% CI) for SGA for exp to the highest levels of total organic halides (≥100 µg/L) = 1.8 (0.9,3.4) |
| | | | | | | | 90.6% of those exposed to CHL ≥10 µg/L were also exposed to total organic halides ≥100 µg/L |
| | | | | | | | Other DBP analyzed: BDCM, DBCM, TBM |
| | | | | | | | |
| | | | | | | | |

| Study/ | Exposure | Reference | | | | |
|---|---|-----------|-----|---|---|--|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| Danileviciute et al. ‡‡ 2012 Lithuania | Estimated internal dose (µg/d) CHL ≥0.1424 (median level) | <0.1424 | | Entire pregnancy 1.31 (0.82, 20.9) GSTM1-1 0.84 (0.42, 1.68) GSTM1-0 1.78 (0.90, 3.50) | Entire pregnancy 1.24 (0.57, 2.68) GSTM1-1 0.34 (0.09, 1.22) GSTM1-0 4.08 (1.20, 13.9) Test for interaction: | |
| | | | | GSTT1-1 1.30 (0.78, 2.17) GSTT1-0 0.99 (0.28,3.58) <u>3rd trimester</u> 1.31 (0.82, 2.08) GSTM1-1 0.88 (0.44, 1.78) GSTM1-0 1.74 (0.89, 3.41) | 12.88 (2.27, 73.2) GSTT1-1 1.9 (0.5, 2.82) GSTT1-0 7.48 (0.13, 409) <u>3rd trimester</u> 1.45 (0.67, 3.13) GSTM1-1 0.35 (0.10, 1.28) GSTM1-0 5.06 (1.50,17.05) | |
| | | | | GSTT1-1 1.18 (0.71, 1.97) GSTT1-0 1.75 (0.50, 6.10) | Test for interaction: 15.86 (2.75,91.40) GSTT1-1 1.35 (0.57, 3.20) GSTT1-0 7.30 (0.14, 391) | |
| Botton et al.* 2015 Spain (3 study sites) and Greece | Estimated internal dose (µg/d) <u>All sites:</u> CHL IQR inc Ingestion (µg/d) | | | | | Entire pregnancy Postnatal weight gain -9.30 (-87.3, 68.7) |
| | All sites: CHL IQR inc | | | | | -40.3 (-122, 41) |

Abbreviations: BDCM - bromodichloromethane; BrTHM - total brominated trihalomethanes; BW - birth weight; CHL - chloroform; CI - confidence interval; conc - concentration; DBCM - dibromochloromethane; dec - decrease; FGR - fetal growth restriction; inc - increase; LBW - low birth weight; med - medium; PTB - preterm birth; SGA - small for gestational age; TCAA – trichloroacetic acid; TTHM - total trihalomethanes; VLBW - very low birth weight.

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|---|--|---------------|--|--|--|--|
| Location | Level | Level | РТВ | SGA | LBW | BW (g) (95% CI) |
| | By site: Gipuzkoa CHLIQR incSabadell CHLIQR incValencia CHLIQR inc | | | | | 9.63 (-174, 193) -151 (-288, -15) 36.7 (-87, 160) |
| Grazuleviciene et al. 2011 ‡ ‡ Lithuania | Estimated internal dose (µg/d) 0.0249–0.2868 0.2868–2.1328 Continuous (per 0.1 µg/d increase) | 0.0013-0.0249 | | <u>3rd trimester</u> 1.19 (0.87, 1.63) 1.22 (0.89, 1.68) 1.04 (1.00, 1.09) | <u>3rd trimester</u> 2.12 (1.11, 4.02) 2.13 (1.15, 3.92) 1.09 (1.01, 1.18) | 3 rd trimester Change in BW in grams of infants below 3,500 g for every 1 μg/d increase in internal dose: -57.8 (-111.6, -4.0) |
| Smith et al. 2015 England | Estimated internal dose (μg/d) CHL ≥0.91–<1.56 ≥1.56 | <0.91 | | | | Entire pregnancy Total population: -16.3 (-39.0, 6.5) -20.9 (-44.6, 2.8) Pakistani origin: 10.3 (-21.2, 41.9) - 48.3 (-84.6, -12.1) White British: |
| | | | | | | -13.3 (-52.9, 26.3) 9.0 (-23.5, 46.5) <u>3rd trimester</u> Total population: -14.8 (-37.7, 8.1) -8.7 (-31.8, 14.3) Pakistani origin: 5.1 (-27.1, 37.4) -42.8 (-78.2, -7.4) |
| Kramer et al. 1992 Iowa | <u>Water conc (μg/L)</u> CHL 1–9 ≥10 | ND <1 | Entire pregnancy 1.1 (0.8, 1.4) 1.1 (0.7, 1.6) | Entire pregnancy 1.3 (0.9, 1.8) 1.8 (1.1, 2.9) | Entire pregnancy 1.1 (0.7, 1.6) 1.3 (0.8, 2.2) | White British: -27.0 (-66.1, 12.1) 9.5 (-26.8, 45.8) |

| Study/ | Exposure | Reference | Odds Ratio (95% CI) | | | |
|---|---|------------------|---|--|---|-----------------|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| Costet et al. 2012 France | <u>Water conc (µg/L)</u> CHL 5–<10 10–<15 ≥15 | < 5 | 3 rd trimester 0.7 (0.4,1.2) 0.5 (0.3,0.9) 0.8 (0.4,1.4) | <u>3rd trimester (as FGR)</u> 0.8 (0.5, 1.2) 1.0 (0.6, 1.5) 0.9 (0.5, 1.4) | | |
| | <u>Estimated internal dose</u> (μg/d) CHL 0.068–<0.133 0.133–<0.237 ≥0.237 | < 0.068 | 1.8 (0.7, 4.8) 0.7 (0.2, 2.1) 1.0 (0.4, 2.9) | 1.1 (0.5, 2.3) 1.2 (0.6, 2.4) 1.0 (0.5, 2.1) | | |
| | Nested TCAA Study Estimated internal dose via ingestion (µg/d) CHL 0.001-<0.006 0.006-<0.015 ≥0.015 | 0–0.001 | 0.7 (0.3, 1.5) 0.8 (0.4, 1.8) 1.2 (0.6, 2.5) | 1.0 (0.6, 1.7) 0.8 (0.4, 1.5) 1.2 (0.7, 2.2) | | |
| Hinckley et al. 2005 Arizona | <u>Water conc (μg/L)</u> CHL 10−16 ≥16 | <10 | No OR were presented Authors reported no associations were observed | <u>3rd trimester</u> 1.02 (0.94, 1.11) 1.01 (0.93, 1.10) | <u>3rd trimester</u> 1.18 (1.00, 1.39) 1.04 (0.88, 1.23) | |
| Infante-Rivard 2004 | Water conc (µg/L) CHL >23.7 | <u><</u> 23.7 | | Entire pregnancy 1.06 (0.63, 1.79) | | |
| Montréal, Canada 1) Wild 2) 1 or | Gene-environment interaction: 90 th percentile CHL conc + categories for mother and newborn variants of CYP2E1 and MTHFR C677T: type 2 variant alleles | | | | | |
| | Newborn CYP2E1*5 CHL >23.7 | <u><</u> 23.7 | | (0.57, 1.74) (0.82, 38.39) | | |
| | MTHFR CHL >23.7 | ≤23.7 | | (0.82, 3.87) (0.38, 1.54) | | |
| | Maternal CYP2E1*5 CHL >23.7 | ≤23.7 | | (0.50, 1.54) (0.73, 26.42) | | |

| Study/ | | | | | | |
|--|---|--------------------------|---|---|---|--|
| Location | Level | Level | РТВ | SGA | LBW | BW (g) (95% CI) |
| | MTHFR CHL >23.7 | ≤23.7 | | (0.46, 2.18) (0.56, 2.32) | | |
| Porter et al. 2005 Maryland | $\label{eq:water conc (\mu g/L)} \ \ \ \ \ \ \ \ \ \ \ \ \ $ | 1 st quintile | | Entire pregnancy 1.24 (1.02, 1.50) 1.08 (0.88, 1.32) 1.12 (0.92, 1.36) 1.04 (0.85, 1.27) | | |
| | | | | <u>3rd trimester</u> 1.02 (0.84, 1.24) 0.96 (0.79, 1.16) 0.98 (0.81, 1.19) 1.07 (0.88, 1.29) | | |
| Toledano et al. 2005 United Kingdom (3 study sites) | <u>Water conc (μg/L)</u> <u>LBW</u> CHL 20–40 >40 | <20 | | | <u>3rd trimester</u> 1.05 (1.03, 1.07) 1.10 (1.07, 1.13) | |
| | <u>VLBW</u> CHL 20–40 >40 | <20 | | | 1.01 (0.96, 1.07) 1.07 (0.99, 1.15) | |
| Savitz et al. † 2005 US (3 study sites) | Water conc (µg/L) CHL >0.1-≤10.9 >10.9-≤30.4 >30.4-≤48.2 >48.2 | ≥0-≤0.1 | <u>3rd trimester</u> 0.68 (0.42, 1.11) 0.76 (0.47, 1.24) 0.52 (0.31, 0.90) 0.54 (0.31, 0.92) | Used quartiles <u>3rd trimester</u> 1.45 (0.79, 2.64) 1.33 (0.71, 2.49) 1.05 (0.54, 2.01) | | 3 rd trimester -18 (-86, 51) -6 (-75, 62) 12 (-56, 80) 28 (-39, 96) |
| | Estimated internal dose (µg/d) CHL >0-≤0.2 >0.2-≤0.8 >0.8-≤1.3 >1.3 | 0 | 1.03 (0.65, 1.66) 0.56 (0.32, 0.96) 0.82 (0.49, 1.37) 0.59 (0.34, 1.01) | <u>Used quartiles</u> 1.16 (0.63, 2.14) 1.26 (0.68, 2.33) 1.14 (0.62, 2.09) | | 10 (-58, 78) -4 (-72, 63) 37 (-31, 105) 32 (-36, 100) |
| Hoffman et al. † 2008 3 US communities | Site 1 (chlorinated) water conc (μg/L) CHL 44.3–49.0 49.1–94.0 | 19.9–44.2 | | Bayesian models <u>3rd trimester</u> 1.9 (0.5, 8.1) 1.7 (0.4, 7.1) | | Bayesian models 3 rd trimester 58 (-51, 165) 49 (-62, 156) |

| Study/ | Exposure | Reference | | | | |
|--|---|--------------------------------------|---|--|-----|--|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | <u>Site 2 (brominated)</u> water conc (μg/L) CHL 11.6–15.6 15.7–22.1 | 6.4–11.5 | | 4.2 (0.6, 33.7) 3.6 (0.5, 30.1) | | 64 (-146, 278) 70 (-146, 294) |
| Levallois et al. 2012 Quebec City, Canada | Water conc (µg/L) CHL 15.96–27.26 27.27–51.07 >51.07 | <15.96 | | <u>3rd trimester</u> 0.9 (0.7, 1.3) 1.0 (0.8, 1.4) 1.2 (0.9, 1.7) | | |
| | Estimated internal dose via total pathway (µg/d) CHL 42.24–80.21 80.22–169.81 >169.81 | <42.24 | | 0.9 (0.7, 1.2) 1.0 (0.7, 1.3) 1.0 (0.8, 1.4) | | |
| Rivera-Nuñez and Wright 2013 | <u>Water conc (µg/L)</u> CHL >5–21 >21–36 >36–52 | ≤5 | 2 nd trimester 1.00 (0.94, 1.06) 1.08 (1.02, 1.14) 1.06 (0.99, 1.12) | <u>3rd trimester</u> 1.01 (0.96, 1.05) 1.00 (0.95, 1.04) 1.04 (1.00, 1.10) | | 3 rd trimester -1 (-7, 5) -9 (-15, -2) -13 (-19, -7) |
| Massachusetts | >52 | | 1.00 (0.94, 1.07) | 1.04 (0.99, 1.09) | | -15 (-21, -8) |
| Summerhayes et al. 2012 New South Wales, | <u>Water conc (μg/L)</u> CHL IQR increase (25 μg/L) | | | <u>Relative Risk</u> <u>3rd trimester</u> 1.04 (1.02, 1.06) | | Entire pregnancy -5.0 (-8.6, -1.4) |
| Australia | 5 th decile 25.00–30.18 10 th decile 56.03–147.94 | 1 st decile 1.68–13.71 | | 1.01 (0.96, 1.07) 1.12 (1.05, 1.18) | | |
| Lewis et al. ‡ 2007 Massachusetts | <u>Water conc (µg/L)</u> TTHM (CHL = 83–93%) 40–<60 ≥60 | <40 | Hazard Ratios 2 nd trimester 0.87 (0.77, 0.99) 0.82 (0.71, 0.94) | | | |
| | Continuous (per 10 µg/L increase) | | 0.95 (0.92, 0.99) <u>Pregnancy average</u> 0.92 (0.82, 1.02) 0.85 (0.74, 0.97) | | | |
| | | | 0.95 (0.91, 0.99) | | | |

| Table 3b. Associations between Chloroform (CHL) Exposure and Preterm Birth (PTB), Small for Gestational Age (SGA), Low Birth |
|--|
| Weight (LBW), and Birth Weight (BW) in Human Studies. |

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|---|--|-----------|---|---|--|--|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | | | <u>4 weeks before birth</u> 1.07 (0.85, 1.34) 1.39 (1.06, 1.81) 1.03 (0.96, 1.11) | | | |
| Wright et al. 2004 Massachusetts | <u>Water conc (µg/L)</u> CHL >26–63 >63–135 | 0–26 | <u>3rd trimester</u> 0.95 (0.91, 0.99) 0.90 (0.84, 0.97) | <u>3rd trimester</u> 1.05 (1.02, 1.09) 1.11 (1.04, 1.17) | / | <u>3rd trimester</u> -14 (-19, -9) -18 (-26, -10) |
| Lewis et al. ‡ 2006 Massachusetts | Water conc (µg/L) TTHM (CHL = 83–93%) 40-<50 | _≤40 | | | 2 nd trimester 1.10 (0.81, 1.49) 1.08 (0.79, 1.49) 1.24 (0.92, 1.67) 1.50 (1.07, 2.10) 1.08 (1.00, 1.17) Caucasian 1.11 (0.69, 1.78) 1.10 (0.67, 1.79) 1.22 (0.76, 1.97) 1.37 (0.80, 2.36) 1.06 (0.95, 1.20) Non-Caucasian 1.08 (0.73, 1.61) 1.09 (0.72, 1.66) 1.27 (0.86, 1.87) 1.60 (1.03, 2.47) 1.40 (1.00, 1.22) | |
| Villanueva et al.* 2011 Spain (5 areas) | Total residential water conc (μg/L) CHL 10% increase | | <u>3rd trimester</u> 1.00 (0.99, 1.01) | <u>3rd trimester</u> 1.00 (0.99, 1.01) | 1.10 (1.00, 1.22) <u>3rd trimester</u> 1.00 (0.99, 1.02) | <u>3rd trimester</u> -0.07 (-1.00, 0.85) |

¹ Hazard ratios for prenatal care paid for by government or Healthy Start.

| Study/ | Exposure | Reference | Odds Ratio (95% CI) | | | |
|------------------------------|--|-----------------------------------|---------------------|-----|---|---|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| Iszatt et al. 2014 | Water conc (µg/L) LBW CHL | | | | Entire pregnancy LBW ² | |
| England | 1) Low inc: ≤10 to dec <10 2) Med dec: 10–<30 3) High dec: 30–65 <u>VLBW</u> CHL | | | | 1) -5 (-9, -1) 2) -5 (-9, -1) 3) -9 (-12, -5) <u>VLBW</u> -7 (-17, 3) | |
| | | | | / | 4 (-7, 16) -16 (-24, -8) | |
| Zhou et al. 2010 China | <u>Water conc (µg/L)</u> CHL 2 nd quartile 3 rd quartile 4 th quartile | 1 st quartile | | | | Odds Ratio Entire pregnancy 0.96 (0.60, 1.53) 1.45 (0.88, 2.40) 1.64 (0.90, 3.00) 1st trimester 1.74 (1.10, 2.77) 0.90 (0.47, 1.74) 0.89 (0.44, 1.77) |
| | | | | | | <u>3rd trimester</u> 1.37 (0.99, 1.88) 1.67 (0.98, 2.85) 1.82 (1.10, 3.02) <u>1st and 2nd trimester</u> 1.10 (0.71, 1.68) 1.62 (1.05, 2.50) |
| Wennborg et al. 2000 | Women working in a laboratory with CHL | Women working in | | | | 0.93 (0.54, 1.60) Entire pregnancy 27 (-136, 190) |
| Sweden | n = 66 | non- laboratory departments | | | | 2. (100, 100) |

² Reported as rate change, which is the percent change calculated as the exponential of the regression coefficient (e.g. rate ratio of after/before) minus 1 and multiplied by 100.

| Iszate tal. Respective cohort SB Water Sampling: Routine motioning of policie valor supply: - at geographically - an informut of 1 times periods and 2002-2002 CHL water some prevalue - an informut of 1 2002-2002 CHL water some prevalue - an informut of 1 2002-2002 CHL water some prevalue - an informut of 1 2002-2002 ULBW and periods and and 2002-2002 The water samples - a minimum of 4 statistical for mation - and periods for and 2002-2002 CHL water conc prevalue - an informut of 1 2002-2002 ULBW and periods and period before and 3-year period before and 3-period the year of birth CHL distribution change (up1): CHL distribution chand period before chandperiod before and mater action the year of b | Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--|--------------------|-------------------------------|-------------------------|---|---|--|---------------------------------------|---|
| Birth and SBVLBW records potnet reported in a minimum of 4 times periods 2000-2002 | | • | | Routine monitoring of | | | were presented | |
| Two sample periodsTable 3a) per yearper year2002/ 38.6 (4.2)affect the rates(calculated from Table 1 of the paper)2000-2002 andwater sampling: 3-year period before and 3-year period before and 3-year period atter EC component -Mater (2005-2007)Other ovariates termoval of the year of birthDither ovariates termoval of the year of birthBackground mean TTHM conc dcrease of 15.1 µg/L in non- dcrease of 30.5 µg/L in termoval of the year of birthBackground mean TTHM conc dcrease of 15.1 µg/L in non- dcrease of 30.5 µg/L in termoval of the year of birthMean (SD) =Maan (SD) =Background mean TTHM conc dcrease of 30.5 µg/L in termoval of the year of birthMean (SD) =Maan (SD) =Maan (SD) =Maan (SD) =Mean (SD) =Maan (SD) =Mean (SD) | | | VLBW outcomes | - at geographically random samples | | | sex, parity, and maternal age | accounted for 94% of the |
| and 2005-2007water sampling: 3-year period after EC intervention19.4 (1.0)considered: considered: Multiple birth on non- Ethnicity (area level Census data)Background mean TT-HM conc decrease of 15.1 gg/L in non- Ethnicity (area level Census data)Background mean TT-HM conc decrease of 15.1 gg/L in non- Ethnicity (area level Census data)Intervention enhanced coagulationPostcode of matemal residence at birth was improves the year of birthMean (SD) =Analysis included an interaction ter attes before and after EC : -29.2 (13.2)Mean (SD) =Called an interaction ter attes before and after text scheme at birth was intervention design of the year of birthMean (SD) =Analysis included an interaction text scheme at birth was text scheme at boundary in use during the water zone boundary of the year or linked to the water zone boundary information to the preceding yearMean (SD) =Correct change (85% CI) text scheme at 51.5 (gg/L in non- EC : -29.2 (13.2)Correct change (85% CI) text scheme at 51.5 (gg/L in non- text scheme at 51.5 (gg/ | | periods - | | per year | 2002) 38.6 (4.2) | | affect the rates | (calculated from Table 1 of the |
| Interventioninterventionchange (µg/L):level Čensus data)statistically significant greater mea decrease of 30.5 µg/L in EC water zonescoagulationPostcode of matemal | | and | | water sampling: 3-year period before and 3-year | 19.4 (1.0) | | considered: Multiple birth | decrease of 15.1 µg/L in non- |
| coagulation water treatment (EC; a process that | | component - | | intervention | change (µg/L): | | level Census | statistically significant greater mean decrease of 30.5 µg/L in |
| a process that improves removal of DBPboundary in use during the year of bithNo EC: -14.0 (17.4)Percent change (95% CI) for rates before and after rate statio of after/before and after the intervention and across the exp across the expthat few social class factors changed over time, thus decreasing the possibility of reducting DBPformation potential) was introduced to 4Water zone boundary information water waterTHM social information was linked to treatment treatmentNo EC: -14.0 (17.4)Percent change (95% CI) for rates before and after tel claulated as the exponential of the regression coefficient (i.e., rate ratio of after/before) to inst 1 and multiplied by tools:the difference in rates before and after tel claulated as the coefficient (i.e., rate ratio of after/before) tools:the difference in rates before and after tel claulated as the coefficient (i.e., rate ratio of after/before) tools:the difference in rates before and after tel claulated as the coefficient (i.e., rate ratio of after/before) tools:the difference in rates before and after tel clauses before and after tel clause before and after tel clause before and after te | | coagulation water | | Postcode of maternal residence at birth was | Overall: -19.2 | | an interaction | Due to the intervention design |
| DBP precursors, reducing DBP formation | | a process that improves | | boundary in use during | No EC: -14.0 (17.4) | for rates before and after | the difference in rates before and | that few social class factors changed over time, thus |
| formation potential) was introduced to 4of the preceding yearlevels (based on THMs (µg/L):minus 1 and multiplied by 100):Analysis was included to included toreduction in conc of TTHMs, | | DBP precursors, | | of the year were linked to | Categories for | exponential of the regression coefficient (i.e., | intervention and across the exp | residual confounding |
| water treatment works (88 of 258 waterinformation was linked to | | formation potential) was | | of the preceding year | levels (based on | minus 1 and multiplied by | Analysis was | reduction in conc of TTHMs, |
| 258 water zones) in 2003-2004A water zone is a supply area with approximately uniform water quality, with a populationincrease ≤10 2004income on birth outcome rates using variable for incomeNo information on individual water useN = 472,526 (live births)≤100,00010 to <30 | | water treatment | | information was linked to | decreases- | 2) 2 (-13, 20) | determine possible | |
| with a population10 to <30incomeOther DBPs analyzed: THMs, BDCM, DBCM, TBM, BrTHMN = 472,526 (live births)≤100,0003) High decreases - 30 to 65deprivation score at water zone levelTTHMs, BDCM, DBCM, TBM, | | 258 water zones) in | | area with approximately | increase ≤10 2) Medium | 3) -4 (-10, 0) | income on birth outcome rates | |
| Two exp metrics were level n = 429,599 constructed for each Exposure metric (live births) water zone: included annual EC identified treatment average THM data SB status conc change for covering the entire | | N = 472,526 | | with a population | 10 to <30 3) High decreases - | | income deprivation score | TTHMs, BDCM, DBCM, TBM, |
| EC identified treatment average THM data SB status conc change for covering the entire | | n = 429,599 | | constructed for each | Exposure metric | | | |
| | | SB | | EC identified treatment status conc change for | average THM data covering the entire | | | |

| et al. ‡ ‡ coho | pregnant | BD | Water Sampling: | A H | | | |
|--|---|--|---|--|---|---|--|
| Lithuania Lithuania Lithu 2007 N = 3 (preg wom n = 3 <u>BD:</u> Hear n = 4 Muso skele n = 3 | unas (2 nd) gest city in ; huania) 07–2009 3341 egnant men) 3,074 : art: = 57 sculo- bletal: = 37 ogenital: | From registry - based data, diagnosed after a live birth and before discharge from hospital: Heart Musculo- skeletal Urogenital | 4 treatment plants: all groundwater sources, each sampled at 3 distances from each plant (near the plant, at 5 and ≥10 km), 4 times/year for 3 years (85 samples in total) Mean quarterly conc was calculated for each plant <u>Exposure Measure</u> : Geocoded maternal address at birth was used to determine CHL exp conc Average conc was calculated for 1 st , 2 nd , and 3 rd months, each trimester, and entire pregnancy Internal dose (total integrated uptake): (inhalation, ingestion & dermal absorption) was calculated from algorithms using interview data, on trimester-specific water consumption including: - size and number of glasses of tap water per day (including cold and boiled water), use of bottled water at home, at work, other - number and average length of showers and baths, swimming pool visits | CHL water conc (μ g/L) Mean (SD): At 3 plants with low THM levels = 0.9 (1.0) At 1 plant with high THM levels = 17.7 (9.0) (54.9% of subjects) Internal dose for 1 st trimester CHL exp: Range (μ g/d): 0.001–2.109 Tertiles (μ g/d): 1) 0.001–0.026 2) 0.026–0.288 3) 0.288–2.109 | OR by tertiles of 1 st trimester internal CHL exp (µg/d): Heart: 1) referent 2) 1.05 (0.53, 2.08) 3) 1.37 (0.72, 2.63) P-trend: 0.245 Continuous (1 µg/d): 1.97 (0.90, 4.35) Musculoskeletal: 1) referent 2) 0.61 (0.29, 1.32) 3) 0.51 (0.22, 1.14) P-trend: 0.111 Continuous (1 µg/d): 0.43 (0.11,1.71) Urogenital: 1) referent 2) 2.21 (0.67, 7.23) 3) 2.50 (0.78, 8.06) P-trend: 0.118 | Models adj for: Heart anomalies: Age BMI Chronic disease Alcohol consumption Fetus number Musculosketal anomalies: BMI Fetus number Previous Premature birth Infant sex Urogenital anomalies: Age BMI Chronic disease Previous premature birth Infant sex Other covariates considered: Ethnicity Education Parity Smoking "among others" | Individual THMs were highly correlated (r = 0.91–0.99) Most women were interviewed during the 3rd trimester (76%); 24% within the 1st month after delivery Collected information on water filter use (yes/ no), however, no adjustment was included in the internal dose calculation based on use No significant difference was seen in filter use habits Accounted for residential mobility by restricting study to women who did not change residence during pregnancy Questionnaire information was collected repeatedly on 10% of subjects Exp data included extensive detailed water use collected prospectively (e.g. filter use, exp at work, showering and bathing, swimming) SB or pregnancy terminations due to congenital anomalies diagnosed prenatally were excluded from the sample Low spatial and temporal variability between the low and high sites Other measured DBPs did not vary across plants and were at low or sub µg/L levels |
| | | | | | Continuous (1 µg/d): | | (including TBM, |

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|--|---------------------|-------------------|----------------------------|--|
| Location | Sampie Sizes | or interest | Estimated uptake factors were used for ingestion (including heated water), inhalation and dermal exp | Dosages | 2.22 (0.69, 7.17) | Conrounders | 5 haloacetonitriles, 2 haloketones, chloropicrin, chloral hydrate, halogenated furanone) Thus, only TTHMs and 3 individual THMs (CHL, BDCM, DBCM) were evaluated BDCM was associated with heart anomalies OR (95% Cl) = 2.16 (1.05, 4.46) in the 1 st month of pregnancy, with a significant dose-response relationship p = 0.02 Significant associations were also seen for a continuous measure for the 1 st 3 months |
| | | | | | | | and the 1 st trimester |
| | | | | | | | Some significant associations were also seen for DBCM and heart anomalies (for a continuous measure), and musculoskeletal anomalies (for a categorical measure) |
| | | | | | | | |
| | | | | | | | |

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|------------------------------------|-------------------------|--|--|---|----------------------------|---|
| lszatt et al. | Case-control | Hypo- spadias | <u>Water Sampling:</u> 6 water companies | CHL water conc (µg /L): | | Models adj for: | CHL was not the predominant THM |
| 2011 | Surgeon | · | provided THM data for | | | Family income | |
| England | recruited male children born in | | 140 water zones | Median = 2.9 | | Low birth weight Folate | THM data were available for 354 of the 468 case mothers |
| | 1997–2002 | | Monitoring data for 1997 was unavailable - 1998 | Quartiles of CHL water conc (µg/L): | OR (95% CI) for exp to CHL in water (µg/L): | supplement use | and 336 of the 485 control mothers |
| | 2000–2003 | | data was used for infants | | | Maternal | |
| | NI 404 400 | | born in 1997 as spatial | 1) 0.0–0.9 | 1) referent | smoking | Used a stochastic model based |
| | N = 191,438 male births | | variation was greater | 2) 1.0–2.9 3) 3.0–6.9 | 2) 1.17 (0.67, 2.03) 3) 0.99 (0.57, 1.69) | weeks 6–18 Maternal | on Bayesian hierarchical mixture distributions to estimate |
| | | | than temporal variation | 4) 7.0–90 | 4) 0.84 (0.49, 1.46) | occupational | the mean conc for TTHM, CHL, |
| | n = 731 invited | | Exposure Measure: | | | exp to | BDCM, DBCM by quarter for |
| | case mothers | | Participants' water zones were geocoded using | Quartiles of CHL ingestion at home | OR (95% CI) for CHL ingestion at home (µg/d): | phthalates Swimming | each water zone |
| | cases | | postal codes then linked | (µg/d): | | | Estimated type of water source |
| | n = 354 | | to their residential water | | | Other covariates | (e.g. ground, surface, etc.) for |
| | e e retue le | | zone and to the THM | 1) 0.0 | 1) referent | considered: | water zones used in the model |
| | controls n = 336 | | conc estimates | 2) >0.0-1.4 | 2) 1.26 (0.79, 2.01) | Family history of | Exp data included detailed |
| | 11 = 550 | | Annual average THM | 3) 1.5–4.2 4) 4.3–65.0 | 3) 1.12 (0.70, 1.79) 4) 1.36 (0.84, 2.22) | hypospadias | water use (e.g. exp at work, |
| | | | levels were estimated | +) +.0-00.0 | 4) 1.00 (0.04, 2.22) | History of | activities such as dishwashing, |
| | | | from quarterly modeled data | Quartiles of CHL total uptake (µg/d): | OR (95% CI) for CHL total uptake (µg/d): | previous stillbirth | and swimming) |
| | | | uala | ioial uplake (µg/u). | uptake (µg/u). | Gestational | Monitoring data for 1997 was |
| | | | Computer assisted | 1) 0–1.37 | 1) referent | diabetes | unavailable |
| | | | telephone interviews | 2)1.38-4.78 | 2) 0.93 (0.56, 1.53) | High intake of | |
| | | | 2000–2003 | 3) 4.79–13.98 | 3) 0.86 (0.52, 1.42) | cold tap water | Long interval between the end |
| | | | | 4)13.99–101 | 4) 0.74 (0.45, 1.21) | or bottled | of the pregnancy and the |
| | | | THM ingestion = amount of cold water | | (from Supplemental material Table 9) | water | interview (2½–6 yrs) |
| | | | consumed at home | | material rable 9) | | No information on paternal exp |
| | | | during 1 st trimester x | | Significant dose response | | previously associated with |
| | | | THM conc | | association with OR (95% CI) presented for highest | | hypospadias, e.g. pesticides |
| | | | Activities = | | exp category: | | Participation rates of eligible |
| | | | duration of | | | | mothers were 64% of cases, |
| | | | dishwashing, bathing, | | Cold tap water | | 33% of controls |
| | | | showering, & | | consumption at home | | |
| | | | swimming | | 1.17 (1.07, 2.76) | | Sample size was decreased |
| | | | x THM conc | | p-trend = 0.01 | | due to lack of valid postal codes, or lack of THM data for |
| | | | Total uptake: | | Total water consumption | | 271 participants |
| | | | Estimates from ingestion | | 1.70 (1.09, 2.67) | | |
| | | | & water use activities | | p-trend = 0.02 | | |
| | Α | | ART Chemical | 86 | | ОЕННА | |

86

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---|---------------------|---|----------------------------|---|
| | | | were multiplied by modeled uptake factors | | Bottled water 1.64 (1.09, 2.48) p-trend = 0.05 Total fluid consumption 1.55 (1.01, 2.39) p-trend = 0.07 | | Other DBPs analyzed include: TTHMs, BDCM, DBCM, TBM, BrTHM BDCM ingestion at home OR (95% CI) (highest exp category 6–50µg/d): 1.65 (1.02, 2.69) P for trend = 0.13 |

| 2005Ioss up to 20I) moderate chlorinated DBFs (CHL was the outreach (LBW, SA, 2000-2004I) moderate chlorinated DBFsperiod (ug/L):Locations (ug/L):Maternal age Black race(20-120 µg/L)2000-2004(LBW, SA, DBFs2) moderate bromination DBFs2) moderate bromination DBFs2) 104 moderate bromination TATA90 (0.6, 1.4)Hispanic ethnicity Hanica bromination Marial status10 programcy losses occurres Education Marial status10 moderate bromination commen800-2004BW, PTB3) low DB levels3) 102All sites = 23.9Kachol use (ug/L):Exp data included extensive detailed water use called of motify prospectively (e.g. fille wormen or planning regrant)Exp data included extensive detailed water use; ex at work; and showering/bathing)Exp data included extensive detailed water use; ex at work; and showering/bathing)n = 2.409 (excluding moveren ns 12For each site, water weeks1) 20.0-20.61) of efferent (1) 20.0-20.6Ethnicity (ug/d):Chlor covariates showering/bathing)at work; and showering/bathing)10 0n = 2.409 (excluding moveren ns 12For each site, water weeks at location that regrancies, movera at e.31) 20.0-20.61) of efferent (ug/d):Ethnicity (ug/d):Authors note that site considered:n = 258Exp ossure pregnancies, motify data area, etc.)Exp ossure pregnancy1) 0.0-20.62) 0.86 (0.55, 1.45)Season sont that site considered:Authors note that site considered:10 0n = 258 <th>Study/ Location</th> <th>Study Design/ Sample Sizes</th> <th>Outcomes of Interest</th> <th>Exposure Measurement Methods</th> <th>Exposure Dosages</th> <th>Results</th> <th>Covariates/ Confounders</th> <th>Comments</th> | Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--|---|---|--|--|--|---|--|---|
| from showering and - No clear linear relationship bathing] was seen between tap water conc and blood | Location Savitz et al. † 2005 US | Sample Sizes Prospective cohort Prenatal clinics and community outreach 2000–2004 N = 3,132 (pregnant women or women planning to become pregnant) n = 2,409 (excluding women >12 weeks gestation, multiple pregnancies, moved out of area, etc.) SAB | of Interest SAB (pregnancy loss up to 20 weeks gestation) (LBW, SGA, BW, PTB outcomes were reported in | Measurement MethodsWater Sampling:3 sites represented:1) moderate chlorinated DBPs (CHL was the dominant species)2) moderate brominated DBPs3) low DBP levelsSites 1 & 2 used chloramination rather than free CHL for termination disinfectionFor each site, water samples were measured weekly at a location that reflected DBP conc throughout the systemExposure Measurement: Tap water exp was the average weekly sample values over time of pregnancyDaily exp: Ingestion - residential tap water conc x consumption (number and cup size per day of tap, filtered, hot, and cold water) x uptake factorsTotal integrated exp - including ingestion, inhalation and dermal absorption (water conc x duration x uptake factors) [inhalation and dermal from showering and | Dosages CHL water conc by site for periconceptional period (μ g/L): Mean = 1) 47.9 2) 12.4 3) 0.2 All sites = 23.9 Quintiles of CHL water conc (μ g/L)): 1) \geq 0.0– \leq 0.6 2) >0.06– \leq 8.6 3) >8.6– \leq 30.27 4) >30.27– \leq 48.71 5) >48.71 Quintiles of CHL total integrated exp (μ g/d): 1) 0 2) >0.0– \leq 0.24 3) >0.24– \leq 0.78 4) >0.78– \leq 1.4 5) >1.4 The above exp categories were for the time period 9 weeks after the last menstrual period to 20 weeks after the last menstrual | OR (95% CI) of CHL water conc, including all three locations (µg/L): 0.9 (0.6, 1.4) OR of CHL water conc (µg/L): 1) referent 2) 0.82 (0.51, 1.34) 3)1.66 (1.06, 2.61) 4) 0.89 (0.55, 1.45) 5) 0.95 (0.58, 1.54) OR of CHL total integrated exp (µg/d): 1) referent 2) 0.88 (0.54, 1.42) 3) 1.15 (071, 1.86) 4) 1.09 (0.68, 1.76) | Confounders Models adj for: Maternal age Black race Hispanic ethnicity Education Marital status Alcohol use Age at menarche Vitamin use Other covariates considered: Ethnicity Income Study site Season Cigarette smoking Alcohol intake Caffeine consumption BMI Employment Diabetes History of spontaneous abortion Previous induced abortion | CHL was dominate THM species at chlorinated DBP site (20–120 µg/L) 81 pregnancy losses occurred before the initial interview Exp data included extensive detailed water use collected mostly prospectively (e.g. filter use, hot or cold water use; exp at work; and showering/bathing) Authors note that site characteristics (e.g., demographics) or the recruitment methods across the sites could possibly have led to biases in the estimated effects of DBPs Research was supported by the American Water Works Association Research Foundation and U.S. EPA No karyotyping of normal or abnormal fetal losses Initial interviews were conducted after pregnancy loss in 31.4% of the women Numerous comparisons were across various exposure periods using various estimates of exposure A biomarker study was conducted by site, and by season for Site 1: - No clear linear relationship was seen between tap |

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|--|---------------------|---------|----------------------------|---|
| Location | Sample Sizes | of Interest | Measurement Methods Estimated DBP levels for hot, cold, unfiltered, and filtered water were adjusted based on empirical laboratory experiments | Dosages | | Confounders | levels for CHL or for any of the other THMs - Baseline THM levels in blood differed across sites; however, not nearly to the extent expected Other DBPs analyzed include: THM4, BDCM, HAA9, total organic halide Sporadic indications of increased risk of SAB associated with higher exp to DBPs were most notable for |
| | | | | | | | ingested total organic halide in the upper quintile: OR (95% CI) = 1.5 (1.0, 2.2) Although this study explicitly included categorization of exp for comparability with results of Waller et al. 1998, the findings of this study were not supportive of those results |
| | | | | | | | |

| • | | | | - | - | . , | |
|---------------------|-------------------------------|-------------------------|--|----------------------------|--|-------------------------------------|--|
| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| Toledano et al. | Retrospective cohort | SB | Water sampling: Samples from 3 water | CHL water conc (µg/L): | ORs (CI) for CHL, for all water utilities combined | Models adj for: | Large sample size |
| 2005 | Birth and | (LBW and VLBW | companies | Mean - not stated | (Supplemental material Table 4.12): | Maternal age Castairs quintile | Hierarchical links built into the model so exp are estimated |
| United | stillbirth | outcomes | Regulations required ≥4 | CHL exp | | | with comparable precision |
| Kingdom (3 water | records | were reported in | samples/year, unless TTHM conc was <50 | categories*: 1) Low <20 | 1) Referent 2) 1.11 (1.03, 1.19) | (Carstairs index is a measure of | across zones and quarters |
| regions) | 1992–1998 (years varied | Table 3a) | µg/L, in which case only 1 sample/year was | 2) Med 20–40 3) High>40 | 3) 1.12 (1.02, 1.23) | socioeconomic deprivation at the | "[C]hloroform showed a similar pattern of risk for |
| | by water utility) | | required | | | level of the | stillbirths and low and very low |
| | N. 000.004 | | •• • • • | *Personal | | enumeration | birth weight to that of TTHM, for |
| | N = 969,304 | | More frequent samples | correspondence | | district, | the overall summary estimates |
| | n = 920,571* | | were required if the standard of 100 µg/L | (2/10/14) | | which has a population=400 | across the three regions and in each individual region" |
| | (excluding | | TTHM was breached | | | on average) | Dessibility of bigh over |
| | births that could not be | | Mean number of | | | Other covariates | Possibility of high exp misclassification due to |
| | assigned water | | samples/year: | | | considered: | weighted averages |
| | zones, etc.) | | Northumbrian $= 4.5$ | | | | |
| | | | United Utilities = 11.2 | | | Sex | Other DBPs analyzed: |
| | <u>SB</u> p = 4.852 | | Severn Trent = 6.3 | | | Interaction | TTHMs, BDCM, BrTHM |
| | n = 4,852 | | Exposure Measurement: | | | Interaction parameters with | No association was found with |
| | *n - from | | Individual postal code | | | all covariates | BDCM or BrTHM |
| | descriptive | | records were extracted | | | were tested in | |
| | table (Table 1 | | from birth registries and | | | final models | |
| | of the paper) | | linked to water zone | | | | |
| | | | Individual THM conc | | | | |
| | | | were modeled, taking | | | | |
| | | | into account seasonal variation and THM | | | | |
| | | | profiles associated with | | | | |
| | | | particular water sources, | | | | |
| | | | to obtain more robust | | | | |
| | | | estimates of mean TTHM | | | | |
| | | | in each zone | | | | |
| | | | Modeled quarterly TTHM | | | | |
| | | | estimates were weighted | | | | |
| | | | (based on the proportion of the trimester in each | | | | |
| | | | quarterly period) and the | | | | |
| | | | weighted average THM | | | | |
| | | | conc for last 93 days | | | | |
| | Δ. | | APT Chamical | 00 | | | |

Study/ Location Study Design/ Outcome Sample Sizes of Interes

Outcomes Exposure of Interest Measurement Methods

Exposure lethods Dosages Results

Covariates/ Confounders

Comments

before births were categorized into 3 levels

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---------|----------------------------|--|
| | | | | | Results | •••••••• | Comments 70% cases and 62% controls had a chlorinated household water supply Joint analysis was conducted with number of cups of tap water consumed and THM level (categorical) Water conc was determined by sampling each subject's residential tap water Accounted for residential mobility Women were eligible to participate if they lived in the study area for first 5+ months of pregnancy, delivered in the study area, and were residents in study area, and were residents in study area, and were residents in study area, and were residents of firet, bottled detailed water use (e.g. filter use and exp at work) Adj THM exp estimates for use of filter, bottled water and boiled drinks Water sampling was not done at time of exp, due to retrospective nature of study design; water was collected 1 year later, so misclassification is possible. |
| | | | Dam) | | | | Subject response rates, with interviews completed, were 68% for controls and 60% for cases |

Referent categories for analyses contained subjects

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---------|----------------------------|---|
| | | | | | | | who had a private well, therefore, risk may be observing effect of private versus public water supply |
| | | | | | | | Other DBPs analyzed include: TTHMs and BDCM |
| | | | | | | | OR (95% CI) for risk of SB with THM exp: - 5+ cold tap water-based drinks and residential TTHM 1–49 (µg/L) = 2.4 (1.1, 1.9) THM ≥50 (µg/L) = 4.0 (1.4, 11) (adj for showering/bathing did not alter these results) |
| | | | | | | | significant effects were also seen for the joint effects of minutes showering/bathing and TTHM exp |

| - | • | | | - | | • | |
|--------------------------------------|--|---|--|--|--|---|--|
| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
| Windham et al. 2003 California | Prospective cohort Women's Reproductive Health Study May 1990– June 1991 N = 1,092 eligible women n = 403 (after 89 dropped out and 61 became ineligible due to moving, early pregnancy, or starting birth control pills) | Menstrual cycle function (measured as: -menstrual cycle length -follicular phase length; -luteal phase length -menses length) | Water sampling: Collected quarterly THM measurements from 10 water utility companies. Calculated utility-wide averages (i.e., average of all measurements taken by a utility company) Exposure measure: Participants' addresses were geocoded, and assigned the appropriate water utility company in the county Participants completed a detailed baseline interview by telephone about water consumption and frequency and duration of showers per week Participants filled out a daily diary Participants were assigned a 90 day exp time period for each cycle (Estimated ingestion uptake for TTHM but not for CHL) | CHL water conc (µg/L): Mean - not reported CHL exp categories (µg/L): 1) 1 st quartile 2) 2 nd -3 rd quartile 3) 4 th quartile (≥17) | Differences (day) (95% CI) for CHL exp categories: <u>Menstrual cycle length</u> 1) referent 2) -0.43 (-0.99, 0.13) 3) -0.30 (-1.0, 0.40) <u>Follicular phase length</u> 1) referent 2) -0.42 (-0.96, 0.12) 3) -0.13 (-0.82, 0.56) OR (95% CI) for risk of having a short luteal phase at the highest CHL quartile level: 2.2 (1.0, 4.7) | Models adj for: Income Age Pregnancy history BMI Caffeine consumption Alcohol consumption Race Smoking Other covariates considered: Demographics Reproductive history Lifestyle factors (i.e., smoking, alcohol consumption, caffeine consumption, and exercise) | Participation rate was about 40% of the eligible population Considered participant mobility by calculating utility measures for each address lived in and using a weighted average Menstrual function parameters were based on biologic measures rather than self-reporting Other DBPs analyzed include: TTHMs, BDCM, DBCM, TBM and BrTHM Monotonic decrease in follicular phase length was observed for TTHM (µg/L):exp: >40-60 -0.39 (-0.98, 0.20) >60 -0.94 (-1.6, -0.24) Similar findings were observed for mean cycle length Significant findings were also observed for BDCM, DBCM, TBM, and BrTHM analyzed by quartile of exp OR (95% CI) for risk of having a long follicular phase at the highest conc of BrTHM: 0.26 (0.12, 0.60) Similar findings were reported for individual brominated compounds |

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--|--|---|---|---|---|---|--|
| Dodds and King * * 2001 Nova Scotia | Retrospective cohort Perinatal database 1988–1995 Singleton births N = 49,842 n = 48,845 (excluded births with unknown gestational age, and women with missing values for adjustment factors) NTD n = 77 Cardiovascular n = 430 Cleft n = 82 Chromosomal n = 96 | BDNeural tube defects (NTD)Cardio- vascular anomaliesCleft defectsChromo- somal abnormalities | Water sampling: Routine monitoring of THMs at water facilitiesSamples taken at irregular intervals 4 times/year from 3 locations within the distribution systems of each facilityExposure measure: Individual levels were determined by TTHM values of the water facility that serves the area of maternal residence at birthNTD: average CHL conc in the facility from 1 month prior to conception to 1 month after conceptionCardiac and cleft defects: average CHL conc in the facility during the 1st 2 months of pregChromosomal: average CHL conc in the facility 3 months before pregnancy | CHL water conc (μ g/L): Mean (SD) = 64.1 Categories of CHL conc (μ g/L): 1) <50 2) 50–74 3) 75–99 4) ≥100 Timing of exp See previous column (Exposure measure) | RR for CHL exp: <u>NTD</u> 1) referent 2) 0.7 (0.4, 1.2) 3) 0.7 (0.3, 1.5) 4) 1.2 (0.7, 2.3) <u>Cardiovascular</u> 1) referent 2) 1.0 (0.8, 1.3) 3) 1.0 (0.8, 1.4) 4) 0.7 (0.5, 1.0) <u>Cleft</u> 1) referent 2) 1.2 (0.7, 2.0) 3) 0.9 (0.4, 2.0) 4) 1.5 (0.8, 2.8) <u>Chromosomal</u> 1) referent 2) 1.3 (0.8, 2.2) 3) 1.9 (1.1, 3.3) 4) 1.4 (0.8, 2.8) | Models adj for: Maternal age Income level (not for cleft defects) Other covariates considered: Parity Maternal smoking Neighborhood family income | CHL accounted for 90% of TTHMs and they were highly correlated ($r = 0.98$) CHL and BDCM were not highly correlated ($r = 0.26$) The study incorporated therapeutic pregnancy terminations for antenatally diagnosed congenital abnormalities Confounders limited to those found in the database No information on ingestion, dermal, or inhalation exp or uptake No information on work water consumption was included Other DBPs analyzed include: BDCM Less than half subjects living in areas with high BDCM also had high CHL conc (>20 µg/L and >100 µg/L respectively) Excess risk was seen at BCDM conc ≥20 µg/L for NTD compared to conc <5 µg/L: RR (95% CI) = 2.5 (1.2, 5.1) |
| | | | | | | | |

Decreased risk was seen at BCDM conc ≥20 ug/L for NTD compared to conc <5 µg/L: RR (95% CI) = **0.3 (0.2, 0.7)**

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--|---|-------------------------|---|--|---|---|--|
| King et al. * * 2000 Nova Scotia | Retrospective cohort Perinatal database 1988–1995 N = 49,756 (singleton births) SB n = 214 | SB | Water sampling: Water samples taken from the Nova Scotia Dept. of the Environment records THMs measured by each facility on average 4 samples per year Monthly estimates predicted by regression analysis Exposure Measure: Mother's residence at time of delivery was linked to the geographic area served by each water facility Individual estimates were averaged predicted values of THMs for the months covering the duration of the mother's pregnancy | CHL water conc (μ g/L): Mean = 64.1 Average exp for 95% of women in referent category = 25–49 μ g/L Quartiles of CHL exp (μ g/L): 1) <50 2) 50–74 3) 75–99 4) ≥100 | RR (95% Cl) by quartile of CHL exp (μ g/L): 1) referent 2) 1.2 (0.85,1.68) 3) 1.35 (0.87, 2.08) 4) 1.56 (1.04, 2.34) Continuous (per 10 μ g/L): 1.04 (1.00, 1.09) In a model with continuous representation of CHL and BDCM (per 10 μ g/L) entered simultaneously (data reported but not shown): RR (95% Cl) for CHL = 1.03 (0.98, 1.07) | Models adj for: Smoking Maternal age Other covariates considered: Parity Infant sex Neighborhood family income | TTHM and CHL were highly correlated ($r = 0.98$) CHL and BDCM ($r = 0.26$) Data restricted to municipalities with >90% households served by public water facilities, reducing probability that subjects in these areas did not use public water supply Individual water behaviors were not taken into account Data restricted to surface water only Other DBPs analyzed include: TTHMs, BDCM, DBCM, TBM A significant association was observed for BDCM and SB in the highest versus lowest exp category (≥ 20 versus < 5 µg/L): RR (95% CI) = 1.98 (1.23, 3.49) |

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------------------------|---|--|--|---|---|--|---|
| Wennborg et al. 2000 Sweden | Retrospective cohort Population base Case-control analysis Medical records, Swedish Employee Board 1990–1994 N = 1052 women n = 697 women (856 pregnancies included mothers who had worked up to the time of conception, excluded women who had become pregnant before employment, twin pregnancies, etc.) SAB: cases n = 73 controls n = 783 | SAB (defined as demaseyconatrol and fetal deaths up to gestational age of 20 weeks) (information about SAB was self- reported) (BW outcome included in detailed summary Table 3a) | Water Sampling: No water sample Exposure Measure: Interview Questionnaire: - laboratory work - period and time worked - exp to individual solvents (one of which was CHL) Exp information collected for time period before, and up to conception | Number of women who reported working in a lab with CHL: yes = 86 no = 770 Work in a lab with CHL: 1) No 2) Yes | OR of work with CHL 1) referent 2) 2.3 (0.9, 5.9) | Models adj for: Maternal age Previous miscarriage Other covariates considered: High blood pressure Other chronic diseases Gynecological Diseases Sexually transmitted infectious diseases Smoking Father's laboratory work at time of conception Presence of small children in the home Previous spontaneous abortions Consecutive pregnancy number | Specific substances in the labs were not measured, just reported use High proportion of non- respondents (27%) Other laboratory exp (e.g. solvents, bacteria) Relied on self-report of SAB No karyotyping of normal or abnormal fetal losses |

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|---|---|--|---------------------------------------|--|--|---|
| Dahl et al. | Retrospective cohort | Fertility | <u>Water Sampling:</u> Not applicable | Categories of CHL- containing root | | Models adj for: | Response rates were dental surgeons = 65% |
| 1999 | Female dental | ("measured as time to | Exposure Measure: | canal sealer (number of fillings | Percent of women | Maternal age Smoking habits | high school teachers = 70% |
| Norway | Female dental surgeons in the Norwegian Dental Association N = 1320 Female high school teachers | pregnancyNumber of root fillingsperdefined aswith CHL-based rootmonths ofcanal sealing material forunprotecteddental surgeonsintercourse3required toResponses to open | | | exposed: 1) 26.7 2) 51.0 3) 15.0 4) 6.7 5) 0.5 Fecundability ratio (CI) of | Medical history Indicating reduced fertility | CHL-based sealing material usage was reported in about 75% of the pregnancies Retrospective time-to- pregnancy is suitable for occupational fertility problems No quantification of CHL was |
| | N = 1084 n = 1408 pregnancies of 1008 women (834 of 558 dental surgeons, and 574 of 450 | | Occupational history was restricted to 6 months prior to pregnancy | | placing CHL-based fillings (Referent = female high school teachers) 1.06 (0.95, 1.10) | | reported Possibility of recall bias of exp with longer wait time to pregnancy |

high school teachers)

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|---|---|---|--|---|---|---|---|
| Waller et al. 1998 California (3 facilities) | Prospective cohort Birth records of a managed health care program (Kaiser) 1989–1991 N = 7,881 pregnant women n = 5,144 pregnancies | SAB (loss at ≤ 20 weeks gestation) | Water Sampling: Monitoring data was obtained from 78 of 85 utilities (serving 96% of the cohort)TTHM distribution system quarterly measurements and annual water quality reports from the utilities were used3 sites were represented: 1) primarily mixed water source 2) primarily surface water 3) primarily ground waterTap water consumption at 8 weeks was based on telephone interviewExposure Measure: Residential drinking water utility was determined by the subject's addressEstimated TTHM levels for each subject were averages of all distributions taken by their utility within the 1st trimester, or average measurements taken within 30 days of the 1st trimesterTelephone interview: daily cold tap water intake at 8 weeks gestation, and total tap water intake (cold plus hot)RT Chemical | CHL water conc (μ g/L): Mean (SD) None stated Category of 1 st trimester CHL in tap water (μ g/L): 1) 0–3 2) 4–16 3) \geq 17 Categories for personal exp to CHL: 1) high: \geq 5 glasses/day cold tap water and 1 st trimester CHL level of \geq 17 μ g/L 2) low: <5 glasses/day of cold tap water and CHL level of <17 μ g/L | Percent SAB by category of 1 st trimester CHL tap water levels (µg/L): 1) 8.1% 2) 10.7% 3) 9.5% p-value = 0.15 OR (95% CI) for SAB with high personal CHL exp (category 1): 0.9 (0.5, 1.6) | Models adj for: Gestational age at interview Maternal age at interview Cigarette smoking History of pregnancy loss Maternal race Employment during pregnancy | Mean total TTHM conc was 46.5 µg/L Exp data included detailed water use (e.g. filter use, and exp at work) Data were collected on hot versus cold tap water usage No data were collected on other routes of exp (e.g. bathing, washing) Other DBPs analyzed: TBM, BDCM, DBCM Significant associations were observed between SAB and high personal exp to TTHMs and BDCM for all regions OR (95% CI) = 2.0 (1.2, 3.5) In a logistic regression model for all regions, adj for all 4 individual THMs simultaneously, the OR (95% CI) for high personal exp to BDCM was significant = 3.0 (1.4, 6.6) However, the degree to which the THMs were correlated was not reported, and no analysis for multicollinearity was mentioned |
| | | | | | | 1 0010 | |

Study/Study Design/OutcomesExposureExposureResultsCovariates/CommentsLocationSample Sizesof InterestMeasurement MethodsDosagesConfounders

Personal exp: TTHM level and cold tap water consumption Table 4b. Associations between Chloroform (CHL) Exposure and Spontaneous Abortion (SAB), Stillbirth, Birth Defects and Fertility in Human Studies.

| Study/ Exposure Reference | | | | Odds | Ratio (95% CI) | |
|---|---|--------------------------|--|------------|---|---|
| Location | Level | Level | SAB | Stillbirth | Birth Defects | Fertility |
| Grazuleviciene et al. ‡ ‡ 2013 Lithuania | Estimate internal dose (μg/d) CHL 0.026–0.288 0.288–2.109 Continuous (per 1 μg/d increase) | 0.001–0.026 | | | 1st trimester exposure Heart anomalies 1.05 (0.53, 2.08) 1.37 (0.72, 2.63) 1.97 (0.90, 4.35) Musculoskeletal anomalies 0.61 (0.29, 1.32) 0.51 (0.22, 1.14) 0.43 (0.11, 1.71) Urogenital anomalies 2.21 (0.67, 7.23) 2.50 (0.78, 8.06) 2.22 (0.69, 7.17) | |
| Iszatt et al. 2011 England | Water conc (μg/L) CHL 1.0–2.9 3.0–6.9 7–90 | 0.0–0.9 | | | Entire pregnancy exposure 1.17 (0.67, 2.03) 0.99 (0.57, 1.69) 0.84 (0.49, 1.46) | |
| | Estimated internal dose (μg/d) CHL 1.38–4.78 4.79–13.98 13.99–101 | | | | 0.93 (0.56, 1.53) 0.86 (0.52, 1.42) 0.74 (0.45, 1.21) | |
| Waller et al. 1998 California (3 facilities) | <u>Water conc (μg/L)</u> CHL ≥17 and 5 glasses/d | <17 and <5 glasses/d | 1 st trimester exposure 0.9 (0.5, 1.6) | | | |
| Windham et al. 2003 California | <u>Water conc (µg/L)</u> CHL 2 nd –3 rd quartile 4 th quartile (≥17) | 1 st quartile | | | | Difference in menstrual cycle length -0.43 (-0.99, 0.13) -0.30 (-1.0, 0.40) Difference in follicular phase length -0.42 (-0.96, 0.12) -0.13 (-0.82, 0.56) |

Abbreviations: CHL - chloroform; CI - confidence interval; conc - concentration; d – day; dec - decrease; inc - increase; L – liter; LMP - last menstrual period; med - medium; NTD - neural tube defects; SAB - spontaneous abortion.

Table 4b. Associations between Chloroform (CHL) Exposure and Spontaneous Abortion (SAB), Stillbirth, Birth Defects and Fertility in Human Studies (cont'd).

| Study/ | Exposure | Reference | | Odds Rati | io (95% CI) | |
|---|---|---------------|---|--|---------------|-----------|
| Location | Level | Level | SAB | Stillbirth | Birth Defects | Fertility |
| Toledano et al. 2005 United Kingdom (3 water regions) | Water conc (µg/L) CHL 20–40 >40 | <20 | | <u>3rd trimester exposure</u> 1.11 (1.03, 1.19) 1.12 (1.02, 1.23) | | |
| Savitz et al. † 2005 US (3 study sites) | Water conc (µg/L) CHL >0.06-≤8.6 >8.6-≤30.27 >30.27-≤48.71 >48.71 Estimated internal dose (µg/d) CHL >0-≤0.24 >0.24-≤0.78 >0.78-≤1.4 >1.4 | ≥0–≤0.06 0 | <u>9 weeks after last</u> <u>menstrual period (LMP) to</u> <u>20 weeks after LMP</u> 0.82 (0.51, 1.34) 1.66 (1.06, 2.61) 0.89 (0.55, 1.45) 0.95 (0.58, 1.54) 0.88 (0.54,1.42) 1.15 (0.71,1.86) 1.09 (0.68,1.76) 1.14 (0.72,1.81) | | | |
| Iszatt et al. 2014 England | <u>Water conc (μg/L)</u> Low inc <u><</u> 10 to dec <10 Med dec 10–<30 High dec 30–65 | | | Entire pregnancy <u>exposure</u> -5 (-9, 20) ¹ 2 (-13, 20) -4 (-16, 8) | | |
| Dodds et al. 2004 Nova Scotia and Eastern Ontario, Canada | <u>Water conc (μg/L)</u> CHL 1–49 50–79 >80 | 0 | | <u>1st + early 2nd trimester</u> <u>exposure</u> 1.8 (1.1, 3.0) 0.9 (0.5, 1.9) 2.2 (1.0, 4.8) | | |
| | Total exposure (μg/L)CHLQuintile 1Quintile 2Quintile 3Quintile 4Quintile 5 | No exposure | | 1.8 (0.9, 3.7) 1.3 (0.6, 3.0) 2.3 (1.1, 4.7) 1.3 (0.6, 2.8) 2.0 (1.0, 4.0) | | |

¹ Reported a rate change, which is the percent change calculated as the exponential of the regression coefficient (e.g. rate ratio of after/before) minus 1 and multiplied by 100.

Table 4b. Associations between Chloroform (CHL) Exposure and Spontaneous Abortion (SAB), Stillbirth, Birth Defects and Fertility in Human Studies (cont'd).

| Study/ | Exposure | Ratio (95% CI) | | | | |
|--|---|---|----------------|--|---|-----------|
| Location | Level | Level | SAB | Stillbirth | Birth Defects | Fertility |
| King et al. * * 2000 Nova Scotia | Water conc (μg/L) CHL 50–74 75–99 ≥100 Continuous (per 10 μg/L increase) | <50 | | Entire pregnancy <u>exposure</u> 1.20 (0.85, 1.68) 1.35 (0.87, 2.08) 1.56 (1.04, 2.34) 1.04 (1.00, 1.09) | | |
| Dodds and King* * 2001 Nova Scotia | <u>Water conc (µg/L)</u> CHL 50–74 75–99 | <50 | | | NTD - 1 month before conception to 1 month after 0.7 (0.4, 1.2) 0.7 (0.3, 1.5) | |
| | ≥100 | | | | 0.7 (0.3, 1.3) 1.2 (0.7, 2.3) <u>Cardiovascular anomalies</u> <u>1st 2 months of pregnancy</u> 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 0.7 (0.5, 1.0) Cleft defects | |
| | | | | | 1st 2 months of pregnancy 1.2 (0.7, 2.0) 0.9 (0.4, 2.0) 1.5 (0.8, 2.8) Chromosomal | |
| | | 14 | | | <u>abnormalities</u> <u>3 months before</u> <u>pregnancy</u> 1.3 (0.8, 2.2) 1.9 (1.1, 3.3) 1.4 (0.8, 2.8) | |
| Wennborg et al. 2000 Sweden | Women working in a laboratory with CHL n = 86 | Women with no laboratory work exposure n = 770 | 2.3 (0.9, 5.9) | | | |

Table 4b. Associations between Chloroform (CHL) Exposure and Spontaneous Abortion (SAB), Stillbirth, Birth Defects and Fertility in Human Studies (cont'd).

| Study/ | Exposure | Reference | Odds Ratio (95% CI) | | | | | |
|---------------------|--|-------------------------|---------------------|------------|---------------|---------------------------------|--|--|
| Location | Level | Level | SAB | Stillbirth | Birth Defects | Fertility | | |
| Dahl et al. 1999 | | | | | | Fecundability Ratio (95% CI) | | |
| Norway | Placement of CHL based root fillings by female dental surgeons | High School teachers | | | | 1.06 (0.95, 1.10) | | |

Table 5a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Male Reproductive Outcomes.

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|---------------------------------|---|--|---|---------------------|--|---|----------------------|
| Zeng et al.† † | Prospective | Sperm | Water sampling: | CHL water conc | Regression coefficients | Models adj for: | CHL was the dominant |
| | cohort | parameters: | One water treatment plant | (µg/L): | (95% CI) by quartile of CHL | Age | species in the water |
| 2014 | | | supplied water | M 40.74 | | - | distribution network |
| Zeng et al.† † 2014 China | Prospective cohort Men who presented to an infertility clinic for semen examination 2011–2012 N = 351 n = 324 (including fertile and sub-fertile men) | Sperm parameters: conc, count, motility Sperm motion parameters: straight line velocity (VSL), curvilinear velocity (VCL), linearity (LIN) | Water sampling: One water treatment plant supplied waterMonthly samples were collected at 3 sites (0.1 km, 4 km, and 8 km from the plant)THM conc in tap water measured within 90 days preceding semen collectionExposure Measurement: Subjects' home tap water THM levels estimated by averaging monthly THM conc from the 3 sampling sites for 90 days preceding semen sample collectionInterviewed to quantify last 3 months' routine water-use activities: • tap water consumption at home and work (including number and size of glasses) • personal hygiene • bathing/ showering • swimming in chlorinated poolsTHM uptake: • models created using self- reported routine water use, THM conc in tap water, and uptake | | Regression coefficients (95% CI) by quartile of CHL uptake through ingestion or showering/bathing: <u>Semen quality</u> <u>Ingestion:</u> (natural log transformation was applied to sperm conc and count) Sperm conc: 1) referent 2) -0.19 (-0.43, 0.05) 3) -0.25 (-0.51, 0.00) 4) -0.28 (-0.53, -0.02) p-trend = 0.03 Continuous = -0.15 (-0.25, -0.04) Sperm count: 1) referent 2) -0.15 (-0.40, 0.10) 3) -0.34 (-0.61, -0.07) 4) -0.22 (-0.49, 0.05) p-trend = 0.05 Continuous = -0.12 (-0.24, -0.01) Sperm motility: 1) referent 2) -4.66 (-9.93, 0.60) 3) -3.19 (-8.80, 2.41) 4) -4.13 (-9.73, 1.47) p-trend = 0.25 Continuous = -1.75 (-4.17, 0.16) | Models adj for: Age Smoking status (current and former vs. never smoker) Alcohol use Education level Abstinence time Other covariates considered: BMI Income Occupational exp | |
| | | | factors | | associations were also | | |
| | | | a 30% factor was applied to boiled tap water consumption to reflect reduced THM conc | | reported for continuous measures of CHL uptake via ingestion and decreased sperm conc $(\beta (95\% \text{ CI}) = -0.15 (-0.25,$ | | |
| | AC | GIH TLV DAR | r Chemical | 105 | | OEHHA | |
| | fo | r Reconsiderat | tion: Chloroform | | | August 2016 | |

Table 5a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Male Reproductive Outcomes (cont'd).

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|--|---------------------|---|----------------------------|----------|
| | | | - bottled water was given a null THM level | | -0.04)) and sperm count (β (95% Cl) = -0.12 (-0.24, -0.01)) | | |
| | | | Exp from swimming in chlorinated pools was not | | Showering/bathing: | | |
| | | | included in analyses because few (4.0%) had swum in the past 3 months | | No significant associations were observed with any semen quality measures | | |
| | | | | | Sperm motion Ingestion: | | |
| | | | | | VSL: 1) referent | | |
| | | | | | 2) -0.25 (-1.85, 1.35) 3) 0.38 (-1.32, 2.08) 4) 1.77 (0.07, 3.47) p-trend = 0.03 | | |
| | | | | | VCL: | | |
| | | | | | 1) referent 2) -1.08 (-3.64, 1.48) 3) -0.28 (-3.00, 2.45) 4) 2.74 (0.01, 5.46) p-trend = 0.03 | | |
| | | | | | LIN: | | |
| | | | | | 1) referent 2) 1.22 (-1.07, 3.52) 3) 1.67 (-0.77, 4.12) 4) 0.00 (-2.44, 2.44) p-trend = 0.94 | | |
| | | | | | Showering/bathing: | | |
| | | | | | VSL: 1) referent 2) -0.30 (-2.04, 1.43) 3) 0.17 (-1.34, 1.69) 4) 1.38 (-1.31, 3.07) p-trend = 0.12 | | |
| | | | | | VCL: 1) referent 2) -0.13 (-2.92, 2.67) 3) 1.90 (-0.54, 4.35) | | |
| | ۵C | | T Chemical | 106 | | ОЕННА | |

Table 5a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Male Reproductive Outcomes (cont'd).

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|--|----------------------------|----------|
| | | | | | 4) 2.32 (-0.40, 5.04) p-trend = 0.04 | | |
| | | | | | LIN: | | |
| | | | | | 1) referent | | |
| | | | | | 2) -0.74 (-3.22, 1.73) | | |
| | | | | | 3) -2.28 (-4.44, -0.11) | | |
| | | | | | 4) -0.17 (-2.58, 2.24) | | |
| | | | | | p-trend = 0.42 | | |
| | | | | | | | |

Table 5a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Male Reproductive Outcomes (cont'd).

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|---|---|---|--|---|---|--|--|
| Iszatt et al. 2013 England and Wales | Case-Referent study (from Chemicals and Pregnancy Study, Chaps- UK) Infertility clinic recruitment (13 clinics in 9 urban centers) 1999–2002 N = 2249 Cases had low motile sperm conc (MSC) n = 642 Controls n = 926 | Semen quality (percent motile sperm was defined as % moving forward at ≥ 5 µm/s) (low MSC was defined relative to days of abstinence) | Water sampling:Routinely collected THM measurements, typically 1 per quarter per water zone - for all water zones covered by 10 water companies in 6 water regions (1,568 water zones)THM data were modeled using Bayesian models to obtain more robust quarterly water zone- specific estimates of the mean conc of each THMExposure Measurement: Participants' postcode of residence was mapped to the corresponding water zoneParticipant exp was the sum of weighted quarterly estimates during the 90 days prior to semen sample collection | CHL water conc (μ g/L): Mean (SD) cases = 25.9 (19.0) controls = 27.3 (19.1) Interquartile range (μ g/L) = 12–38 | OR for Low MSC, per 10 µg/L increase CHL: 1.00 (0.92, 1.09) OR per inter-quartile increase for MSC as a continuous variable, sperm conc, and % motile sperm: no significant relationship was found for any of these outcomes (results only presented in graphic form) | Models adj for: Surgery to testes Regular alcohol consumption Occupational exp to glycol ether Abstinence (for models of sperm conc, % motile sperm, and MSC) Other covariates considered: Age Ethnicity Social class Regular smoking Wearing restrictive underwear Previous conception by the male Manual work Season of semen sampling | TTHM and CHL were highly correlated (r = 0.95) 75% of men from the original Chaps-UK study were eligible for the investigation due to availability of water company data Analysis of quarterly THM data from the water companies showed greater variance between than within water zones A 74-day exp window was investigated, but no material difference was observed Used multi-level modeling and sensitivity analysis No data were collected on: inhalation or dermal exp personal water use workplace (though majority of participants were employed (93.6% of cases, 96.2% of controls)) |

Other DBPs analyzed: TTHMs; BrTHMs

a sum)

(variations in TBM, DBCM, and BDCM conc were too small for analysis except as

Table 5a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Male Reproductive Outcomes (cont'd).

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|--|----------------------------|---|
| | Sample Sizes | | | | Multivariate regression coefficients (β) for CHL tertiles: (natural log transformation was applied to sperm conc and count) Sperm conc (million/mL) 1) 0 (referent) 2) -0.04 (-0.12, 0.04) 3) -0.08 (-0.16, 0.01) p (trend) = 0.07 Sperm count (millions) 1) 0 (referent) 2) -0.02 (-0.11, 0.08) 3) -0.07 (-0.16, 0.03) p (trend) = 0.19 Sperm motility (%) 1) 0 (referent) 2) 2.19 (-2.27, 6.64) 3) 1.35 (-3.13, 5.82) p (trend) = 0.55 Curvilinear velocity (µm/s) 1) 0 (referent) 2) 1.03 (-1.28, 3.34) 3) 2.15 (-0.17, 4.47) p (trend) = 0.07 Straight-line velocity (µm/s) 1) 0 (referent) 2) 0.89 (-0.59, 2.38) 3) 1.95 (0.46, 3.44) p (trend) = 0.01 Linearity (%) 1) 0 (referent) 2) 1.13 (-0.86, 3.12) | | CHL accounted for >90% of ΣTHMs All results for ΣTHMs were very similar to those of CHL The suggestive positive dose-response relationship between CHL and curvilinear velocity, and significant dose-response relationship between CHL and straight- line velocity were contrary to expectations A single blood sample was used to assess exp but intra- individual variability is not known Taking blood samples before any major water use might have missed important routine exp and reduced variability in exp assessments between individuals Sperm parameters not included in the statistical analysis due to high interdependence include: morphology; beat cross frequency; average path velocity; amplitude of lateral head displacement; straightness Other DBPs analyzed: THMs; TTHMs; BrTHMs |
| | Δ. | | PT Chomical | 109 | 3) 1.19 (-0.80, 3.19) p (trend) = 0.24 | ОЕННА | BDCM was significantly associated with decreased sperm count in the 2 nd tertile but there was no dose |

Table 5a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Male Reproductive Outcomes (cont'd).

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------|-------------------------------|-------------------------|---------------------------------|---------------------|---|----------------------------|--|
| | | | | | Serum total testosterone 1) 0 (referent) | | response (β=- 0.13 million (- 0.22, -0.03) , p = 0.01) |
| | | | | | 2) 0.92 (-35.25, 37.09) 3) -9.83 (-46.14, 26.47) p (trend) = 0.59 | | DBCM was significantly associated with linearity in the 2 nd tertile (-4.74% (-8.07, -1.42)) but there was no dose-response relationship |
| | | | | | | | - |

Table 5a. Detailed Summaries of Human Studies of Chloroform (CHL) Exposure and Male Reproductive Outcomes (cont'd).

| Study/ Location | Study Design/ Sample Sizes | Outcomes of Interest | Exposure Measurement Methods | Exposure Dosages | Results | Covariates/ Confounders | Comments |
|--------------------------------|--|--|---|---|---|---|---|
| Chang et al. 2001 Taiwan | Case study N = 1 (the subject was a laboratory worker who presented for infertility after the ventilation system in his workplace had shut down for 8 months ("exposure")) | Infertility Astheno- spermia (reduced sperm motility) | Exp scenario was reconstructed based on laboratory records and subject's description of work habits and conditions Field study: active air sampling using collection tubes and passive air sampling using badges Authors also conducted an experiment to determine evaporation rate of solvents and estimate conc in air Interview to determine exp time Semen analysis was conducted ~1 year prior to exp (during a complete fertility screening test) and 3 times after exp ended | Active air samples of CHL (ppm) = 8.5 Passive air samples of CHL (ppm) = 4.6 Authors also estimated CHL conc of 4.5 ppm based on evaporation CHL estimated at 450 ppm for 2 hours at the beginning of the workday (6 times/week) due to overnight accumulation and lack of ventilation | Semen parameters had been normal at fertility screening ~1 year prior to exp (May 1996) with 92% normal morphology and 95% motile at a normal speed at 30 min after ejaculation Exp occurred from August 1996 to April 1997 In samples following exp the proportions of motile sperm were as follows: July = 26% August = 11% October = 40% During the post-exp period: - sperm counts increased from 68.6 to 90.6 million/mL - white blood counts decreased from 15–20/high power field (HPF) to 1– 2/HPF - path velocity (µm/sec) increased from 35 to 50 | Use of drugs, alcohol, tobacco; and history of surgery had not changed Subject was also exposed to "considerable amounts" of tetrahydrofuran and isooctane to prepare for analysis of petrochemical products Authors state these chemicals have not been linked with male reproductive hazards No reported exp to extreme heat or radiation Anti-sperm antibody was negative Hormone levels, semen volume, sperm count, and morphology were normal Diagnoses of necrospermia, seminal tract infection, protein- carboxyl methylase deficiency, and axonemal defect | Possible underestimation of the evaporation of CHL due to no stirring, wiping, or other operations in simulation experiment Possible misclassification from the inability to completely reconstruct the exp setting due to ethical considerations Authors note that CHL has been associated with abnormal sperm morphology, which could affect motility; however, the authors reported that the semen analysis after exp showed normal morphology Morphology was left blank in Table 1 |

were excluded

| | | | | β-coeffic | cients (95% CI) | |
|----------------------------------|---|--------------------|--|---|--|---|
| Study/ Location | Exposure Level | Reference Level | Sperm Concentration ¹ (million/mL) | Sperm Count ¹ (million) | Sperm Motility (%) & Motile Sperm Concentration (MSC) | Sperm Motion ² |
| Zeng et al. † † 2014 China | Estimated internal <u>dose by ingestion</u> <u>(µg/d)</u> CHL 0.005–0.011 0.011–0.019 ≥0.019 P for trend Continuous ³ Estimated internal <u>dose by</u> | <0.005 | -0.19 (-0.43, 0.05) -0.25 (-0.51, 0.00) -0.28 (-0.53, -0.02) 0.03 -0.15 (-0.25, -0.04) | -0.15 (-0.40, 0.10) -0.34 (-0.61, -0.07) -0.22 (-0.49, 0.05) 0.05 -0.12 (-0.24, -0.01) | Sperm motility (%) -4.66 (-9.93, 0.60) -3.19 (-8.80, 2.41) -4.13 (-9.73, 1.47) 0.25 -1.75 (-4.17, 0.66) | Ingestion VSL 0.25 (-1.85, 1.35) 0.38 (-1.32, 2.08) 1.77 (0.07, 3.47) 0.03 VCL -1.08 (-3.64, 1.48) -0.28 (-3.00, 2.45) 2.74 (0.01, 5.46) |
| | showering/bathing CHL 0.64–0.126 0.126–0.246 ≥0.246 P for trend Continuous ³ | <0.064 | 0.10 (-0.16, 0.36) -0.07 (-0.30, 0.15) -0.04 (-0.29, 0.21) 0.13 -0.05 (-0.15, 0.05) | 0.00 (-0.28, 0.28) 0.07 (-0.17, 0.32) 0.04 (-0.23, 0.31) 0.74 0.01 (-0.10, 0.11) | -0.86 (-6.58, 4.86) -2.57 (-7.57, 2.43) 0.26 (-5.30, 5.83) 0.41 -0.44 (-2.61, 1.74) | 0.03 LIN There were no significant findings Showering/Bathing Straight-line velocity There were no significant findings Curvilinear velocity -0.13 (-2.92, 2.67) 1.90 (-0.54, 4.35) 2.32 (-0.40, 5.04) 0.04 |

Table 5b. Associations between Chloroform (CHL) Exposure and Sperm Parameters in Human Studies.

OEHHA August 2016

Abbreviations: CHL - chloroform; CI - confidence interval; conc - concentration; L - liter; LIN- linearity; MSC - motile sperm concentration; VCL - curvilinear velocity; VSL - straightline velocity.

¹ Natural log transformation was applied. ² Units of measurement for sperm motion parameters were straight-line velocity = μ m/s, curvilinear velocity = μ m/s, linearity = %, path velocity = μ m/sec.

³ Continuous - quartiles of uptake (µg/day).

| | | | | β-coeffic | ients (95% CI) | |
|---|--|------------------------|--|--|--|---|
| Study/ Location | Exposure Level | Reference Level | Sperm Concentration ¹ (million/mL) | Sperm Count ¹ (million) | Sperm Motility (%) & Motile Sperm Concentration (MSC) | Sperm Motion ² |
| | | | | | | Linearity -0.74 (-3.22, 1.73) -2.28 (-4.44, -0.11) -0.17 (-2.58, 2.24) 0.42 |
| Iszatt et al. 2013 England and Wales | <u>Water conc (µg/L)</u> Upper quartile Mean: Cases = 25.9 Controls = 27.3 | Lower quartile (12) | No significant relationship was observed for the effect of CHL on sperm conc (results presented graphically) | Not assessed | Low MSC per 10 µg/L increase in CHL: Odds ratio = 1.00 (0.92, 1.09) No significant relationship was observed for the effect of CHL on change in percent motile sperm | Not assessed |
| Zeng et al. † † 2013 China | Blood conc (ng/L) 35.87–66.35 >66.35 P for trend | <35.87 | -0.04 (-0.12, 0.04) -0.08 (-0.16, 0.01) 0.07 | -0.02 (-0.11, 0.08) -0.07 (-0.16, 0.03) 0.19 | 2.19 (-2.27, 6.64) 1.35 (-3.13, 5.82) 0.55 | Curvilinear velocity 1.03 (-1.28, 3.34) 2.15 (-0.17, 4.47) 0.07 Straight-line velocity 0.89 (-0.59, 2.38) 1.95 (0.46, 3.44) 0.01 Linearity 1.13 (-0.86, 3.12) 1.19 (-0.80, 3.19) 0.24 |

Table 5b. Associations between Chloroform (CHL) Exposure and Sperm Parameters in Human Studies (cont'd).

| | | | | β-coefficie | nts (95% CI) | |
|--------------------------------|---|--------------------|---|--|---|--|
| Study/ Location | Exposure Level | Reference Level | Sperm Concentration ¹ (million/mL) | Sperm Count ¹ (million) | Sperm Motility (%) & Motile Sperm Concentration (MSC) | Sperm Motion ² |
| Chang et al. 2001 Taiwan | Active air samples of CHL = 8.5 ppm Passive air samples of CHL = 4.6 ppm Estimated air CHL for 2 hours at the beginning of the workday = 450 ppm | | Not assessed | Authors state that sperm count was normal ~1 year prior to exposure. During the post- exposure period: sperm counts were as follows (by time since end of exposure): \approx 3 months: 68.6 \approx 4 months: 73.8 \approx 6 months: 90.6 | Semen parameters at screening ~1 year prior to exposure had been normal, with 95% motile at a normal speed at 30 min after ejaculation During the post- exposure period: the percentage of motile sperm were as follows (by time since end of exposure): \approx 3 months: 26% \approx 4 months: 11% \approx 6 months: 40% | Path velocity \approx 3 months: 35 \approx 4 months: 40 \approx 6 months: 50 |

Table 5b. Associations between Chloroform (CHL) Exposure and Sperm Parameters in Human Studies (cont'd).

3. Animal Studies of Reproductive and Developmental Toxicity of Chloroform

| | | Experin | nental Parame | eters | | | F (Effects | | |
|-------------------------|---|--|---|--|---|--|--|---|---|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Maternal Toxicity+ | Developmental Toxicity+ | Comments |
| Schwetz et al., 1974 | "Reagent grade" chloroform, Burdick & Jackson Lab, Inc. Sample assayed: purity 99.30% | Sprague-Dawley rats 8-77 females/group | Inhalation teratology study Food and water withheld during exposure; ad lib at night | 7 hr/day; GD 6- 15 | 0, 30, 100, 300 ppm Plus feed- restricted, "starved" control (3.7 g food, daily, GD 6-16) | Standard teratology evaluation SGPT* activity determined in pregnant and non-pregnant rats | ↓ feed consumption 100 & 300 ppm; only on GD 6-7 for 30 ppm ↓ BW on GD 13 at 30, 100, & 300 ppm; on GD 21 at 100 & 300 ppm ↓ absolute liver weight at 300 ppm; ↑ relative liver weight at 100 & 300 ppm | 300 ppm: ↓ pregnancy rate (3/20) ↓ litter size ↑ resorptions Altered sex ratio (M:F; 34:66) ↓ fetal weight & crown-rump length (CRL) 100 ppm: ↑ gross anomalies 30 ppm: ↑ skeletal anomalies ↓ CRL | No effect on SGPT in any group Starved controls: ↓ fetal growth measures, but no effect on viability |
| US EPA, 1978 | "Analytical grade" chloroform, Mallinckrodt, purity not specified | Sprague-Dawley rats 10 females/group | Inhalation teratology study | 1 hr/day; GD 7- 14 | 0; 4.6 mg/l (950 ppm = 110 mg/kg); 10.9 mg/l (2200 ppm = 260 mg/kg); 20.1 mg/l (4100 ppm = 480 mg/kg); plus feed- restricted control | Standard teratology evaluation | All: ↓ food consumption during days of treatment. 20.1 mg/l: All slept through exposure 1 death; ↓ BW^ 10.9 mg/l: Some slept through exposure | Feed-restricted controls: ↑ embryotoxicity ↓ fetal wt ↓ caudal ossification centers 20.1 mg/l: ↑ embryotoxicity ↓ fetal wt | Feed-restricted controls appear to have been matched to food consumption by the high concentration group. |

Table 6. Studies of Developmental Toxicity of Chloroform in the Rat, Inhalation Route.

Table 6. Studies of Developmental Toxicity of Chloroform in the Rat, Inhalation Route (cont'd).

| Baeder & Hoffman, 1988 | Chloroform, source and purity not specified, measured by infrared gas analyzer | Wistar rats 20-21 females/group | Inhalation teratology study | 7 hr/day; GD 7- 16 | 0, 30, 100, 300 ppm | Standard teratology evaluation | All concentrations: ↓ feed consumption (GD 14-17 & 17-21) ↑ BW on GD 0 ↓ BW GD 17 ↓ heart wt GD 21 100 & 300 ppm only: ↓ BW GD 21 | All concentrations: ↑ total (early) resorbed litters (no statistical evaluation) ↓CRL 300 ppm: ↓fetal weight | - |
|------------------------------------|--|---|---|---|--|---|--|--|------------------------------------|
| Garcia- Estrada et al., 1990 | Chloroform, source and purity not specified | Sprague-Dawley rats 3 females/group. | Inhalation developme ntal toxicity study Mated, sperm in vaginal smear= gestation day (GD) 1 | Inhalation (two 10-minute periods/day) GD 17 to GD 21 | Controls: No exposure Treated: Cotton impregnated with the chemical, placed inside of hermetic exposure chamber. No concentration provided. Authors reported that the chamber was saturated with chloroform | Pup body weight (BW), body length, cranial size and diameter at birth, 24, 48 and 72h of age. Random selection of 2 pups per litter for perfusion and histological analysis of the cerebellum (2 pups from each of 3 litters at 24, 48, and 72 hours) | Not evaluated | Decreased pup BW, body length and cranial diameter at all time points - Statistically significant (p <0.01) at some time points Decreased number of Purkinje cells at 24, 48, and 72 hours post-natally (p <0.01) at all time points No abortions, resorptions or neonatal mortality were found | Spanish language publication |
| Baeder & Hoffman, 1991 | "Reagent grade" chloroform, Merck, purity 99.0-99.4% | Wistar rats 22-25 females/group; 20 females/group evaluated | Inhalation teratology study | 7 hr/day; GD 7- 16 | 0, 3, 10, 30 ppm | Standard teratology evaluation | All concentrations, GD 7-14, and 30 ppm all times: ↓ feed consumption 10 & 30 ppm only: ↓ BW & wt gain | All concentrations: ↑ ossification variations/fetus (not per litter) 30 ppm: ↓ fetal weight & CRL | |

+ All effects listed significantly differ from controls at p < 0.05 level unless otherwise noted in table; ^ no statistical analysis reported; * Serum glutamic-pyruvic transaminase

| | | Experi | mental Parame | ters | | | (Effe | Results cts/NOEL/LOEL) | |
|------------------------|---|--|--|--|-------------------------------|--|--|---|---|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Maternal Toxicity+ | Developmental Toxicity+ | Comments |
| Murray et al., 1979 | "spectral grade" chloroform, Mallinckrodt , purity not specified | CF-1 mice 34-40 females/group | Inhalation teratology study, varied days of exposure | 7 hrs/day, GD 6-15, 1-7, or 8-15 | 0, 100 ppm | Standard teratology evaluation Maternal SGPT* activity determined on GD-16 following exposure on GD 6-15 | GD 6-15: 1/35 maternal death ↑ SGPT activity GD 1-7 or 8-15: ↓ wt gain, GD 6-15 or 8-15: ↑ absolute & relative liver wt | GD 1-7: ↑resorptions (2 litters completely resorbed) GD 1-7 or 6-15: ↓pregnancy rate GD 1-7 or 8-15: ↓fetal BW & CRL ↑retarded ossification of sternebrae GD 8-15: ↑cleft palate GD 1-7, 6-15, & 8-15: ↑ delayed ossification of skull bones | Study also included in table on female reproductive effects below |

Table 7. Study of Developmental Toxicity of Chloroform in the Mouse, Inhalation Route.

+ All effects listed significantly differ from controls at p < 0.05 level unless otherwise noted in table; * Serum glutamic-pyruvic transaminase

| | | Experi | mental Parame | ters | | | | Results s/NOEL/LOEL) | |
|--------------------------|---|--|--|---|---|---|--|---|--|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Maternal Toxicity+ | Developmental Toxicity+ | Comments |
| | Chloroform, Mallinckrodt; purity not specified | Sprague-Dawley rats 6 females/group | Range- finding teratology study | Oral gavage, corn oil vehicle; dose divided 2X per day; GD 6-15 | 0, 79, 126, 300, 316, 501 mg/kg- day | Fetal viability, wt, sex; Histology on liver and kidney from 2 dams per group on GD 20 | > 126 mg/kg-day: ↓ feed consumption and wt gain 316 & 501 mg/kg-day: 1 and 4 maternal deaths, respectively | 501 mg/kg-day: No live fetuses from 2 surviving dams 316 mg/kg-day: ↑ resorptions ↓ litter size and fetal wt | Data described in text only; no tables. No statistics |
| Thompson et al., 1974 | As above | Sprague-Dawley rats 25 females/group | Teratology study | As above | 0, 20, 50, 126 mg/kg- day | Standard teratology evaluation; Histology on liver, kidney, and heart from 2 dams per group on GD 15 | 126 mg/kg-day: Clinical symptoms ↓ feed consumption 126 & 50 mg/kg-day: ↓wt gain Fatty changes in livers | 126 mg/kg-day: ↑ implantations ↓fetal wt ↑ bilateral extra lumbar ribs (fetal incidence, not litter) | |
| Ruddick et al., 1983 | Chloroform, Caledon Laboratories, purity 99% | Sprague-Dawley rats 15 females/group | Teratology study | Oral gavage, corn oil vehicle,1X daily; GD 6-15 | 0, 100, 200, 400 mg/kg- day | Standard teratology evaluation. Maternal hematology, marrow cytology, serum & liver biochemistry, organ histology | All doses: ↓ wt gain ↑ liver wt (relative) ↓ hemoglobin & hematocrit ↓ sorbitol dehydrogenase 400 mg/kg-day: ↑ kidney wt (relative) ↓ red blood cell counts 200 & 400 mg/kg-day: ↑ inorganic phosphorus & cholesterol | 400 mg/kg-day: ↓ fetal wt ↑ aberrant sternebrae (8/8 surviving litters affected, no statistics) ↑ runts (8/8 surviving litters affected, no statistics) | At 400 mg/kg-day 4 dams died before term, and 3 were not pregnant. No details provided, but stated as not due to treatment. |

Table 8. Studies of Developmental Toxicity of Chloroform in the Rat, Oral Route.

119

| Lim et al., 2004 | Chloroform, source and purity not specified | Wistar rats Nulliparous 200–250 g 4 females/group | Effect of <i>in</i> <i>utero</i> and lactational exposure to chloroform on birth wt and postnatal indicators of type 2 diabetes On postnatal day (PND) 1, litters were evaluated and then culled to 3 males each. N=3/litter; 4 litters/group | Chloroform administered in drinking water from 2 wk prior to mating until parturition (<i>in utero</i> exposure only) or until weaning (<i>in</i> <i>utero</i> + lactational exposure) | 0, 75 μg/L | Litter size, sex ratio, birth wt, postnatal growth. Fasting glucose concentration: on PND 1, and at 4 and 26 weeks of age. Oral glucose tolerance test at 4 and 26 weeks of age. Pancreas β -cell area. | Not evaluated | At PND 1, pups of dams exposed to chloroform had significantly higher serum glucose levels and lower insulin levels; not due to β-cell depletion in the neonatal pancreas. No change in glucose homeostasis in response to a glucose challenge at 4 or 26 weeks of age. No effect on birth wt; however, with chloroform <i>in utero</i> only exposure offspring had significantly lower body wts at weaning (PND 21), but not at 26 weeks of age. With chloroform <i>in utero</i> + lactational exposure, reduced postnatal growth continued through 26 weeks. No effect on litter size or sex ratio at birth. | Animals exposed to chloroform during fetal and neonatal development did not exhibit persistent metabolic changes associated with the onset of type 2 diabetes. However, these animals did exhibit impaired postnatal growth, indicating some alteration in offspring physiology. |
|---------------------|--|--|--|--|------------|--|---------------|---|--|
|---------------------|--|--|--|--|------------|--|---------------|---|--|

| | | Experi | mental Parame | ters | | | (Effe | Results cts/NOEL/LOEL) | |
|---|--|--|--|---|-------------------------------|---|-------------------|--|----------|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Maternal Toxicity | Developmental Toxicity+ | Comments |
| Burkhalter & Balster, 1979; Balster & Borzelleca, 1982 | "Nanograde purity" chloroform, Mallinckrodt | Albino ICR mice Males and females treated prior to mating Housed 3 female:1 male for mating 5 females/group | Behavioral teratology study Liveborn litters culled to 8 pups | Daily by gavage, 3 weeks prior to mating, through mating (up to 21 days), gestation and lactation, directly to weaned pups Emulphor vehicle (polyoxyethylated vegetable oil and saline) | 0, 31.1 mg/kg-day | Righting reflex, Forelimb placing, Forepaw grasp, Rooting reflex, Cliff drop aversion, Auditory startle, Bar holding ability, Eye opening, Motor performance and learning measures | Not discussed | ↓postnatal wt gain (not statistically significant) ↓ scores for forelimb placement on PND 5 & 7 | |

Table 9. Study of Developmental Toxicity of Chloroform in the Mouse, Oral Route.

Table 10. Study of Developmental Toxicity of Chloroform in the Rabbit, Oral Route.

| | | Experi | mental Parame | eters | | | (Effect | Results s/NOEL/LOEL) | |
|--------------------------|---|--|--|--|--|---|--|--|---|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Maternal Toxicity+ | Developmental Toxicity+ | Comments |
| Thompson et al., 1974 | Chloroform, Mallinckrodt; purity not specified | Dutch-belted rabbits 5 females/group | Range- finding teratology study | GD 6-18, split dose 2X/day by gavage | 0, 25, 63, 100, 159, 251, 398 mg/kg-day | C-section on GD 29 Fetal viability, weight, CRL, sex Histology on does' heart, liver, kidney | > 100 mg/kg-day: 100% maternal death 100 mg/kg-day: 3/5 does died 63 mg/kg-day: Anorexia, weight loss 25 mg/kg-day: Mild diarrhea and anorexia | 100 mg/kg-day: No viable conceptuses 63 mg/kg-day: 2/4 not pregnant ↓ fetal viability | Data described in text, no tables No statistics |
| | As above | Dutch-belted rabbits 15 females/group | Teratology study | GD 6-16, single dose 1X/day by gavage | 0, 20, 35, 50 mg/kg-day | C-section on GD 29, fetuses incubated 24 hrs Standard teratology evaluation | 50 mg/kg-day: 4/15 maternal deaths ↓ BW gains | All doses, and controls: Aborted litters (1-4/15, no statistics or apparent dose response) 20 & 50 mg/kg-day: ↓ fetal wt 20 & 35 mg/kg-day: ↑ fetal incidence of incompletely ossified skull bones | Rat experiments described in table above |

| | | Experi | mental Parame | ters | | | (| | |
|-------------------------|---|--|---|--|---|--|-----------------------|---|----------|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure Doses/ (Route/Period/ Concen- Frequency/ trations Vehicle) | | Endpoints Assessed | Maternal Toxicity+ | Developmental Toxicity+ | Comments |
| Teixidó et al., 2015 | Chloroform, Sigma- Aldrich, purity not specified | Zebrafish embryos, 4 hours post fertilization (hpf) | In vitro whole embryo culture 30 embryos/con centration; 10 embryos/con centration X 3 independent spawning events (n=3) | 72 hours exposure in buffered embryo medium | 0, 0.14, 0.31, 0.63, 1.26 mM in buffered embryo medium | Mortality checked at 8, 28, 52, 76 hpf LC_{50} at end of test EC_{50} (fraction of abnormal embryos) Teratogenic index (TI) = LC_{50}/EC_{50} "Fingerprint endpoint" = concentration-response $+ \ge 50\%$ of malformed embryos showing index malformation Hatching success Minimum concentration to inhibit growth (MCIG) = significant \downarrow tail length Comet assay | Not relevant | $\begin{array}{l} EC_{20} = 0.7 \text{ mM} (84.7 \text{ mg/L})\\ EC_{50} = 0.85 \text{ mM} (100.3 \text{ mg/L})\\ LC_{50} = 2.1 \text{ mM} (286.5 \text{ mg/L})\\ TI = 2.5\\ MCIG = 1.26 \text{ mM}\\ Fingerprint \text{ endpoints} = eyes,\\ heart, tail (78.4\%, 75.7\%, 78.4\%,\\ respectively)\\ \downarrow \text{ hatching success at 76 hpf: } 0.63,\\ 1.26 \text{ mM}\\ \downarrow \text{ motility of unhatched embryos}\\ after \text{ dechorionation on 76 hpf}\\ Comet \text{ assay: } EC_{50} \text{ produced}\\ significant \text{ DNA damage compared}\\ to \text{ solvent control group} \end{array}$ | |

Table 11. Study of Developmental Toxicity of Chloroform in Zebrafish, in vitro.

| | | Experi | mental Parame | ters | | | Result (Effects/NOEL | | |
|------------------------------|---|---|--|--|--|--|---|---|--|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Systemic Toxicity+ | Reproductive Toxicity+ | Comments |
| Schwetz et al., 1974 | "Reagent grade" chloroform, Burdick & Jackson Lab, Inc. Sample assayed: purity 99.30% | Sprague-Dawley rats 8-77 females/group | Inhalation teratology study Food and water withheld during exposure; ad lib at night | 7 hr/day; GD 6- 15 | 0, 30, 100, 300 ppm plus feed- restricted, "starved" control (3.7 g food, daily, GD 6-16) | Standard teratology evaluation SGPT* activity determined in pregnant and non-pregnant rats | ↓ feed consumption 100 & 300 ppm; only on GD 6-7 for 30 ppm ↓ BW on GD 13 at 30, 100, & 300 ppm; on GD 21 at 100 & 300 ppm ↑ absolute liver wt at 300 ppm; ↓ relative liver wt at 100 & 300 ppm | 300 ppm: ↓ pregnancy rate (3/20) ↓ litter size ↑ resorptions | No effect on SGPT in any group Starved controls: ↓ fetal body measures, but no effect on viability |
| Baeder & Hoffman, 1988 | Chloroform, source and purity not specified, measured by infrared gas analyzer | Wistar rats 20-21 females/group | Inhalation teratology study | 7 hr/day; GD 7- 16 | 0, 30, 100, 300 ppm | Standard teratology evaluation | All concentrations: ↓ feed consumption (GD 14-17 & 17-21) ↑ BW on GD 0 ↓ BW GD 17 ↓ heart wt GD 21 100 & 300 ppm only: ↓ BW GD 21 | ↑ in completely resorbed litters at all concentrations of chloroform | |
| Baeder & Hoffman, 1991 | "Reagent grade" chloroform, Merck; purity 99.0-99.4% | Wistar rats 22-25 females/group; 20 pregnant females/group evaluated | Inhalation teratology study | 7 hr/day; GD 7- 16 | 0, 3, 10, 30 ppm | Standard teratology evaluation | All concentrations, GD 7-14, and 30 ppm all times: ↓ feed consumption 10 & 30 ppm only: ↓ BW & wt gain (no stats) | 1 lost litter at 30 ppm (not statistically significant) No effect on litter size or resorption frequency | |

Table 12. Studies of Female Reproductive Toxicity of Chloroform in Rats, Inhalation Route.

Table 13. Study of Female Reproductive Toxicity of Chloroform in Mice, Inhalation Route.

| | | Experi | mental Parame | ters | | Endpoints Assessed | (Effec | | |
|------------------------|--|--|--|--|-------------------------------|--|--|--|--|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | | Systemic Toxicity+ | Reproductive Toxicity+ | Comments |
| Murray et al., 1979 | "Spectral grade" chloroform, Mallinckrodt, purity not specified | CF-1 mice 34-40 females/group | Inhalation teratology study, varied days of exposure | 7 hrs/day, GD 6-15, 1-7, or 8-15 | 0, 100 ppm | Standard teratology evaluation Maternal SGPT* activity determined on GD-16 following exposure on GD 6-15 | GD 6-15: 1/35 maternal death ↑ SGPT activity GD 1-7 or 8-15: ↓ wt gain, GD 6-15 or 8-15: ↑ absolute & relative liver wt | GD 1-7: ↑resorptions (2 litters completely resorbed) GD 1-7 or 6-15: ↓pregnancy rate | Study also described in table on development al effects above |

+ All effects listed significantly differ from controls at p < 0.05 level unless otherwise noted in table ; * Serum glutamic-pyruvic transaminase;

| | | Experi | mental Parame | ters | | Endpoints | Results (Effects/NOEL/ | | |
|--------------------------|---|--|---|--|---|--|---|--|--|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Systemic Toxicity+ | Reproductive Toxicity+ | Comments |
| | Chloroform, Mallinckrodt, purity not specified | Sprague-Dawley rats 6 females/group | Range- finding oral teratology study | Oral gavage, dose divided 2X per day; GD 6-15 corn oil vehicle | 0, 79, 126, 300, 316, 501 mg/kg- day | Fetal viability, wt, sex; Histology on liver and kidney from 2 dams/group on GD 20 | > 126 mg/kg-day: ↓ feed consumption and wt gain 316 & 501 mg/kg-day: Maternal deaths | 501 mg/kg-day: No live fetuses from 2 surviving dams 316 mg/kg-day: ↑ resorptions ↓ litter size | Data described in text only; no tables No statistics |
| Thompson et al., 1974 | As above | Sprague-Dawley rats 25 females/group | Oral teratology study | As above | 0, 20, 50, 126 mg/kg- day | Standard teratology evaluation; Histology on liver, kidney, and heart from 2 dams/group on GD 15 | 126 mg/kg-day: Clinical symptoms ↓ feed consumption 126 & 50 mg/kg-day: ↓wt gain Fatty changes in livers | 126 mg/kg-day: ↑ implantations | |
| Ruddick et al., 1983 | Chloroform, Caledon Laboratories purity 99% | Sprague-Dawley rats 15 females/group | Oral teratology study | Oral gavage, 1X daily; GD 6- 15 corn oil vehicle | 0, 100, 200, 400 mg/kg- day | Standard teratology evaluation. Maternal hematology, marrow cytology, serum & liver biochemistry, organ histology | All doses: ↓ wt gain ↑ liver wt (relative) ↓ hemoglobin & hematocrit ↓ sorbitol dehydrogenase 400 mg/kg-day: ↑ kidney wt (relative) ↓ red blood cell counts 200 & 400 mg/kg-day: ↑ inorganic phosphorus & cholesterol | No effect on live litter size or resorption frequency | |

Table 14. Studies of Female Reproductive Toxicity of Chloroform in Rats, Oral Route.

| | | Experi | mental Parame | ters | | | | Results s/NOEL/LOEL) | |
|-------------------------------------|---|---|---|--|--|--|--|---|--|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Systemic Toxicity+ | Reproductive Toxicity+ | Comments |
| Chapin et al., 1977 NTP, 1988 | Chloroform, Aldrich Chemical Co., purity >99% | VAF CrI:CD-1 (ICR)BR mice 20 male and female pairs/group; 40 control pairs | Continuous breeding study. P0: all dose groups evaluated F1: control & high dose only | Oral, gavage, P0 dosed daily for 1 week prior to, 14 weeks during, & 3 weeks after co- habitation. Final F1 litters treated after weaning corn oil vehicle | 0, 6.6, 15.9, 41.2 mg/kg-day | P0: Clinical signs, bw, water consumption, fertility and litter data. F1: body and organ wt | 41.2 mg/kg-day, P0: ↓Maternal wt at delivery of 4th litter 41.2 mg/kg-day, F1 females: ↑ absolute & adjusted liver wt Minimal to moderate hepatocellular degeneration | 41.2 mg/kg-day, F1: ↑ fertility index ↑ female pups/litter ↑ female + male pups/litter | All P0 groups delivered 4 litters Study also described in table on male effects below |
| US EPA, 1980 | "Pesticide quality" chloroform, Matheson Coleman Bell, distilled by test lab to remove diethyl carbonate impurity | B6C3F1 mice 30 females /group; 40 controls | 90-day subacute toxicity study | 90-day drinking water study Fresh solutions prepared 2X/week | 0, 20, 40, 60, 90, 180, 270 mg/kg- day 2 control groups: ad lib, and water consumption matched to high-dose group | Daily observations Weekly BW Days 0, 30, 60, & 90; 10 rats/group sacrificed for pathology and biochemistry | Deaths at 60, 90, 270 mg/kg-day Effects on BW at ≥ 60 mg/kg-day during first three weeks (no clear dose response) Fatty liver ↑ at 270 mg/kg- day, at each of the 3 sacrifice time-points; also ↑ for water-matched controls at final sacrifice | | No pathological changes noted for any group at any time in mammary, ovaries, or uterus |

Table 15. Studies of Female Reproductive Toxicity of Chloroform in Mice, Oral Route.

Table 16. Study of Female Reproductive Toxicity of Chloroform in Rabbits, Oral Route.

| | | Experi | mental Parame | ters | | | | Results s/NOEL/LOEL) | |
|--------------|---|--|---|--|--|--|---|---|---|
| | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Systemic Toxicity+ | Reproductive Toxicity+ | Comments |
| Thompson | Chloroform, Mallinckrodt, purity not specified | Dutch-belted rabbits 5 females/group | Range- finding oral teratology study | GD 6-18, split dose 2X/day by gavage | 0, 25, 63, 100, 159, 251, 398 mg/kg-day | Fetal viability, weight, CRL, sex Histology on does' heart, liver, kidney | 159, 251, 398 mg/kg-day: 100% maternal death 100 mg/kg-day: 3/5 maternal deaths 63 mg/kg-day: Anorexia, weight loss 25 mg/kg-day: Mild diarrhea and anorexia | 100 mg/kg-day: No viable conceptuses 63 mg/kg-day: 2/4 not pregnant ↓ fetal viability | Data from range- finding study described in text, no tables; no statistical analysis |
| et al., 1974 | As above | Dutch-belted rabbits 15 females/group | Oral teratology study | GD 6-16, single dose 1X/day by gavage | 0, 20, 35, 50 mg/kg-day | C-section on GD 29, fetuses incubated 24 hrs Standard teratology evaluation | 50 mg/kg-day: 4/15 maternal deaths ↓ BW gains (data not provided, but stated to be significant) | All doses, and controls: Aborted litters (1-4/15, no statistics or apparent dose response) | |

| | | Experi | mental Parame | ters | | Endpoints Assessed | (Effect | | |
|-------------------------|--|---|---|--|--------------------------------------|--|---|---|---|
| | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | | Systemic Toxicity | Reproductive Toxicity | Comments |
| Heywood et al., 1979 | Chloroform, source and purity not specified | Beagle dogs Dosed, untreated controls, and controls given alternate toothpaste: 8 dogs/sex/group Vehicle toothpaste controls: 16 dogs/sex/group | 7.5 year chronic study Treatment ceased at week 376; all animals sacrificed at week 395- 399 | Doses mixed into toothpaste and given in capsules | 0, 15, 30 mg/kg-day; 6 days/wk | Clinical symptoms, food and water consumption, clinical exams, biochemistry terminal histopathology | At end of treatment: Dose-related ↑biochemical indicators of liver damage; appeared reversible during recovery phase, at least in some dogs Significance levels varying among dose and week of measurement from p < 0.05-0.001) | No treatment-related changes in ovaries or uteri "Nodular hyperplasia of mammary gland" in 3 females at 15 mg/kg- day, in 5 vehicle controls, and 1 untreated control No statistical analysis | Preliminary study included in paper not reported here as no reproductive endpoints assessed |

Table 17. Study of Female Reproductive Toxicity of Chloroform in Beagle Dogs, Oral Route.

Table 18. Study of Male Reproductive Toxicity of Chloroform in Mice, Inhalation Route.

| | | Experi | mental Parame | ters | | | (Effect | | |
|----------------------|--|--|--|--|-------------------------------|-----------------------------------|---|---|--|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Systemic Toxicity | Reproductive Toxicity | Comments |
| Land et al., 1981 | Chloroform, Fischer Scientific, purity not specified Delivered to inhalation cages in air | Mice Males, 15 controls, (10) 9 "survivors" in each dose group | Sperm morphology study Sacrifice at 28 days following 1st day of exposure | Inhalation, 4 hr/day, 5 consecutive days | 0, 0.04, 0.08% in air | Epididymal sperm morphology | Not discussed Appears that 1 animal in each dose group died | 0.04 & 0.08%: ↑ frequency of abnormal sperm morphology (p < 0.01) | Normal mouse spermatoge nesis cycle 35-36 days; 28 day evaluation mid-cycle |

Table 19. Study of Male Reproductive Toxicity of Chloroform in Rats, Oral Route.

| | | Experi | mental Parame | ters | | Endpoints Assessed | | lesults /NOEL/LOEL) | |
|-----------------|---|--|----------------------------|--|---|--|---|--|---|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | | Systemic Toxicity+ | Reproductive Toxicity+ | Comments |
| US EPA, 1980 | "pesticide quality" chloroform, Matheson Coleman Bell, distilled by test lab to remove diethyl carbonate impurity | Osborne-Mendel rats 30 males/group; 40 controls Additional controls paired for water- consumption | Subacute toxicity study | 90-day drinking water study Fresh solutions prepared 2X/week | 0, 20, 38, 57, 81, 160 mg/kg-day 2 control groups: ad lib, and water consumption matched to high-dose group | Daily observations Weekly BW Days 0, 30, 60, & 90; 10 rats/group sacrificed for pathology and biochemistry | 160 mg/kg-day, all days: ↓ BW, also seen in watermatched controls 81 mg/kg-day: ↓ BW for 1st week of treatment | 160 mg/kg-day, day 30 sacrifice: One case each of testicular hyperplasia and interstitial cell hyperplasia (not clear if single animal) | NS reduction in water consumption with chloroform Mouse portion of study discussed in table on female effects above |


Table 20. Study of Male Reproductive Toxicity of Chloroform in Mice, Oral Route.

| | | Experi | mental Paramet | ters | | Endpoints Assessed | (Effect | | |
|--------------------------------------|--|---|---|--|------------------------------------|---|---|--|--|
| Reference | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | | Systemic Toxicity+ | Reproductive Toxicity+ | Comments |
| Chapin et al., 1997; NTP, 1988 | Chloroform, Aldrich Chemical Co., purity >99% | VAF CrI:CD-1 (ICR)BR mice 20 male and female pairs/group; 40 control pairs | Continuous breeding study. P0: all dose groups evaluated F1: control & high dose only | Oral, gavage, P0 dosed daily for 1 week prior to, 14 weeks during, & 3 weeks after co- habitation. Final F1 litters treated after weaning corn oil vehicle | 0, 6.6, 15.9, 41.2 mg/kg-day | P0: Clinical signs, BW, water consumption, fertility and litter data. F1: Sperm data, body and organ weights | 41.2 mg/kg-day, P0: ↓Maternal wt at delivery of 4 th litter 41.2 mg/kg-day, F1 females: ↑ absolute & adjusted liver wt Minimal to moderate hepatocellular degeneration | 41.2 mg/kg-day, P0: ↑ fertility index ↑ female pups/litter ↑ female + male pups/litter F1: ↑ Absolute right epididymal wt Minimal to mild degeneration of epididymal ductal epithelium. | All P0 groups delivered 4 litters Study also described in table on female effects above |

| | | Experi | mental Parame | ters | | Endpoints Assessed Clinical | | Results s/NOEL/LOEL) | |
|-------------------------|--|---|---|--|--------------------------------------|--|--|---|---|
| | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | | Systemic Toxicity | Reproductive Toxicity | Comments |
| Heywood et al., 1979 | Chloroform, source and purity not specified | Beagle dogs Dosed, untreated controls, and controls given alternate toothpaste: 8 dogs/sex/group Vehicle toothpaste controls: 16 dogs/sex/group | 7.5 year chronic study Treatment ceased at week 376; all animals sacrificed at week 395- 399 | Doses mixed into toothpaste and given in capsules | 0, 15, 30 mg/kg-day; 6 days/wk | Clinical symptoms, food and water consumption, clinical exams, biochemistry terminal histo- pathology | At end of treatment: Dose-related ↑biochemical indicators of liver damage; appeared reversible during recovery phase, at least in some dogs Significance levels varying among dose and week of measurement from p < 0.05-0.001) | "Ectopic testes with inhibition of spermatogenesis" in 2 dogs at 30 mg/kg-day, 1 dog at 15 mg/kg-day, and 1 untreated control No statistical analysis reported | Preliminary study included in paper not reported here as no reproductive endpoints assessed |

Table 21. Study of Male Reproductive Toxicity of Chloroform in Beagle Dogs, Oral Route.

Figure 10. Schematic of Protocol for Multigeneration Reproductive Toxicity Study with Satellite Components Used by Borzelleca and Carchman, 1982.



| Reference | Experimental Parameters | | | | | | Results (Effects/NOEL/LOEL) | | |
|--|---|--|---|---|---|--|---|---|---|
| | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period/ Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Maternal/Systemic Toxicity+ | Developmental/Reproductive Toxicity+ | Comments |
| Borzelleca and Carchman, 1982 | Chloroform, Fischer Scientific, purity 99% | ICR Swiss mice (obtained at 7 weeks of age and then quarantined for 2 weeks) Co-habited for 1 week at a ratio of 1 male to 3 females N=10 males/ group N=30 females/ group | See figure 1 for diagram. Multi- generation reproductive toxicity study; with satellite studies. Parental matings produced 3 F1 litters; F1b matings produced 2 F2 litters. F/1C and F/2B litters were divided between dominant lethal, teratology, and 21-day survival studies. | Drinking water, continuous exposure Vehicle: emulphor (poly- ethoxylated vegetable oil):water (1:1000) | 0.0 (distilled, deionized water and vehicle control groups), 0.1, 1.0, 5.0 mg/ml | No methods description included, endpoints assessed can only be inferred from reported results | ↓ Body weight gain (both sexes) in F/0 and F/1B generations exposed to 5.0 mg/ml, and F/1B females exposed to 1.0 mg/ml ↓ 21-day survival: F/0 males and females, 5.0 mg/ml F/1B males, all doses F/1B females, 5.0 mg/ml Enlarged livers, 5.0 mg/ml, F/0 and F/1B "almost all animals" Final necropsies found liver pathology "characteristic of chlorinated hydrocarbon toxicity" | ↓ gestation index* at 5.0 mg/ml: F/1A, F/1C, F/2A; but not for F/1B or F/2B. ↓ mating index** at 0.1 mg/ml, F/1C; and at 5.0 mg/ml for F/1A, F/1B, and F/2A; but not F/1C or F/2B. ↓ litter size at 5.0 mg/ml for F/1A, F/1B, F/1C, F/2A, and F/2B (as reported in table 13 of the study). ↓ viability Index# (PND 4) at 1.0 mg/ml F/1B; and at 5.0 mg/ml in F/1A, F/1B, and F/2A litters. ↓ lactation index## at 1.0 mg/ml in F/1A litters; and at 5.0 mg/ml in F/1A and F/2A litters . | Document is an unpublished study, provided to US EPA by the Medical College of Virginia. Some tables cite to an "in press" reference – no evidence could be found that the paper was ever published |

Table 22. Study of Multigeneration Reproductive Toxicity of Chloroform in Mice, Oral Route.

Table 22. Study of Multigeneration Reproductive Toxicity of Chloroform in Mice, OralRoute (cont'd).

| | Experimental Parameters | | | | | | Results (Effects/NOEL/LOEL) | | |
|---|---|--|---------------------------------|--|-------------------------------|-----------------------|--|---|--|
| | Chemical (Source/ Purity/ Preparation) | Animal Model (Species/ Strain/Sex/Age) N (Control/ Treated) | Study Design | Exposure (Route/Period / Frequency/ Vehicle) | Doses/ Concen- trations | Endpoints Assessed | Maternal/Systemic Toxicity+ | Developmental/Reproductive Toxicity+ | Comments |
| | | , | Dominant lethal satellite | As above | As above | As above | As above | No significant dominant lethal effects | |
| Borzelleca and Carchman, 1982 (continued) | | | Teratology satellite | As above | As above | As above | As above | From tables 20 – 22: No significant effects of treatment noted on number of litters, number of implantations per dam, live fetuses per litter, percent of implants resorbed, or sex ratio in F/1C or F/2B generations. No evidence for an effect of treatment on external, internal, or skeletal abnormalities from F/1C or F/2B generations skeletal abnormality not assessed for F/2B. | Fetuses do not appear to have been weighed in the teratology component of the protocol. |
| | | - Ni fomeloo delive | 21-Day survival satellite | As above | As above | As above | Decreased 21-day survival in exposed males and females from F/0 and F/1B; lowest effective concentration = 0.1 mg/ml | | |

*gestation index = N females delivering live young/N pregnant females X 100

**mating index = N pairs mating/N pairs cohabited X 100# viability index = N live offspring per litter on PND4/N live offspring per litter at birth X 100

lactation index = N live offspring per litter at weaning (PND21)/N live offspring born (adjusted for culling if necessary) X 100

4. Summary

Preterm Birth

Eight epidemiologic studies specifically examined the risk of preterm birth associated with chloroform exposure. Five of these studies found no significant association (Kramer et al. 1992; Hinckley et al. 2005; Villanueva et al. 2011; Costet et al. 2012; Rivera-Nuñez and Wright 2013). One study did not analyze the risk from exposure to chloroform specifically (Patelarou et al. 2011), but reported no increased risk with exposure to total trihalomethanes. Interestingly, three studies (Wright et al. 2004; Savitz et al. 2005; Lewis et al. 2007) observed a significant, fairly consistent, inverse risk of preterm birth associated with chloroform exposure (i.e., a protective effect). It is not clear what mechanism may be responsible for this association, if it is real; however, Savitz et al. (2005) postulated that perhaps some selective loss leaves a heartier group of surviving fetuses who are less prone to be adversely affected by chemical exposures.

No effects of chloroform on gestation length were reported in experimental studies in animals.

Small for Gestational Age

A large number of epidemiologic studies examined the risk of small for gestational age associated with exposure to chloroform. Ten studies observed no increased risk or no statistically significant increased risk with chloroform exposure (Hinckley et al. 2005; Porter et al. 2005; Savitz et al. 2005; Hoffman et al. 2008; Grazuleviciene et al. 2011; Villanueva et al. 2011; Costet et al. 2012; Danileviciute et al. 2012; Levallois et al. 2012; Rivera-Nuñez and Wright, 2013). In three studies increased risk of small for gestational age was reported in a dose-dependent manner (Kramer et al. 1992; Wright et al. 2004; Summerhayes et al. 2012). One other study assessed the association between chloroform exposure and small for gestational age (as intrauterine growth restriction) and included consideration of a gene-environment interaction (Infante-Rivard, 2004). This case-control study examined two genetic polymorphisms, one in the CYP2E1 gene (G1259C), and another in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene (C677T). The results showed an increased odds ratio with certain polymorphisms; however, these were not statistically significant. The Developmental and Reproductive Toxicant (DART) Identification Committee reviewed these data in 2004 and asked that OEHHA request Dr. Infante-Rivard to reanalyze the data using a less conservative cutoff. The results of the analysis were not statistically significant. Dr. Infante-Rivard did not agree with the use of this cutoff as she believed the cutoff should be based on where effects are likely. The chloroform levels in this study were not high and the sample size was small (see Appendix C: Re-analysis of Data from Two Chloroform

Epidemiological Studies: Wennborg et al. (2000) and Infante-Rivard (2004)). In the study by Patelarou et al. (2011), the risk from exposure to chloroform was not specifically analyzed.

As described below under "Low Birth Weight", experimental studies in several species of laboratory animals reported adverse effects of maternal chloroform exposure on fetal weight. Crown-rump length was also reduced in rats (Schwetz et al. 1974; Baeder and Hoffman 1988, 1991; Garcia-Estrada et al. 1990) and mice (Murray et al. 1979) exposed by inhalation.

Low Birth Weight

There are a number of well-conducted epidemiologic studies with extensive exposure assessment that examined the risk for low birth weight in association with chloroform exposure. Statistically significant increased risks were observed in studies by Toledano et al. (2005), Lewis et al. (2006), Iszatt et al. (2014), Danileviciute et al. (2012), and Grazuleviciene et al. (2011). The findings of particular interest are from a nested case-control study (Danileviciute et al., 2012), which was part of the European Commission Health Impacts of long-term Exposure to Disinfection By-products in Drinking Water in Europe (HiWATE) study. This study included extensive exposure assessment as well as analysis of the maternal genetic polymorphisms for two metabolic genes and disinfection by-product-related gene-environment interactions. A large statistically-significant increased risk of low birth weight was observed in chloroform-exposed women, assessed as estimated internal dose, who had the GSTM1-0 (glutathione-S-transferase M1 null) genotype but not in those with the GSTM1-1 (glutathione-S-transferase M1) genotype. These associations were more pronounced when interactions between genotype and chloroform exposure were examined.

Reduced fetal weights were also reported in experimental animal studies in rats following maternal exposure to chloroform by the inhalation (Schwetz et al. 1974; US EPA 1978; Baeder and Hoffman 1988, 1991) and oral (Thompson et al. 1974; Ruddick et al. 1983) routes of exposure, as well as in mice exposed by inhalation (Murray et al. 1979) and rabbits exposed orally (Thompson et al. 1974).

Birth Weight

The association between chloroform exposure and birth weight was examined in ten epidemiologic studies. Four of the studies reported no significant association (Wennborg et al. 2000; Savitz et al. 2005; Hoffman et al. 2008; Villanueva et al. 2011). Six of the studies observed statistically significant decrements in birth weight with chloroform exposure (Wright et al. 2004; Zhou et al. 2010; Grazuleviciene et al. 2011; Summerhayes et al. 2012; Rivera-Nuñez and Wright 2013; Smith et al. 2015) with most of these showing evidence of a dose-response relationship. Of note is the study by

Smith et al. (2015), which reported no significant findings when examining the total study population. However, a significant dose-dependent decrement in birth weight was associated with chloroform exposure, assessed as estimated internal dose, in infants of Pakistani origin in comparison to those of white British origin.

Spontaneous Abortion

Three epidemiologic studies were identified that examined the risk of spontaneous abortion in relation to chloroform exposure; one reported an elevated risk estimate. In the retrospective cohort study by Wennborg et al. an elevated risk of spontaneous abortion (OR = 2.3 (95% CI, 0.9, 5.9) was associated with working in a laboratory with chloroform, which was assessed through a questionnaire. The Developmental and Reproductive Toxicant (DART) Identification Committee reviewed these data in 2004 and asked that OEHHA request Dr. Wennborg to reanalyze the data excluding previous spontaneous abortions. In the re-analysis the resulting odds ratio did not change substantially; however, with the narrower 95% CI this association was now statistically significant (OR = 2.1 (95% CI, 1.1, 4.0)). (see Appendix C: Re-analysis of Data from Two Chloroform Epidemiological Studies: Wennborg et al. (2000) and Infante-Rivard (2004)).

Reported effects of chloroform in experimental studies in animals on indices of fetal viability resulting from exposure by the inhalation route included decreased litter size in rats (Schwetz et al. 1974; Baeder and Hoffman 1988) and increased resorptions in rats (Schwetz et al. 1974) and mice (Murray et al. 1979). Exposure by the oral route resulted in increased resorptions in rats and decreased fetal viability in rabbits (Thompson et al. 1974). One study in rats exposed orally reported no effect on live litter size or resorption frequency (Ruddick et al. 1983).

Stillbirth

Four epidemiologic studies examined stillbirths in association with chloroform water concentration. In an intervention study (Iszatt et al., 2014), changes in water treatment methods by the utilities company resulted in increases or decreases in water chloroform concentration, however, no significant changes in stillbirth rates were observed in association with changes in chloroform concentration. Three studies observed an increased risk of stillbirth with chloroform exposure, although in two studies the estimates were not consistently statistically significant (Dodds et al. 2004; King et al., (2000). The results of Toledano et al. (2005) showed a small but statistically significant increased risk of stillbirth.

Birth Defects

Of the three epidemiologic studies that examined the risk of birth defects with exposure to chloroform (Dodd and King, 2001; Iszatt et al., 2011; Grazuleviciene et al., 2011), only one reported an association, that being with chromosomal abnormalities (Dodd and King, 2001). This study is notable in that it was one of the few studies in this dataset to sample the participants' tap water.

In experimental studies of chloroform conducted in animals, an increase in gross and skeletal anomalies in rats (Schwetz et al. 1974) and an increased incidence of cleft palate in mice (Murray et al. 1979) exposed by inhalation were reported. Effects on ossification and skeletal development were reported in studies of several species including rats (US EPA 1978; Baeder and Hoffman 1991; Thompson et al. 1974; Ruddick et al. 1983), mice (Murray et al. 1979) and rabbits (Thompson et al. 1974). Some of the effects may be indicative of general developmental delay, rather than frank malformations.

Postnatal Weight Gain

One prospective cohort study examined postnatal weight gain in infants born in 3 study sites (Botton et al., 2015). The results showed a statistically significant decrease in postnatal weight gain with chloroform exposure as estimated internal dose through ingestion in the community with the highest chloroform water concentrations.

In experimental studies of chloroform conducted in animals, pup body weight was reduced in rats exposed via maternal inhalation exposure during gestation (Garcia-Estrada et al. 1990), as was weight at weaning in rats exposed only during gestation (Lim et al. 2004).

Fertility

An occupational retrospective cohort study conducted by Dahl et al. (1999) examined fertility in female dental surgeons. Chloroform exposure was assessed using a questionnaire concerning the number of root fillings with chloroform-based root canal sealing material placed per week. No association was observed for time to pregnancy.

One experimental study in mice exposed to chloroform by inhalation reported reduced pregnancy rate (Murray et al. 1979), while another study in mice exposed orally reported an increased fertility index associated with exposure (Chapin et al. 1977; NTP 1988).

Menstrual Cycle Function

In a prospective study of menstrual cycle length, (Windham et al., 2003), no significant association was evident for chloroform exposure and cycle length.

Sperm Quality

Four studies examined associations between chloroform exposure in men and sperm quality, with two studies reporting significant decreases in sperm quality, one study reporting a suggestive dose-response association, and another study observing no association.

In the human case study by Chang et al. (2001), investigators reconstructed the exposure situation created by a ventilation system shut down lasting months. Significantly reduced sperm motility was reported following chloroform exposure as compared to the normal baseline measures taken before exposure. After exposure stopped sperm motility improved.

Two related studies include a cross-sectional study (Zeng et al, 2013) and a prospective cohort study (Zeng et al., 2014), which examined a number of different indices of sperm quality including various measures of sperm motion. Zeng et al. (2013) reported a suggestive dose response association between blood chloroform concentration and decreased sperm concentration. An unexpected reverse association was also observed where increases in blood chloroform concentration resulted in increased straight-line velocity. Zeng et al. (2014) reported statistically significant associations including significant trends between chloroform exposure (measured as estimated internal dose via ingestion) and decreased sperm concentration as well as some suggestive associations with sperm concentration.

An experimental study of sperm morphology in mice exposed to chloroform by inhalation reported an increased incidence of abnormal sperm morphology (Land et al. 1981). Studies of chloroform in rats (US EPA 1980), mice (Chapin et al. 1977; NTP 1988) and dogs (Heywood et al. 1979) reported low incidences of testicular and epididymal abnormalities.

References

Backer, L. C., Q. Lan, B. C. Blount, J. R. Nuckols, R. Branch, C. W. Lyu, S. M. Kieszak, M. C. Brinkman, S. M. Gordon, W. D. Flanders, M. Romkes and K. P. Cantor (2008). "Exogenous and endogenous determinants of blood trihalomethane levels after showering". Environmental Health Perspectives 116(1): 57-63.

Baeder, C. and T. Eofmann (1988). "Inhalation embryotoxicity study of chloroform in Wistar rats". Pharma Research Toxicology and Pathology.

Baeder, C. and T. Hofmann (1991). "Chloroform: Supplementary Embryotoxicity Study in Wistar Rats". Pharma Development Toxicology.

Balster, R. L. and J. F. Borzelleca (1982). "Behavioral toxicity of trihalomethane contaminants of drinking water in mice". Environmental Health Perspectives 46: 127-36.

Blount, B. C., L. C. Backer, L. L. Aylward, S. M. Hays and J. S. LaKind (2011). Human Exposure Assessment for DBPs: Factors Influencing Blood Trihalomethane Levels A2 - Nriagu, J.O. Encyclopedia of Environmental Health. Burlington, Elsevier: 100-7.

Borzelleca, J. F. and R. A. Carchman (1982). Effects of selected organic drinking water contaminants on male reproduction. Unpublished report provided to US EPA. PB82-259847. 148 pages.

Botton, J., M. Kogevinas, E. Gracia-Lavedan, E. Patelarou, T. Roumeliotaki, C. Iniguez, L. Santa Marina, J. Ibarluzea, F. Ballester, M. A. Mendez, L. Chatzi, J. Sunyer and C. M. Villanueva (2015). "Postnatal weight growth and trihalomethane exposure during pregnancy". Environmental Research 136: 280-8.

Burkhalter, J. E. and R. L. Balster (1979). "Behavioral teratology evaluation of trichloromethane in mice". Neurobehavioral Toxicology 1(3): 199-205.

Chang, H. Y., Y. M. Lin, P. C. Hsu and Y. L. Guo (2001). "Reduction of sperm motility in a male laboratory worker exposed to solvents: a case study". Environmental Health Perspectives 109(7): 753-6.

Chapin, R., D. K. Gulati, E. Hope, R. C. Mounce, S. Russell and K. B. Poonacha (1997). "Chloroform". Environmental Health Perspectives 105(Supplement 1).

Costet, N., R. Garlantezec, C. Monfort, F. Rouget, B. Gagniere, C. Chevrier and S. Cordier (2012). "Environmental and urinary markers of prenatal exposure to drinking water disinfection by-products, fetal growth, and duration of gestation in the PELAGIE birth cohort (Brittany, France, 2002-2006)". American Journal of Epidemiology 175(4): 263-75.

Dahl, J. E., J. Sundby, A. Hensten-Pettersen and N. Jacobsen (1999). "Dental workplace exposure and effect on fertility". Scandinavian Journal of Work, Environment & Health 25(3): 285-90.

Danileviciute, A., R. Grazuleviciene, J. Vencloviene, A. Paulauskas and M. J. Nieuwenhuijsen (2012). "Exposure to drinking water trihalomethanes and their association with low birth weight and small for gestational age in genetically susceptible women". International Journal of Environmental Research and Public Health 9(12): 4470-85.

Dodds, L., W. King, A. C. Allen, B. A. Armson, D. B. Fell and C. Nimrod (2004). "Trihalomethanes in Public Water Supplies and Risk of Stillbirth". Epidemiology 15(2): 179-86.

Dodds, L. and W. D. King (2001). "Relation between trihalomethane compounds and birth defects". Journal of Occupational and Environmental Medicine 58(7): 443-6.

Fenster, L., K. Waller, G. Windham, T. Henneman, M. Anderson, P. Mendola, J. W. Overstreet and S. H. Swan (2003). "Trihalomethane Levels in Home Tap Water and Semen Quality". Epidemiology 14(6): 650-8.

Fiss, E. M., K. L. Rule and P. J. Vikesland (2007). "Formation of chloroform and other chlorinated byproducts by chlorination of triclosan-containing antibacterial products". Environmental Science & Technology 41(7): 2387-94.

García-Estrada, J., A. Navarro-Ruiz, J. Bañuelos-Pineda, V. Gómez, E. Albarrán-Rodríguez and P. Garzón (1990). "[Inhalation of organic solvents during the last third of pregnancy in Sprague-Dawley rats. Somatometric and cerebellar consequences in newborn animals]". Archivos de investigación médica 21(4): 311-7.

Grazuleviciene, R., V. Kapustinskiene, J. Vencloviene, J. Buinauskiene and M. J. Nieuwenhuijsen (2013). "Risk of congenital anomalies in relation to the uptake of trihalomethane from drinking water during pregnancy". Journal of Occupational and Environmental Medicine 70(4): 274-82.

Grazuleviciene, R., M. J. Nieuwenhuijsen, J. Vencloviene, M. Kostopoulou-Karadanelli, S. W. Krasner, A. Danileviciute, G. Balcius and V. Kapustinskiene (2011). "Individual exposures to drinking water trihalomethanes, low birth weight and small for gestational age risk: a prospective Kaunas cohort study". Environmental Health 10: 32.

Haddad, S., G. C. Tardif and R. Tardif (2006). "Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes". Journal of Toxicology and Environmental Health Part A 69(23): 2095-136.

Heywood, R., R. J. Sortwell, P. R. Noel, A. E. Street, D. E. Prentice, F. J. Roe, P. F. Wadsworth, A. N. Worden and N. J. Van Abbe (1979). "Safety evaluation of toothpaste containing chloroform. III. Long-term study in beagle dogs". Journal of Environmental Pathology and Toxicology 2(3): 835-51.

Hinckley, A. F., A. M. Bachand and J. S. Reif (2005). "Late Pregnancy Exposures to Disinfection By-products and Growth-Related Birth Outcomes". Environmental Health Perspectives 113(12): 1808-13.

Hoffman, C. S., P. Mendola, D. A. Savitz, A. H. Herring, D. Loomis, K. E. Hartmann, P. C. Singer, H. S. Weinberg and A. F. Olshan (2008). "Drinking water disinfection by-product exposure and fetal growth". Epidemiology 19(5): 729-37.

Infante-Rivard, C. (2004). "Drinking Water Contaminants, Gene Polymorphisms, and Fetal Growth". Environmental Health Perspectives 112(11): 1213-6.

Iszatt, N., M. J. Nieuwenhuijsen, J. Bennett, N. Best, A. C. Povey, A. A. Pacey, H. Moore, N. Cherry and M. B. Toledano (2013). "Chlorination by-products in tap water and semen quality in England and Wales". Journal of Occupational and Environmental Medicine 70(11): 754-60.

Iszatt, N., M. J. Nieuwenhuijsen, J. E. Bennett and M. B. Toledano (2014). "Trihalomethanes in public drinking water and stillbirth and low birth weight rates: an intervention study". Environment International 73: 434-9.

Iszatt, N., M. J. Nieuwenhuijsen, P. Nelson, P. Elliott and M. B. Toledano (2011). "Water consumption and use, trihalomethane exposure, and the risk of hypospadias". Pediatrics 127(2): e389-97.

King, W. D., L. Dodds and A. C. Allen (2000). "Relation between stillbirth and specific chlorination by-products in public water supplies". Environmental Health Perspectives 108(9): 883-6.

Kramer, M. D., C. F. Lynch, P. Isacson and J. W. Hanson (1992). "The association of waterborne chloroform with intrauterine growth retardation". Epidemiology 3(5): 407-13.

LaKind, J. S., D. Q. Naiman, S. M. Hays, L. L. Aylward and B. C. Blount (2010). "Public health interpretation of trihalomethane blood levels in the United States: NHANES 1999-2004". Journal of Exposure Science and Environmental Epidemiology 20(3): 255-62.

Land, P. C., E. L. Owen and H. W. Linde (1981). "Morphologic changes in mouse spermatozoa after exposure to inhalational anesthetics during early spermatogenesis". Anesthesiology 54(1): 53-6.

Landi, S., N. M. Hanley, S. H. Warren, R. A. Pegram and D. M. DeMarini (1999). "Induction of genetic damage in human lymphocytes and mutations in Salmonella by trihalomethanes: role of red blood cells and GSTT1-1 polymorphism". Mutagenesis 14(5): 479-82.

Levallois, P., S. Gingras, S. Marcoux, C. Legay, C. Catto, M. Rodriguez and R. Tardif (2012). "Maternal exposure to drinking-water chlorination by-products and small-for-gestational-age neonates". Epidemiology 23(2): 267-76.

Lewis, C., I. H. Suffet, K. Hoggatt and B. Ritz (2007). "Estimated effects of disinfection by-products on preterm birth in a population served by a single water utility". Environmental Health Perspectives 115(2): 290-5.

Lewis, C., I. H. Suffet and B. Ritz (2006). "Estimated effects of disinfection by-products on birth weight in a population served by a single water utility". American Journal of Epidemiology 163(1): 38-47.

Lim, G. E., S. I. Stals, J. J. Petrik, W. G. Foster and A. C. Holloway (2004). "The effects of in utero and lactational exposure to chloroform on postnatal growth and glucose tolerance in male Wistar rats". Endocrine 25(3): 223-8.

Lynberg, M., J. R. Nuckols, P. Langlois, D. Ashley, P. Singer, P. Mendola, C. Wilkes, H. Krapfl, E. Miles, V. Speight, B. Lin, L. Small, A. Miles, M. Bonin, P. Zeitz, A. Tadkod, J. Henry and M. B. Forrester (2001). "Assessing exposure to disinfection by-products in women of reproductive age living in Corpus Christi, Texas, and Cobb county, Georgia: descriptive results and methods". Environmental Health Perspectives 109(6): 597-604.

Murray, F. J., B. A. Schwetz, J. G. McBride and R. E. Staples (1979). "Toxicity of inhaled chloroform in pregnant mice and their offspring". Toxicology and applied pharmacology 50(3): 515-22.

National Toxicology Program (NTP 1988). Chloroform reproduction and fertility assessment in CD-1 mice when administered by gavage. Report by Environmental Health Reseach and Testing, Inc., to National Toxicology Program. NTP-89-018(NTIS PB89-148639). [Gulati et al. 1988 is an alternative citation.]

Nuckols, J. R., D. L. Ashley, C. Lyu, S. M. Gordon, A. F. Hinckley and P. Singer (2005). "Influence of Tap Water Quality and Household Water Use Activities on Indoor Air and Internal Dose Levels of Trihalomethanes". Environmental Health Perspectives 113(7): 863-70.

Patelarou, E., S. Kargaki, E. G. Stephanou, M. Nieuwenhuijsen, P. Sourtzi, E. Gracia, L. Chatzi, A. Koutis and M. Kogevinas (2011). "Exposure to brominated trihalomethanes in drinking water and reproductive outcomes". Journal of Occupational and Environmental Medicine 68(6): 438-45.

Porter, C. K., S. D. Putnam, K. L. Hunting and M. R. Riddle (2005). "The effect of trihalomethane and haloacetic acid exposure on fetal growth in a Maryland county". American Journal of Epidemiology 162(4): 334-44.

Riederer, A. M., R. Dhingra, B. C. Blount and K. Steenland (2014). "Predictors of blood trihalomethane concentrations in NHANES 1999-2006". Environmental Health Perspectives 122(7): 695-702.

Rivera-Nunez, Z. and J. M. Wright (2013). "Association of brominated trihalomethane and haloacetic acid exposure with fetal growth and preterm delivery in Massachusetts". Journal of Occupational and Environmental Medicine 55(10): 1125-34.

Ruddick, J. A., D. C. Villeneuve, I. Chu and V. E. Valli (1983). "A teratological assessment of four trihalomethanes in the rat". Journal of Environmental Science and Health 18(3): 333-49.

Rule, K. L., V. R. Ebbett and P. J. Vikesland (2005). "Formation of Chloroform and Chlorinated Organics by Free-Chlorine-Mediated Oxidation of Triclosan". Environmental Science & Technology 39(9): 3176-85.

Savitz, D. A., P. C. Singer, K. E. Hartmann, A. H. Herring, H. S. Weinberg, C. Makarushka, C. Hoffman, R. Chan and R. Maclehose (2005). "Drinking Water Disinfection By-Products and Pregnancy Outcome".

Savitz, D. A., P. C. Singer, A. H. Herring, K. E. Hartmann, H. S. Weinberg and C. Makarushka (2006). "Exposure to drinking water disinfection by-products and pregnancy loss". American Journal of Epidemiology 164(11): 1043-51.

Schwetz, B. A., B. K. Leong and P. J. Gehring (1974). "Embryo- and fetotoxicity of inhaled chloroform in rats". Toxicology and applied pharmacology 28(3): 442-51.

Smith, R. B., S. C. Edwards, N. Best, J. Wright, M. J. Nieuwenhuijsen and M. B. Toledano (2015). "Birth Weight, Ethnicity, and Exposure to Trihalomethanes and Haloacetic Acids in Drinking Water during Pregnancy in the Born in Bradford Cohort". Environmental Health Perspectives 124(5): 681-9.

Summerhayes, R. J., G. G. Morgan, H. P. Edwards, D. Lincoln, A. Earnest, B. Rahman and J. R. Beard (2012). "Exposure to trihalomethanes in drinking water and small-for-gestational-age births". Epidemiology 23(1): 15-22.

Teixido, E., E. Pique, J. Gonzalez-Linares, J. M. Llobet and J. Gomez-Catalan (2015). "Developmental effects and genotoxicity of 10 water disinfection by-products in zebrafish". Journal of Water and Health 13(1): 54-66.

Thompson, D. J., S. D. Warner and V. B. Robinson (1974). "Teratology studies on orally administered chloroform in the rat and rabbit". Toxicology and applied pharmacology 29(3): 348-57.

Toledano, M. B., M. J. Nieuwenhuijsen, N. Best, H. Whitaker, P. Hambly, C. de Hoogh, J. Fawell, L. Jarup and P. Elliott (2005). "Relation of Trihalomethane Concentrations in Public Water Supplies to Stillbirth and Birth Weight in Three Water Regions in England". Environmental Health Perspectives 113(2): 225-32.

Tylleskär-Jensen, J. (1967). "[Chloroform--a cause of pregnancy toxemia?]". Nordisk medicin 77(26): 841-2.

US EPA. (11/9/2015). "Stage 1 and Stage 2 Disinfectants and Disinfection Byproducts Rules." from https://www.epa.gov/dwreginfo/stage-1-and-stage-2-disinfectants-and-disinfection-byproducts-rules.

OEHHA

August 2016

US EPA (1980) Effects of chloroform in the drinking water of rats and mice: ninety-day subacute toxicity study. US EPA Research Reporting Series: Environmental Health Effects Research Publication No. U.S. EPA-600/1-80-030

US EPA (1978) Teratology and acute toxicology of selected chemical pesticides administered by inhalation. US EPA Research Reporting Series: Environmental Health Effects Research Publication No. U.S. EPA-600/1-78-003.

Villanueva, C. M., E. Gracia-Lavedan, J. Ibarluzea, L. Santa Marina, F. Ballester, S. Llop, A. Tardon, M. F. Fernandez, C. Freire, F. Goni, X. Basagana, M. Kogevinas, J. O. Grimalt, J. Sunyer and I. Project (2011). "Exposure to trihalomethanes through different water uses and birth weight, small for gestational age, and preterm delivery in Spain". Environmental Health Perspectives 119(12): 1824-30.

Waller, K., S. H. Swan, G. DeLorenze and B. Hopkins (1998). "Trihalomethanes in drinking water and spontaneous abortion". Epidemiology 9(2): 134-40.

Wennborg, H., L. Bodin, H. Vainio and G. Axelsson (2000). "Pregnancy outcome of personnel in Swedish biomedical research laboratories". Journal of Occupational and Environmental Medicine 42(4): 438-46.

Whitaker, H. J., M. J. Nieuwenhuijsen and N. G. Best (2002). "The Relationship between Water Concentrations and Individual Uptake of Chloroform: A Simulation Study". Environmental Health Perspectives 111(5): 688-94.

Windham, G. C., K. Waller, M. Anderson, L. Fenster, P. Mendola and S. Swan (2003). "Chlorination By-Products in Drinking Water and Menstrual Cycle Function". Environmental Health Perspectives 111(7): 935-41.

Wright, J. M., J. Schwartz and D. W. Dockery (2004). "The Effect of Disinfection Byproducts and Mutagenic Activity on Birth Weight and Gestational Duration". Environmental Health Perspectives 112(8): 920-5.

Wright, M. J. and Z. Rivera-Nuñez (2011). "Effect of water disinfection type on adverse fetal outcomes". Journal AWWA 103(10): 67-75.

Zeng, Q., Y. Z. Chen, L. Xu, H. X. Chen, Y. Luo, M. Li, J. Yue, A. L. Liu, Y. F. Li and W. Q. Lu (2014). "Evaluation of exposure to trihalomethanes in tap water and semen quality: a prospective study in Wuhan, China". Reproductive Toxicology 46: 56-63.

Zeng, Q., M. Li, S. H. Xie, L. J. Gu, J. Yue, W. C. Cao, D. Zheng, A. L. Liu, Y. F. Li and W. Q. Lu (2013). "Baseline blood trihalomethanes, semen parameters and serum total testosterone: a cross-sectional study in China". Environment International 54: 134-40.

Zhou, W., Y. Li and S. Xie (2010). "Relationship between exposure to disinfection byproducts during pregnancy and term infants birth weight". Journal of Environment and Health 27(1): 17-20. Appendix A. Tables of Associations between Chloroform and Other Disinfection By-Products Exposure and Reproductive Outcomes in Human Studies.

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|---|--|-----------|-----|---|--|-----------------|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| Danileviciute et al. ‡‡ 2012 Lithuania | Estimated internal dose (μg/d) CHL ≥0.1424 (median level) | <0.1424 | | Entire pregnancy 1.31 (0.82, 20.9) GSTM1-1 0.84 (0.42, 1.68) GSTM1-0 1.78 (0.90, 3.50) | Entire pregnancy 1.24 (0.57, 2.68) GSTM1-1 0.34 (0.09, 1.22) GSTM1-0 4.08 (1.20, 13.9) Test for interaction: 12.88 (2.27, 73.2) | |
| | | | | GSTT1-1 1.30 (0.78, 2.17) GSTT1-0 0.99 (0.28,3.58) <u>3rd trimester</u> 1.31 (0.82, 2.08) GSTM1-1 0.88 (0.44, 1.78) GSTM1-0 1.74 (0.89, 3.41) | GSTT1-1 1.9 (0.5, 2.82) GSTT1-0 7.48 (0.13, 409) <u>3rd trimester</u> 1.45 (0.67, 3.13) GSTM1-1 0.35 (0.10, 1.28) GSTM1-0 5.06 (1.50,17.05) | |
| | | | | GSTT1-1 1.18 (0.71, 1.97) GSTT1-0 1.75 (0.50, 6.10) | S.06 (1.30,17.03) Test for interaction: 15.86 (2.75,91.40) GSTT1-1 1.35 (0.57, 3.20) GSTT1-0 7.30 (0.14, 391) | |
| | BDCM ≥0.0280 | <0.0280 | | <u>3rd trimester</u> 1.31 (0.82, 2.09) GSTM1-1 1.05 (0.52, 2.10) GSTM1-0 | 3 rd trimester 1.26 (0.58, 2.72) GSTM1-1 0.55 (0.16, 1.89) GSTM1-0 | |

Abbreviations: BDCM - bromodichloromethane; BrTHM - total brominated trihalomethanes; BW - birth weight; CHL - chloroform; CI - confidence interval; conc - concentration; DBCM - dibromochloromethane; dec - decrease; FGR - fetal growth restriction; inc - increase; LBW - low birth weight; med - medium; PTB - preterm birth; SGA - small for gestational age; TCAA – trichloroacetic acid; TTHM - total trihalomethanes; VLBW - very low birth weight.

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|---|--|-----------|-----|---|--|---|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | DBCM ≥0.0026 | <0.0026 | | 1.43 (0.73, 2.81) GSTT1-1 1.29 (0.77, 2.15) GSTT1-0 1.03 (0.29, 3.69) <u>3rd trimester</u> 1.68 (0.97, 2.89) GSTM1-1 1.63 (0.73, 3.64) GSTM1-0 1.55 (0.72, 3.36) GSTT1-1 1.89 (1.01, 3.54) GSTT1-0 | 2.74 (0.88, 8.51) Test for interaction: 5.29 (1.03, 27.15) GSTT1-1 1.36 (0.58, 3.22) GSTT1-0 0.89 (0.05, 15.9) <u>3rd trimester</u> 1.54 (0.65, 3.63) GSTM1-1 1.36 (0.36, 5.11) GSTM1-0 1.78 (0.55, 5.75) GSTT1-1 1.41 (0.54, 3.70) GSTT1-0 | |
| Botton et al.* 2015 Spain (3 study sites) and Greece | Estimated internal dose(µg/d)All sites:CHLIQR incBrTHMIQR incIngestion (µg/d)All sites:CHLIQR incBrTHMIQR incBrTHMIQR incBy site:GipuzkoaCHLIQR incBrTHMIQR incBrTHMIQR incSabadellIQR inc | | | 1.04 (0.31, 3.53) | 0.54 (0.02, 12.51) | Entire pregnancy Postnatal weight gain -9.30 (-87.3, 68.7) -17.2 (-63.4, 29.1) -40.3 (-122, 41) -45.6 (-118, 26.5) 9.63 (-174, 193) 18.0 (-181, 217) -151 (-288, -15) |

| Exposure | Reference | | Odds Ratio (95% C | I) | |
|--|--|---|--|---|---|
| Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| BrTHM IQR inc | | | | | -146 (-280, -12.3) |
| <u>Valencia</u> CHL IQR inc | | | | | 36.7 (-87, 160) |
| | | | 3 rd trimester | 3 rd trimester | 36.7 (-79.9, 153) 3 rd trimester |
| <u>(μg/d)</u> 0.0249–0.2868 0.2868–2.1328 Continuous (per 0.1 μg/d increase) | 0.0013-0.0249 | | 1.19 (0.87, 1.63) 1.22 (0.89, 1.68) 1.04 (1.00, 1.09) | 2.12 (1.11, 4.02) 2.13 (1.15, 3.92) 1.09 (1.01, 1.18) | Change in BW in grams of infants below 3,500 g for every 1 μg/d increase in internal dose: -57.8 (-111.6, -4.0) |
| BDCM 0.0124–0.0501 0.0501–0.3359 Continuous (per 0.01 µg/d increase) | 0.0001–0.0124 | | 1.37 (1.00, 1.88) 1.25 (0.91, 1.73) 1.20 (0.90, 1.62) | 1.64 (0.89, 3.02) 1.80 (1.00, 3.26) 1.04 (1.00, 1.10) | -25.7 (-57.2, 5.8) |
| DBCM 0-0.0039 0.0039-0.0644 Continuous (per 0.01 µg/d increase) | 0 | | 1.76 (0.56, 1.03) 0.85 (0.63, 1.15) 1.06 (0.92, 1.22) | 2.44 (1.05, 5.70) 2.42 (1.03, 5.66) 1.23 (0.93, 1.61) | -45.9 (-207.6, 114.8) |
| Estimated internal dose $(\mu g/d)$ CHL $\geq 0.91 - <1.56$ ≥ 1.56 | <0.91 | | | | Entire pregnancy Total population: -16.3 (-39.0, 6.5) -20.9 (-44.6, 2.8) |
| | | | | | Pakistani origin: 10.3 (-21.2, 41.9) - 48.3 (-84.6, -12.1) White British: -13.3 (-52.9, 26.3) |
| | | | | | 9.0 (-23.5, 46.5) <u>3rd trimester</u> Total population: -14.8 (-37.7, 8.1) -8.7 (-31.8, 14.3) |
| | Level BrTHM IQR inc Valencia CHL IQR inc BrTHM IQR inc BrTHM IQR inc Estimated internal dose (µg/d) 0.0249–0.2868 0.2868–2.1328 Continuous (per 0.1 µg/d increase) BDCM 0.0124–0.0501 0.0501–0.3359 Continuous (per 0.01 µg/d increase) DBCM 0–0.0039 0.0039–0.0644 Continuous (per 0.01 µg/d increase) Estimated internal dose (µg/d) CHL ≥0.91–<1.56 | LevelLevelBrTHMIQR inc $Valencia$ CHLIQR incBrTHMIQR incBrTHMIQR incEstimated internal dose (µg/d)0.0013-0.02490.2868-2.1328 Continuous (per 0.1 µg/d increase)0.0013-0.0249BDCM 0.0124-0.0501 0.0501-0.3359 Continuous (per 0.01 µg/d increase)0.0001-0.0124DBCM 0-0.0039 0.0039-0.0644 Continuous (per 0.01 µg/d increase)0DBCM 0-0.0039 0.0039-0.0644 Continuous (per 0.01 µg/d increase)0Estimated internal dose (µg/d) CHL ≥0.91-<1.56 | LevelLevelPTBBrTHMIQR inc $Valencia$ CHLIQR incBrTHMIQR inc $Valencia$ CHL $Valencia$ IQR incBrTHMIQR inc $Valencia$ CHLBrTHMIQR inc $Valencia$ (µg/d)0.0249-0.2868 0.2868-2.1328 Continuous (per 0.1 µg/d increase) $0.0013-0.0249$ BDCM 0.0124-0.0501 0.0501-0.3359 Continuous (per 0.01 µg/d increase) $0.0001-0.0124$ DBCM 0-0.0039 0.0039-0.0644 Continuous (per 0.01 µg/d increase) 0 DBCM 0-0.01 µg/d increase) 0 DBCM 0-0.01 µg/d increase) 0 Continuous (per 0.01 µg/d increase) 0 | Level Level PTB SGA BrTHM IQR inc SGA SGA Walencia CHL IQR inc 3rd trimester SGA BrTHM IQR inc 119 (0.87, 1.63) 122 (0.89, 1.68) 0.0249-0.2868 0.0013-00249 1.19 (0.87, 1.63) 1.22 (0.89, 1.68) 0.2868-2.1328 0.0013-00249 1.37 (1.00, 1.88) 1.04 (1.00, 1.09) BDCM 0.0124-0.0501 0.0001-0.0124 1.37 (1.00, 1.88) 1.25 (0.91, 1.73) 0.0501-0.3359 0.0001-0.0124 1.37 (1.00, 1.81) 1.20 (0.90, 1.62) 1.20 (0.90, 1.62) DBCM 0 0 1.76 (0.56, 1.03) 0.85 (0.63, 1.15) 1.06 (0.92, 1.22) DBCM 0 0.039-0.0644 0 1.76 (0.56, 1.03) 0.85 (0.63, 1.15) 1.06 (0.92, 1.22) DBCM 0.01 µg/d increase) 0 1.76 (0.56, 1.03) 0.85 (0.63, 1.15) 1.06 (0.92, 1.22) DBCM 0.01 µg/d increase) 0 0.77 (0.02, 1.22) 1.06 (0.92, 1.22) 1.06 (0.92, 1.22) | Level Level PTB SGA LBW BrTHM IQR inc IQR inc |

Study/ Exposure Reference Odds Ratio (95% CI) Level Level PTB SGA LBW Location BW (q) (95% CI) Pakistani origin: 5.1 (-27.1, 37.4) -42.8 (-78.2, -7.4) White British: -27.0 (-66.1, 12.1) 9.5 (-26.8, 45.8) Entire pregnancy Total population: BDCM ≥0.12-<0.21 <0.12 -11.1 (-33.9, 11.8) ≥0.21 -17.9 (-41.5, 5.7) Pakistani origin: -11.5 (-43.3, 20.2) - 49.8 (-86.3, -13.4) White British: 8.2 (-31.6, 48.1) 10.9 (-26.4, 48.2) 3rd trimester Total population: -9.9 (-32.9, 13.0) -10.2 (-33.4, 13.0) Pakistani origin: -1.2(-33.2, 30.9)-48.7 (-84.8, -12.5) White British: -4.2 (-43.8, 35.5) 15.2 (-21.1, 51.6) Entire pregnancy Kramer et al. Water conc (µg/L) Entire pregnancy Entire pregnancy 1992 CHL 1-9 ND <1 1.1 (0.8, 1.4) 1.3 (0.9, 1.8) 1.1 (0.7, 1.6) 1.8 (1.1, 2.9) ≥10 1.1 (0.7, 1.6) 1.3 (0.8, 2.2) lowa BDCM 1-9 ND <1 1.1 (0.9, 1.5) 1.2 (0.8, 1.7) 1.0 (0.5, 1.9) 1.7 (0.9, 2.9) <u>></u>10 1.0 (0.6, 1.5) 1.0 (0.7, 1.5) DBCM 1–3 ND <1 1.1 (0.7, 1.4) 1.0 (0.7, 1.5) 0.7 (0.5, 1.1) >4 0.9 (0.1, 8.6) 0.8 (0.4, 1.4) no cases TBM >1 ND <1 1.1 (0.8, 1.4) 1.1 (0.7, 1.6) 0.9 (0.6, 1.5)

| Study/ | Exposure Reference Odds Ratio (95% CI) | | | | | | |
|---------------------------------|--|---|---------|--|---|-----|-----------------|
| Location | | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| Costet et al. 2012 France | Water of CHL | <u>:onc (μg/L)</u> 5–<10 10–<15 ≥15 | < 5 | 3rd trimester 0.7 (0.4,1.2) 0.5 (0.3,0.9) 0.8 (0.4,1.4) | 3rd trimester (as FGR) 0.8 (0.5, 1.2) 1.0 (0.6, 1.5) 0.9 (0.5, 1.4) | | |
| | BDCM | 9–<13 13–<16 ≥16 | <9 | 1.1 (0.7, 2.0) 0.7 (0.4, 1.3) 0.8 (0.4, 1.5) | 0.8 (0.5, 1.2) 0.9 (0.6, 1.4) 1.0 (0.6, 1.6) | | |
| | DBCM | 13–<15 15–<18 ≥18 | <13 | 1.0 (0.6, 1.8) 1.3 (0.7, 2.5) 0.8 (0.4,1.5) | 1.0 (0.6, 1.6) 1.3 (0.8, 2.1) 1.2 (0.8, 1.9) | | |
| | ТВМ | 5–<7.5 7.5–<10 ≥10 | < 5 | 0.7 (0.4, 1.3) 1.0 (0.5, 2.0) 1.1 (0.6, 2.0) | 1.4 (0.8, 2.2) 1.3 (0.8, 2.3) 1.4 (0.8, 2.3) | | |
| | | ed internal dose | | | | | |
| | <u>(µg/d)</u> СНL | 0.068–<0.133 0.133–<0.237 ≥0.237 | < 0.068 | 1.8 (0.7, 4.8) 0.7 (0.2, 2.1) 1.0 (0.4, 2.9) | 1.1 (0.5, 2.3) 1.2 (0.6, 2.4) 1.0 (0.5, 2.1) | | |
| | BDCM | 0.083-<0.141 0.141-<0.226 ≥0.226 | <0.083 | 0.6 (0.2, 1.6) 0.9 (0.4, 2.2) 0.7 (0.3, 1.8) | 1.5 (0.7, 3.2) 1.5 (0.7, 3.1) 1.6 (0.8, 3.4) | | |
| | DBCM | 0.118-<0.188 0.188-<0.267 ≥0.267 | <0.118 | 0.7 (0.2, 1.9) 0.9 (0.3, 2.4) 0.8 (0.3, 2.2) | 1.6 (0.7, 3.6) 1.7 (0.8, 3.8) 1.9 (0.9, 4.1) | | |
| | ТВМ | 0.057-<0.113 0.113-<0.205 ≥0.205 | <0.057 | 0.5 (0.2, 1.3) 1.2 (0.5, 3.0) 0.8 (0.2, 2.6) | 1.1 (0.6, 2.2) 0.9 (0.4, 1.9) 1.8 (0.8, 3.9) | | |
| | Estimativi via inge CHL 0.00 | <u>TCAA Study</u> ed internal dose stion (μg/d) 01–<0.006 06–<0.015 | 0-0.001 | 0.7 (0.3, 1.5) 0.8 (0.4, 1.8) 1.2 (0.6, 2.5) | 1.0 (0.6, 1.7) 0.8 (0.4, 1.5) 1.2 (0.7, 2.2) | | |

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|-------------------------|---|----------------------|--|--|---|-----------------|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | BDCM 0.0005-<0.0016 0.0016-<0.004 ≥0.004 DBCM 0.0008-<0.0023 0.0023-<0.267 ≥0.0052 | 0–0.0005 0–0.0008 | 0.8 (0.3, 1.5) 1.0 (0.5, 1.9) 1.5 (0.7, 2.8) 0.7 (0.3, 1.5) 1.2 (0.6, 2.3) 1.5 (0.7, 2.9) | 1.3 (0.7, 2.2) 1.1 (0.6, 2.0) 1.3 (0.7, 2.3) 1.4 (0.8, 2.4) 1.2 (0.7, 2.2) 1.4 (0.8, 2.5) | | |
| | TBM 0.0003-<0.0013 0.0013-<0.0034 ≥.0.0034 | 0–0.0003 | 0.9 (0.5, 1.8) 1.1 (0.5, 2.2) 1.3 (0.6, 2.7) | 1.4 (0.8, 2.4) 1.4 (0.8, 2.6) 1.1 (0.6, 2.2) | | |
| Hinckley et al. 2005 | <u>Water conc (µg/L)</u> CHL 10–16 ≥16 | <10 | No OR were presented Authors reported no | <u>3rd trimester</u> 1.02 (0.94, 1.11) 1.01 (0.93, 1.10) | <u>3rd trimester</u> 1.18 (1.00, 1.39) 1.04 (0.88, 1.23) | |
| Arizona | BDCM 13–18 ≥18 | <13 | associations were observed | 0.93 (0.85, 1.01) 1.03 (0.95, 1.12) | 1.05 (0.89, 1.24) 1.04 (0.88, 1.23) | |
| | DBCM 12–16 ≥16 | <12 | | 0.96 (0.89, 1.05) 1.01 (0.94, 1.10) | 1.00 (0.84, 1.18) 1.05 (0.89, 1.24) | |
| Infante-Rivard 2004 | Water conc (µg/L) CHL >23.7 | <u><</u> 23.7 | | Entire pregnancy 1.06 (0.63, 1.79) | | |
| Montréal, Canada | TTHM >29.4 | <u><</u> 29.4 | | 0.97 (0.57, 1.62) | | |
| | BDCM >6.3 | ≤6.3 | | 0.84 (0.50, 1.43) | | |
| | DBCM >3.9 | ≤3.9 | | 0.62 (0.27, 1.44) | | |
| | TBM >1.22 | ≤1.22 | | 2.44 (0.19, 31.10) | | |
| | Gene-environment interaction: 90 th percentile CHL (or TTHM) conc + categories for mother and newborn variants of CYP2E1 and MTHFR C677T: 3) Wild type 4) 1 or 2 variant alleles | | | | | |

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|-----------------------------------|---|---|-----|---|-------|-----------------|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | Newborn CYP2E1*5 CHL >23.7 MTHFR CHL >23.7 Maternal CYP2E1*5 CHL >23.7 MTHFR THM >29.4 Maternal CYP2E1*5 TTHM >29.4 Maternal CYP2E1*5 TTHM >29.4 MTHFR TTHM >29.4 | ≤23.7 ≤23.7 ≤23.7 ≤23.7 ≤29.4 ≤29.4 ≤29.4 | | 3) 0.99 (0.57, 1.74) 4) 5.62 (0.82, 38.39) 3) 1.78 (0.82, 3.87) 4) 0.83 (0.38, 1.54) 3) 0.88 (0.50, 1.54) 4) 4.40 (0.73, 26.42) 3) 1.00 (0.46, 2.18) 4) 1.12 (0.56, 2.32) 1) 0.82 (0.47, 1.45) 2) 13.20 (1.19, 146.72) 1) 1.63 (0.72, 3.71) 2) 0.76 (0.38, 1.54) 1) 0.83 (0.48, 1.44) 2) 6.54 (0.59, 71.45) 1) 0.98 (0.46, 2.10) 2) 0.94 (0.47, 1.89) | | |
| Porter et al. 2005 Maryland | Water conc (µg/L) CHL (Mean = 34.1) 2 nd quintile 3 rd quintile 4 th quintile 5 th quintile BDCM (Mean = 13.4) | <29.4 1 st quintile | 155 | Entire pregnancy 1.24 (1.02, 1.50) 1.08 (0.88, 1.32) 1.12 (0.92, 1.36) 1.04 (0.85, 1.27) 3 rd trimester 1.02 (0.84, 1.24) 0.96 (0.79, 1.16) 0.98 (0.81, 1.19) 1.07 (0.88, 1.29) Entire pregnancy 1.05 (0.87, 1.27) 0.96 (0.79, 1.17) 1.07 (0.89, 1.30) 0.97 (0.80, 1.18) | ОЕННА | |

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|--|---|-----------|-----|---|--|-----------------|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | DBCM (Mean = 4.35) | | | $\frac{3^{rd} \text{ trimester}}{0.92 (0.76, 1.12)} \\ 1.04 (0.86, 1.25) \\ 0.92 (0.76, 1.12) \\ 0.92 (0.76, 1.12) \\ 0.98 (0.81, 1.19) \\ \hline \\ \\ \\ \hline \\ \hline \\ \\ \hline \\ \\ \hline \\ \\ \hline \\ \hline \\ \\ \hline \\ \hline \\ \\ \hline \\ \\ \hline \\ \hline \\ \hline \\ \\ \hline \hline \\ \hline \\ \hline \\ \hline \\ \hline \hline \hline \hline \\ \hline \hline \hline \hline \\ \hline \hline \hline \hline \hline \\ \hline \hline \hline \hline \hline \\ \hline \hline \hline \hline \hline \hline \\ \hline \\ \hline \hline$ | | |
| Taladara at al | | | | 1.01 (0.83, 1.23) | Ord trime actor | |
| Toledano et al. 2005 United Kingdom (3 study sites) | Water conc (μg/L) LBW CHL 20-40 >40 BDCM 6-12 | <20 <6 | | | <u>3rd trimester</u> 1.05 (1.03, 1.07) 1.10 (1.07, 1.13) 1.02 (0.99, 1.04) | |
| | VLBW 20–40 >40 | <0 | | | 1.02 (0.99, 1.04) 0.99 (0.97, 1.05) 1.01 (0.96, 1.07) 1.07 (0.99, 1.15) | |
| | BDCM 6-12 >12 | <6 | | | 1.07 (0.99, 1.15) 1.01 (0.95, 1.07) 0.98 (0.92, 1.04) | |

ACGIH TLV DART Chemical for Reconsideration: Chloroform OEHHA August 2016

| Study/ | E | Exposure | Reference | | Odds Ratio (95% CI) | | |
|---|----------------------------------|--|-----------|---|--|-----|--|
| Location | | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| Savitz et al. † 2005 US (3 study sites) | Water co | onc (μg/L) >0.1–≤10.9 >10.9–≤30.4 >30.4–≤48.2 >48.2 | ≥0-≤0.1 | <u>3rd trimester</u> 0.68 (0.42, 1.11) 0.76 (0.47, 1.24) 0.52 (0.31, 0.90) 0.54 (0.31, 0.92) | Used quartiles <u>3rd trimester</u> 1.45 (0.79, 2.64) 1.33 (0.71, 2.49) 1.05 (0.54, 2.01) | | <u>3rd trimester</u> -18 (-86, 51) -6 (-75, 62) 12 (-56, 80) 28 (-39, 96) |
| | BrTHM | >3.4–≤12.7 >12.7–≤17.1 >17.1-≤32.5 >32.5 | ≥0.0-≤3.4 | 0.58 (0.35,0.97) 0.45 (0.25, 0.78) 0.51 (0.29, 0.88) 1.03 (0.65, 1.63) | 0.86 (0.45, 1.66) 1.03 (0.54, 1.97) 1.58 (0.88, 2.83) | | 12 (-55, 79) 51 (-17, 119) 29 (-40, 97) -54 (-126, 17) |
| | BDCM | >1.1-≤10.8 >10.8-≤13.2 >13.2-≤19.7 >19.7 | ≥0.0-≤1.1 | 0.63 (0.38, 1.04) 0.47 (0.27, 0.83) 0.69 (0.41, 1.15) 0.96 (0.60, 1.54) | 1.06 (0.55, 2.02) 1.07 (0.56, 2.07) 1.63 (0.90, 2.96) | | -15 (-82, 52) 42 (-26, 110) -10 (-78, 58) -21 (-91, 49) |
| | <u>Estimate</u> (μg/d) CHL | ed internal dose >0-≤0.2 >0.2-≤0.8 >0.8-≤1.3 >1.3 | 0 | 1.03 (0.65, 1.66) 0.56 (0.32, 0.96) 0.82 (0.49, 1.37) 0.59 (0.34, 1.01) | <u>Used quartiles</u> 1.16 (0.63, 2.14) 1.26 (0.68, 2.33) 1.14 (0.62, 2.09) | | 10 (-58, 78) -4 (-72, 63) 37 (-31, 105) 32 (-36, 100) |
| | BrTHM | >0.1-≤0.2 >0.2-≤0.3 >0.3-≤0.7 >0.7 | ≥0.0-≤0.1 | 0.78 (0.47, 1.28) 0.60 (0.35, 1.04) 0.68 (0.40, 1.15) 0.76 (0.46, 1.26) | 1.02 (0.54, 1.95) 0.89 (0.45, 1.75) 1.65 (0.93, 2.94) | | -20 (-87, 47) -4 (-72, 63) -31 (-99, 37) -31 (-101, 39 |
| | BDCM | >0-≤0.1 >0.1-≤0.3 >0.3-≤0.4 >0.4 | 0 | 0.77 (0.47, 1.26) 0.65 (0.38, 1.11) 0.60 (0.35, 1.03) 0.76 (0.46, 1.26) | 1.15 (0.62, 2.14) 1.05 (0.54, 2.02) 1.35 (0.75, 2.43) | | -27 (-95, 41) 20 (-48, 87) -20 (-88, 47) -20 (-89, 50) |
| Hoffman et al. † 2008 3 US communities | | <u>hlorinated)</u> <u>nc (µg/L)</u> 44.3–49.0 49.1–94.0 | 19.9–44.2 | | Bayesian models <u>3rd trimester</u> 1.9 (0.5, 8.1) 1.7 (0.4, 7.1) | | Bayesian models 3 rd trimester 58 (-51, 165) 49 (-62, 156) |
| | BDCM | 11.9–14.1 14.2–28.5 | 8.2–11.8 | | 1.4 (0.6, 3.2) 1.5 (0.6, 3.7) | | -8 (-84, 64) -28 (-126, 51) |

OEHHA August 2016

| Study/ | | Exposure | Reference | | Odds Ratio (95% CI) | | | |
|------------------------------------|-----------------------|---|---------------|---|--|-------|--|--|
| Location | | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) | |
| | DBCM | 3.3–4.4 4.5–9.1 | 1.1–3.2 | | 1.3 (0.6, 2.9) 1.9 (0.8, 5.3) | | 0 (-73, 77) -16 (-102, 67) | |
| | | <u>prominated)</u> pnc (µg/L) 11.6–15.6 | 6.4–11.5 | | 4.2 (0.6, 33.7) | | 64 (-146, 278) | |
| | | 15.7–22.1 | | | 3.6 (0.5, 30.1) | | 70 (-146, 294) | |
| | BDCM | 20.2–22.9 23–29.2 | 15.8–20.1 | | 0.8 (0.3, 1.9) 0.9 (0.4, 2.4) | | 90 (-15, 191) 73 (-50, 176) | |
| | DBCM | 19.4–26 26.1–38.7 | 15.2–19.3 | | 0.7 (0.3, 1.6) 0.7 (0.2, 1.7) | | 105 (7, 215) 100 (-15, 224) | |
| Levallois et al. 2012 | Water c CHL | <u>onc (µg/L)</u> 15.96–27.26 27.27–51.07 | <15.96 | | <u>3rd trimester</u> 0.9 (0.7, 1.3) 1.0 (0.8, 1.4) | | | |
| Quebec City, Canada | | >51.07 | | | 1.2 (0.9, 1.7) | | | |
| | BrTHM | 3.12–5.00 5.01–9.02 >9.02 | <3.12 | | 1.0 (0.7, 1.3) 0.9 (0.6, 1.2) 0.9 (0.7, 1.2) | | | |
| | | <u>ed internal dose</u> <u>pathway (µg/d)</u> 42.24–80.21 80.22–169.81 | <42.24 | | 0.9 (0.7, 1.2) 1.0 (0.7, 1.3) | | | |
| | | >169.81 | | | 1.0 (0.8, 1.4) | | | |
| | BrTHM | 7.55–14.62 14.63–26.08 >26.08 | <7.55 | | 0.9 (0.7, 1.3) 0.9 (0.7, 1.3) 0.8 (0.6, 1.1) | | | |
| Rivera-Nuñez and Wright 2013 | <u>Water c</u> CHL | onc (μg/L) >5–21 >21–36 >36–52 | ≤5 | 2 nd trimester 1.00 (0.94, 1.06) 1.08 (1.02, 1.14) 1.06 (0.99, 1.12) | <u>3rd trimester</u> 1.01 (0.96, 1.05) 1.00 (0.95, 1.04) 1.04 (1.00, 1.10) | | <u>3rd trimester</u> -1 (-7, 5) -9 (-15, -2) -13 (-19, -7) | |
| Massachusetts | | >52 | | 1.00 (0.94, 1.07) | 1.04 (0.99, 1.09) | | -15 (-21, -8) | |
| | BDCM | >1-4 >4-6 >6-10 >10 | <u><</u> 1 | 0.96 (0.91, 1.01) 0.99 (0.94, 1.04) 0.90 (0.86, 0.95) 0.93 (0.88, 0.98) | 1.04 (1.00, 1.08) 1.08 (1.03, 1.12) 1.09 (1.04, 1.14) 1.09 (1.04, 1.13) | | -11 (-17, -5) -14 (-21, -8) -20 (-26, -14) -16 (-22, -10) | |
| | ∆ | | T Chemical | 158 | | OEHHA | | |

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|--|--|--------------------------------------|---|--|-----|--|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | BrTHM >2–5 >5–8 >8–13 >13 | ≤2 | 0.97 (0.92, 1.01) 0.96 (0.91, 1.01) 0.89 (0.85, 0.94) 0.92 (0.88, 0.97) | 1.00 (0.97, 1.04) 1.06 (1.02, 1.10) 1.08 (1.04, 1.12) 1.05 (1.00, 1.09) | | -10 (-16, -4) -17 (-23, -11) -19 (-25, -13) -13 (-19, -7) |
| Summerhayes et al. 2012 New South Wales, Australia | Water conc (μg/L) CHL IQR increase (25 μg/L) 5 th decile 25.00–30.18 10 th decile 56.03–147.94 | 1 st decile 1.68–13.71 | | <u>Relative Risk</u> <u>3rd trimester</u> 1.04 (1.02, 1.06) 1.01 (0.96, 1.07) 1.12 (1.05, 1.18) | | Entire pregnancy -5.0 (-8.6, -1.4) |
| | BDCM 13.17–14.43 21.96–52.55 | 2.95-9.78 | | 1.04 (0.99, 1.09) 1.10 (1.04, 1.16) | | |
| Lewis et al. ‡ 2007 Massachusetts | $\frac{\text{Water conc } (\mu g/L)}{\text{TTHM } (\text{CHL} = 83-93\%)}$ $\frac{40-<60}{\geq 60}$ | <40 | Hazard Ratios 2 nd trimester 0.87 (0.77, 0.99) 0.82 (0.71, 0.94) | | | |
| | Continuous (per 10 µg/L increase) | | 0.95 (0.92, 0.99) <u>Pregnancy average</u> 0.92 (0.82, 1.02) 0.85 (0.74, 0.97) 0.95 (0.91, 0.99) <u>4 weeks before birth¹</u> 1.07 (0.85, 1.34) 1.39 (1.06, 1.81) | | | |
| Wright et al. 2004 Massachusetts | Water conc (μg/L) CHL >26–63 >63–135 BDCM >5–13 >13–46 | 0–26 0–5 | 1.03 (0.96, 1.11) <u>3rd trimester</u> 0.95 (0.91, 0.99) 0.90 (0.84, 0.97) 0.89 (0.85, 0.93) 0.92 (0.85, 0.99) | <u>3rd trimester</u> 1.05 (1.02, 1.09) 1.11 (1.04, 1.17) 1.1 (1.07, 1.14) 1.15 (1.08, 1.22) | | 3 rd trimester -14 (-19, -9) -18 (-26, -10) -12 (-17, -8) -12 (-20, -3) |

¹ Hazard ratios for prenatal care paid for by government or Healthy Start. **ACGIH TLV DART Chemical**

| Study/ | Exposure | Reference | | Odds Ratio (95% CI |) | |
|---|---|-------------|--|--|--|--|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| Lewis et al. ‡ 2006 Massachusetts | <u>Water conc (μg/L)</u> TTHM (CHL = 83–93%) 40–<50 50–<60 | <u>≤</u> 40 | | | 2 nd trimester 1.10 (0.81, 1.49) 1.08 (0.79, 1.49) | |
| | 60–<70 <u>≥</u> 70 | | | | 1.24 (0.92, 1.67) 1.50 (1.07, 2.10) | |
| | Per 10 µg/L increase | | | | 1.08 (1.00, 1.17) | |
| | | | | | <u>Caucasian</u> 1.11 (0.69, 1.78) 1.10 (0.67, 1.79) 1.22 (0.76, 1.97) 1.37 (0.80, 2.36) | |
| | | | | | 1.06 (0.95, 1.20) | |
| | | | | | Non-Caucasian 1.08 (0.73, 1.61) 1.09 (0.72, 1.66) 1.27 (0.86, 1.87) 1.60 (1.03, 2.47) | |
| | | | | | 1.10 (1.00, 1.22) | |
| Villanueva et al.* 2011 | Total residential water conc (μg/L) CHL 10% increase | | <u>3rd trimester</u> 1.00 (0.99, 1.01) | <u>3rd trimester</u> 1.00 (0.99, 1.01) | <u>3rd trimester</u> 1.00 (0.99, 1.02) | <u>3rd trimester</u> -0.07 (-1.00, 0.85) |
| Spain (5 areas) | BrTHM 10% increase | | 1.01 (0.98, 1.03) | 1.00 (0.99, 1.02) | 1.01 (0.98, 1.03) | 0.36 (-1.19, 1.92) |
| Iszatt et al. 2014 | <u>Water conc (µg/L)</u> <u>LBW</u> CHL | | | | Entire pregnancy LBW ² 1) -5 (-9, -1) | |
| England | 1) Low inc: ≤10 to dec <10 2) Med dec: 10–<30 3) High dec: 30–65 | | | | 2) -5 (-9, -1) 3) -9 (-12, -5) | |
| | BDCM 1) Low inc: ≤10 to dec <10 | | | | -3 (-8, 2) | |

² Reported as rate change, which is the percent change calculated as the exponential of the regression coefficient (e.g. rate ratio of after/before) minus 1 and multiplied by 100.

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|---------------------|--|--------------------------|-----|---------------------|--|--|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | 2) Med dec: 10–<30 3) High dec: 30–65 | | | | -8 (-12, -5) -7 (-11, -4) | |
| | DBCM 1) Low inc: ≤10 to dec | | | | -7 (-10, -3) | |
| | <10 2) Med dec: 10–<30 3) High dec: 30–65 | | | | -9 (-14, -5) -5 (-9, -1) | |
| | VLBW CHL | | | | <u>VLBW</u> -7 (-17, 3) 4 (-7, 16) -16 (-24, -8) | |
| | BDCM | | | | -12 (-22, 0) -10 (-18, -1) -3 (-12, 8) | |
| | DBCM | | | | -9 (-17, -1) -13 (-23, -1) -2 (-12, 9) | |
| Zhou et al. 2010 | Water conc (µg/L) | | | | | Odds Ratio Entire pregnancy |
| China | CHL 2 nd quartile 3 rd quartile 4 th quartile | 1 st quartile | | | | 0.96 (0.60, 1.53) 1.45 (0.88, 2.40) 1.64 (0.90, 3.00) |
| | | | | | | <u>1st trimester</u> 1.74 (1.10, 2.77) 0.90 (0.47, 1.74) 0.89 (0.44, 1.77) |
| | | | | | | <u>3rd trimester</u> 1.37 (0.99, 1.88) 1.67 (0.98, 2.85) 1.82 (1.10, 3.02) |
| | | | | | | <u>1st and 2nd trimester</u> 1.10 (0.71, 1.68) 1.62 (1.05, 2.50) 0.93 (0.54, 1.60) |
| | | T Chomical | 161 | | OEI | |

| Study/ | Exposure | Reference | | Odds Ratio (95% CI) | | |
|-----------------------------------|--|--|-----|---------------------|-----|--|
| Location | Level | Level | PTB | SGA | LBW | BW (g) (95% CI) |
| | BrTHM 2 nd quartile 3 rd quartile 4 th quartile | 1 st quartile | | | | Entire pregnancy 1.03 (0.65, 1.66) 1.58 (0.95, 2.63) 1.06 (0.57, 1.96) <u>3rd trimester</u> 1.40 (0.99, 1.98) 1.21 (0.81, 1.81) 1.51 (1.05, 2.17) |
| Wennborg et al. 2000 Sweden | Women working in a laboratory with CHL n = 66 | Women working in non- laboratory departments | | | | Entire pregnancy 27 (-136, 190) |

Stillbirth, Birth Defects, Fertility and Menstrual Cycle Function in Human Studies. Odds Ratio (95% CI) Study/ Exposure Reference Level Location Level SAB Stillbirth Birth Defects Fertility Grazuleviciene et Estimated internal dose 1st trimester exposure al. ‡‡ Heart anomalies (µg/d) 2013 CHL 0.026-0.288 0.001-0.026 1.05 (0.53, 2.08) 0.288-2.109 1.37 (0.72, 2.63) Lithuania Continuous (per 1 µg/d 1.97 (0.90, 4.35) increase) BDCM 0.013-0.051 0.000-0.013 1.74 (0.85, 3.54) 0.051-0.436 1.82 (0.89, 3.69) 1.70 (1.09, 2.66) Continuous (0.1 µg/d) DBCM 0.002-0.006 0.000-0.002 0.73 (0.36, 1.48) 0.006-0.093 1.35 (0.73, 2.51) 1.25 (1.01, 1.54) Continuous (0.01 μ g/d) Musculoskeletal

Table A4c. Associations between Chloroform (CHL) and Other Disinfection By-Products Exposure and Spontaneous Abortion (SAB),

abortion; TBM - bromoform.

Abbreviations: BDCM - bromodichloromethane; BrTHM - total brominated trihalomethanes; CHL - chloroform; CI - confidence interval; conc - concentration; d - day; DBCM - dibromochloromethane; d - day; dec - decrease; inc - increase; L - liter; LMP - last menstrual period; med - medium; NTD - neural tube defects; SAB - spontaneous

anomalies 0.61 (0.29, 1.32) 0.51 (0.22, 1.14) 0.43 (0.11, 1.71)

1.18 (0.51, 2.71) 1.29 (0.57, 2.92) 0.97 (0.46, 2.06)

0.95 (0.42, 2.18) 1.16 (0.52, 2.57) 1.20 (0.91, 1.58)

1.65 (0.48, 5.67) 2.87 (0.92, 8.99) 1.57 (0.74, 3.37)

0.92 (0.29, 2.87) 1.79 (0.65, 4.90) 1.17 (0.80, 1.72)

Urogenital anomalies 2.21 (0.67, 7.23) 2.50 (0.78, 8.06) 2.22 (0.69, 7.17)

| Study/ | | Exposure | Reference | | | io (95% CI) | |
|----------------------------------|----------------------|---|-----------|-----|------------|--|-----------|
| Location | | Level | Level | SAB | Stillbirth | Birth Defects | Fertility |
| Iszatt et al. 2011 England | Water c | <u>onc (μg/L)</u> 1.0–2.9 3.0–6.9 7–90 | 0.0–0.9 | | | Entire pregnancy <u>exposure</u> 1.17 (0.67, 2.03) 0.99 (0.57, 1.69) 0.84 (0.49, 1.46) | |
| | BrTHM | 11–18 19–24 25–70 | 0–10 | | | 1.02 (0.63, 1.65) 0.82 (0.51, 1.34) 1.06 (0.66, 1.71) | |
| | BDCM | 1.1–5.0 6–9 10–23 | 0.0–1.0 | | | 1.15 (0.71, 1.88) 0.83 (0.51, 1.35) 1.05 (0.65, 1.68) | |
| | DBCM | 4–7 8–10 11–34 | 0–3 | | | 1.00 (0.61, 1.64) 0.91 (0.56, 1.47) 0.92 (0.57, 1.49) | |
| | ТВМ | 2.5–3.9 4.0–6.9 7–27 | 0.0–2.4 | | | 0.94 (0.56, 1.58) 0.88 (0.54, 1.45) 1.06 (0.66, 1.69) | |
| | | ed internal dose | | | | | |
| | <u>(µg/d)</u> CHL | 1.38–4.78 4.79–13.98 13.99–101 | 0–1.37 | | | 0.93 (0.56, 1.53) 0.86 (0.52, 1.42) 0.74 (0.45, 1.21) | |
| | BrTHM | 1.674–3.204 3.205–6.24 6.25–48 | 0–1.673 | | | 1.54 (0.94, 2.55) 0.70 (0.42, 1.17) 1.04 (0.63, 1.72) | |
| | BDCM | 0.314–1.057 1.058–2.275 2.276–24 | 0–0.313 | | | 1.21 (0.79, 1.87) 1.13 (0.73, 1.74) 1.20 (0.78, 1.85) | |
| | DBCM | 0.454–0.96 0.97–2.13 2.14–19 | 0–0.453 | | | 0.93 (0.56, 1.54) 0.70 (0.42, 1.16) 0.90 (0.54, 1.47) | |
| | ТВМ | 0.481–0.894 0.895–1.901 1.902–13 | 0-0.480 | | | 1.06 (0.64,1.76) 0.87 (0.52, 1.46) 0.92 (0.55, 1.56) | |

| Study/ | Exposure | Reference | Odds Ratio (95% CI) | | | | |
|---|---|--------------------------|--|---|---------------|--|--|
| Location | Level | Level | SAB | Stillbirth | Birth Defects | Fertility | |
| Waller et al. 1998 | Water conc (µg/L)CHL< | <17 and <5 glasses/d | 1 st trimester exposure 0.9 (0.5, 1.6) | | | | |
| California (3 facilities) | BDCM ≥18 and 5 glasses/d | <18 and <5 glasses/d | 2.0 (1.2, 3.5) | | | | |
| | DBCM ≥31 and 5 glasses/d | <31 and <5 glasses/d | 1.3 (0.7, 2.4) | | | | |
| | TBM ≥16 and 5 glasses/d | <16 and <5 glasses/d | 1.0 (0.5, 2.0) | | | | |
| Windham et al. 2003 California | <u>Water conc (μg/L)</u> CHL 2 nd –3 rd quartile 4 th quartile (≥17) | 1 st quartile | | | | Difference in menstrual cycle length -0.43 (-0.99, 0.13) -0.30 (-1.0, 0.40) | |
| | BrTHM 2 nd –3 rd quartile 4 th quartile (≥45) | 1 st quartile | | | | Difference in folicular phase length -0.42 (-0.96, 0.12) -0.13 (-0.82, 0.56) Difference in menstrual cycle length -0.72 (-1.4, -0.04) -1.2 (-2.0, -0.40) Difference in folicular | |
| Toledano et al. | Water conc (µg/L) | | | 3 rd trimester exposure | | <u>phase length</u> -0.66 (-1.3, 0.02) -1.1 (-1.9, -0.29) | |
| 2005 United Kingdom (3 water regions) | CHL 20-40 >40 BDCM 6-12 >12 | <20 | | 1.11 (1.03, 1.19) 1.12 (1.02, 1.23) 0.96 (0.88, 1.04) 0.99 (0.91, 1.07) | | | |

| Study/ | Exposure | Reference | | Odds Ratio | Odds Ratio (95% CI) | | | |
|---|--|-------------|---|--|---------------------|-----------|--|--|
| Location | Level | Level | SAB | Stillbirth | Birth Defects | Fertility | | |
| Savitz et al. † 2005 US (3 study sites) | <u>Water conc (μg/L)</u> CHL >0.06–≤8.6 >8.6–≤30.27 | ≥0–≤0.06 | <u>9 weeks after last</u> <u>menstrual period (LMP) to</u> <u>20 weeks after LMP</u> 0.82 (0.51, 1.34) 1.66 (1.06, 2.61) | | | | | |
| | >30.27–≤48.71 >48.71 | | 0.89 (0.55, 1.45) 0.95 (0.58, 1.54) | | | | | |
| | BrTHM >3.13-≤12.3 >12.3-≤17.83 >17.83-≤32.26 >32.26 | ≥0-≤3.13 | 0.92 (0.57, 1.47) 0.96 (0.58, 1.59) 1.1 (0.68, 1.76) 1.54 (0.96, 2.46) | | | | | |
| | Estimated internal dose (µg/d) CHL >0-≤0.24 >0.24-≤0.78 >0.78-≤1.4 >1.4 | 0 | 0.88 (0.54,1.42) 1.15 (0.71,1.86) 1.09 (0.68,1.76) 1.14 (0.72,1.81) | | | | | |
| | BrTHM >0.08-≤0.2 >0.2-≤0.38 >0.38-≤0.82 >0.82 | ≥0–≤0.8 | 0.79 (0.47, 1.33) 0.94 (0.57, 1.56) 1.34 (0.84, 2.14) 1.48 (0.9, 2.44) | | | | | |
| Iszatt et al. 2014 | Water conc (µg/L) | | | Entire pregnancy exposure | | | | |
| England | Low inc \leq 10 to dec <10 Med dec 10–<30 High dec 30–65 | | | -5 (-9, 20) ¹ 2 (-13, 20) -4 (-16, 8) | | | | |
| Dodds et al. 2004 Nova Scotia and Eastern Ontario, Canada | <u>Water conc (μg/L)</u> CHL 1–49 50–79 >80 | 0 | | <u>1st + early 2nd trimester</u> <u>exposure</u> 1.8 (1.1, 3.0) 0.9 (0.5, 1.9) 2.2 (1.0, 4.8) | | | | |
| | Total exposure (µg/L) CHL Quintile 1 Quintile 2 Quintile 3 | No exposure | | 1.8 (0.9, 3.7) 1.3 (0.6, 3.0) 2.3 (1.1, 4.7) | | | | |

¹ Reported a rate change, which is the percent change calculated as the exponential of the regression coefficient (e.g. rate ratio of after/before) minus 1 and multiplied by 100.

| Study/ | Exposure | Reference | | | | |
|--|---|-----------|-----|---|---|-----------|
| Location | Level | Level | SAB | Stillbirth | Birth Defects | Fertility |
| | Quintile 4 Quintile 5 BDCM 1–4 | 0 | | 1.3 (0.6, 2.8) 2.0 (1.0, 4.0) 1.7 (1.0, 3.0) | | |
| | 5–9 ≥10 | | | 0.9 (0.5, 1.9) 2.2 (1.0, 4.9) | | |
| King et al. * * 2000 Nova Scotia | Water conc (μg/L) CHL 50–74 75–99 ≥100 Continuous (per 10 μg/L increase) | <50 | | Entire pregnancy exposure 1.20 (0.85, 1.68) 1.35 (0.87, 2.08) 1.56 (1.04, 2.34) 1.04 (1.00, 1.09) | | |
| | BDCM 5-9 10-19 ≥20 | <5 | | 1.07 (0.77, 3.19) 1.44 (0.90, 2.27) 1.98 (1.23, 3.49) | | |
| Dodds and King * * 2001 | Water conc (µg/L) | | | | NTD - 1 month before conception to 1 month after | |
| Nova Scotia | CHL 50–74 75–99 ≥100 | <50 | | | 0.7 (0.4, 1.2) 0.7 (0.3, 1.5) 1.2 (0.7, 2.3) | |
| | BDCM 5–9 10–19 ≥20 | <5 | | | 1.4 (0.8, 2.3) 0.6 (0.2, 1.5) 2.5 (1.2, 5.1) | |
| | | | | | <u>Cardiovascular anomalies</u> <u>1st 2 months of pregnancy</u> 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 0.7 (0.5, 1.0) 1.0 (0.8, 1.2) 0.7 (0.5, 1.0) 0.3 (0.2, 0.7) | |
| | | | | | <u>Cleft defects</u> <u>1st 2 months of pregnancy</u> 1.2 (0.7, 2.0) 0.9 (0.4, 2.0) 1.5 (0.8, 2.8) | |

| Table A4c. Associations between Chloroform (CHL) and Other Disinfection By-Products Exposure and Spontaneous Abortion (SAB | 5), |
|--|-----|
| Stillbirth, Birth Defects, Fertility and Menstrual Cycle Function in Human Studies (cont'd). | |

| Study/ | Exposure | Reference | Odds Ratio (95% CI) | | | | |
|-----------------------------------|---|---|---------------------|------------|---|--|--|
| Location | Level | Level | SAB | Stillbirth | Birth Defects | Fertility | |
| | | | | | 0.7 (0.4, 1.2) 1.1 (0.6, 2.1) 0.6 (0.2, 1.9) <u>Chromosomal</u> <u>abnormalities</u> <u>3 months before</u> <u>pregnancy</u> 1.3 (0.8, 2.2) 1.9 (1.1, 3.3) 1.4 (0.8, 2.8) 1.0 (0.6, 1.5) 0.7 (0.4, 1.6) 0.9 (0.4, 2.3) | | |
| Wennborg et al. 2000 Sweden | Women working in a laboratory with CHL n = 86 | Women with no laboratory work exposure n = 770 | 2.3 (0.9, 5.9) | | | | |
| Dahl et al. 1999 Norway | Placement of CHL based root canal fillings by female dental surgeons | High School teachers | | | | Fecundability Ratio (95% CI) 1.06 (0.95, 1.10) | |

| | | | β-coefficients (95% CI) | | | | |
|----------------------------------|---|--------------------|---|---|---|--|--|
| Study/ Location | Exposure Level | Reference Level | Sperm Concentration ¹ (million/mL) | Sperm Count ¹ (million) | Sperm Motility (%) & Motile Sperm Concentration (MSC) | Sperm Motion ² | |
| Zeng et al. † † 2014 China | Estimated internal dose by ingestion (µg/d) CHL 0.005–0.011 0.011–0.019 ≥0.019 P for trend Continuous ³ | < 0.005 | -0.19 (-0.43, 0.05) -0.25 (-0.51, 0.00) -0.28 (-0.53, -0.02) 0.03 -0.15 (-0.25, -0.04) | -0.15 (-0.40, 0.10) -0.34 (-0.61, -0.07) -0.22 (-0.49, 0.05) 0.05 -0.12 (-0.24, -0.01) | <u>Sperm motility (%)</u> -4.66 (-9.93, 0.60) -3.19 (-8.80, 2.41) -4.13 (-9.73, 1.47) 0.25 -1.75 (-4.17, 0.66) | Ingestion Straight-line velocity (VSL) CHL -0.25 (-1.85, 1.35) 0.38 (-1.32, 2.08) 1.77 (0.07, 3.47) 0.03 BrTHM | |
| | BrTHM 0.001–0.002 0.002–0.003 ≥0.003 P for trend Continuous ³ | <0.001 | -0.23 (-0.44, -0.01) -0.16 (-0.42, 0.11) -0.26 (-0.52, -0.01) 0.05 -0.13 (-0.24, -0.02) | -0.31 (-0.54, -0.09) -0.26 (-0.53, 0.02) -0.21 (-0.48, 0.06) 0.09 -0.11 (-0.23, 0.01) | -4.23 (-8.86, 0.41) 0.72 (-5.06, 6.50) -3.76 (-9.39, 1.88) 0.40 -1.59 (-4.02, 0.84) | -0.25 (-1.65, 1.15) 2.18 (0.44, 3.93) 1.76 (0.06, 3.46) 0.01 | |
| | Estimated internal dose by showering/bathing CHL 0.064–0.126 0.126–0.246 ≥0.246 | <0.064 | 0.10 (-0.16, 0.36) -0.07 (-0.30, 0.15) -0.04 (-0.29, 0.21) | 0.00 (-0.28, 0.28) 0.07 (-0.17, 0.32) 0.04 (-0.23, 0.31) | -0.86 (-6.58, 4.86) -2.57 (-7.57, 2.43) 0.26 (-5.30, 5.83) | <u>Curvilinear velocity</u> (VCL) <u>CHL</u> -1.08 (-3.64, 1.48) -0.28 (-3.00, 2.45) 2.74 (0.01, 5.46) | |
| | P for trend Continuous ³ BrTHM 0.036–0.069 0.069–0.120 ≥0.120 | <0.036 | 0.13 -0.05 (-0.15, 0.05) 0.09 (-0.15, 0.34) -0.14 (-0.40, 0.11) -0.10 (-0.34, 0.14) | 0.74 0.01 (-0.10, 0.11) 0.21 (-0.05, 0.46) 0.07 (-0.20, 0.34) 0.01 (-0.24, 0.26) | 0.41 -0.44 (-2.61, 1.74) 1.66 (-3.69, 7.01) -2.37 (-7.95, 3.22) -1.79 (-7.00, 3.43) | 0.03 <u>BrTHM</u> -0.94 (-3.19, 1.31) 3.21 (0.40, 6.02) 2.53 (-0.21, 5.27) | |
| | | | | | | | |

Abbreviations: BDCM - bromodichloromethane; BrTHM - total brominated trihalomethanes; CHL - chloroform; CI - confidence interval; d – day; conc - concentration; DBCM - dibromochloromethane; L – liter; LIN - linearity; MSC - motile sperm concentration; VCL - curvilinear velocity; VSL - straight-line velocity.

OEHHA August 2016

¹ Natural log transformation was applied.

² Units of measurement for sperm motion parameters were straight-line velocity = μ m/s, curvilinear velocity = μ m/s, linearity = %, path velocity = μ m/sec.

³ Continuous - quartiles of uptake (µg/day).

| | | | | β-coeffic | ients (95% CI) | |
|--------------------|-------------------|--------------------|---|---------------------------------------|---|---|
| Study/ Location | Exposure Level | Reference Level | Sperm Concentration ¹ (million/mL) | Sperm Count ¹ (million) | Sperm Motility (%) & Motile Sperm Concentration (MSC) | Sperm Motion ² |
| | | | (million/mL) | | Concentration (MSC) | Linearity (LIN) There were no significant findings for any of the DBPs <u>Showering/Bathing</u> <u>Straight-line velocity</u> (VSL) There were no significant findings <u>Curvilinear velocity</u> (VCL) <u>CHL</u> -0.13 (-2.92, 2.67) 1.90 (-0.54, 4.35) 2.32 (-0.40, 5.04) 0.04 <u>BrTHM</u> 0.65 (-1.95, 3.25) -0.01 (-2.73, 2.70) |
| | | | | | | 3.23 (0.70, 5.77) 0.02 Linearity (LIN) CHL -0.74 (-3.22, 1.73) -2.28 (-4.44, -0.11) -0.17 (-2.58, 2.24) 0.42 BrTHM -1.79 (-4.12, 0.54) -0.70 (-3.13, 1.74) -1.75 (-4.02, 0.52) 0.25 |

| | β-coefficients (95% CI) | | | | | | |
|---|--|------------------------|--|---------------------------------------|---|--------------|--|
| Study/Location | Exposure Level | Reference Level | Sperm Concentration⁴ (million/mL) | Sperm Count ¹ (million) | Sperm Motility (%) & Motile Sperm Concentration (MSC) | Sperm Motion | |
| Iszatt et al. 2013 England and Wales | <u>Water conc (µg/L)</u> CHL Upper quartile Mean: Cases = 25.9 Controls = 27.3 BrTHM Mean: Cases = 13.1 Controls= 13.2 | Lower quartile (12) | No significant relationship was observed for the effect of CHL on sperm conc (results presented graphically) No significant relationship was observed for the effect of BrTHM on sperm conc (results presented graphically) | Not assessed | Low MSC per 10 µg/L increase in CHL: Odds ratio = 1.00 (0.92, 1.09) No significant relationship was observed for the effect of CHL on change in percent motile sperm Low MSC per 10 µg/L increase in BrTHM: 0.93 (0.58, 1.49) No significant relationship was observed for the effect of BrTHM on change in percent motile sperm | Not assessed | |

⁴ Natural log transformation was applied.

| x | | | β-coefficients (95% CI) | | | | |
|----------------------------------|--|--------------------|---|--|---|--|--|
| Study/ Location | Exposure Level | Reference Level | Sperm Concentration ¹ (million/mL) | Sperm Count ¹ (million) | Sperm Motility (%) & Motile Sperm Concentration (MSC) | Sperm Motion ² | |
| Zeng et al. † † 2013 China | Blood conc (ng/L) CHL 35.87–66.35 >66.35 P for trend | < 35.87 | -0.04 (-0.12, 0.04) -0.08 (-0.16, 0.01) 0.07 | -0.02 (-0.11, 0.08) -0.07 (-0.16, 0.03) 0.19 | 2.19 (-2.27, 6.64) 1.35 (-3.13, 5.82) 0.55 | Curvilinear velocity <u>CHL</u> 1.03 (-1.28, 3.34) 2.15 (-0.17, 4.47) 0.07 | |
| | BDCM 1.02–2.35 >2.35 P for trend | < 1.02 | -0.07 (-0.15, 0.02) -0.02, (-0.10, 0.06) 0.61 | -0.13 (-0.22, -0.03) -0.04 (-0.13, 0.06) 0.44 | -0.16 (-4.62, 4.30) -0.70 (-5.16, 3.76) 0.76 | <u>Straight-line velocity</u> <u>CHL</u> 0.89 (-0.59, 2.38) 1.95 (0.46, 3.44) | |
| | DBCM 0.68–1.00 >1.00 P for trend | < 0.68 | -0.07 (-0.21, 0.07) -0.10 (-0.25, 0.06) 0.13 | -0.06 (-0.23, 0.10) -0.11 (-0.29, 0.06) 0.14 | -1.92 (-9.43, 5.58) -4.24 (-12.37, 3.89) 0.26 | 0.01 <u>Linearity</u> CHL | |
| | BrTHM 3.03–4.71 >4.71 P for trend | <3.03 | -0.03 (-0.11, 0.05) -0.01 (-0.09, 0.08) 0.83 | -0.04 (-0.14, 0.06) -0.02 (-0.12, 0.08) 0.67 | 1.95 (-2.48, 6.38) -0.07 (-4.59, 4.45) 0.97 | 1.13 (-0.86, 3.12) 1.19 (-0.80, 3.19) 0.24 | |
| | | | | | | <u>DBCM</u> -4.74 (-8.07, -1.42) 0.03 (-3.57, 3.63) 0.23 There were no other significant findings for any other DBPs | |

| | | | β-coefficients (95% CI) | | | | | | | |
|--------------------------------|---|--------------------|---|--|---|---|--|--|--|--|
| Study/ Location | Exposure Level | Reference Level | Sperm Concentration ¹ (million/mL) | Sperm Count ¹ (million) | Sperm Motility (%) & Motile Sperm Concentration (MSC) | Sperm Motion ² | | | | |
| Chang et al. 2001 Taiwan | Active air samples of CHL = 8.5 ppm Passive air samples of CHL = 4.6 ppm Estimated air CHL for 2 hours at the beginning of the workday = 450 ppm | | Not assessed | Authors state that sperm count was normal ~1 year prior to exposure. During the post- exposure period: sperm counts were as follows (by time since end of exposure): ≈ 3 months: 68.6 ≈ 4 months: 73.8 ≈ 6 months: 90.6 | Semen parameters at screening ~1 year prior to exposure had been normal, with 95% motile at a normal speed at 30 min after ejaculation During the post- exposure period: the percentage of motile sperm were as follows (by time since end of exposure): ≈ 3 months: 26% ≈ 4 months: 11% ≈ 6 months: 40% | Path velocity ≈ 3 months: 35 ≈ 4 months: 40 ≈ 6 months: 50 | | | | |

Appendix B. Tables of Exposure Measures, Uptake Factors Used In Estimating Internal Dose, and Windows of Exposure in Human Studies.

Α.

| Study | CHL Concentration (µg/L) | TTHM Concentration (µg/L) | BDCM Concentration (µg/L) | DBCM Concentration (µg/L) |
|--------------------------------------|---|---|--|---|
| Iszatt et al. 2014 | Mean ¹ (SD): Before EC (2000–2002) 38.6 (4.2) | Mean (SD): Before EC (2000–2002) 49.3 (5.2) | Mean (SD): Before EC (2000–2002) 7.5 (0.8) | Mean (SD): Before EC (2000–2002) 2.5 (0.1) |
| | <u>After EC (2005–2007)</u> 19.4 (1.0) | After EC (2005–2007) 28.9 (1.4) | After EC (2005–2007) 6.3 (0.4) | <u>After EC (2005–2007)</u> 2.4 (0.2) |
| Iszatt et al. 2013 | Mean (SD): Cases: 25.9 (19.0) Controls: 27.3 (19.1) Range of means across 9 sites: | Mean (SD): Cases: 39.1 (19.5) Controls: 40.6 (20.0) Range of means across 9 sites: | Not reported | Not reported |
| Rivera-Nuñez and Wright 2013 | 3.2–51.6 Mean in 3 rd trimester: 30.6 | 12.2–61.0 Mean in 3 rd trimester 38.1 | Mean in 3 rd trimester 6.1 | Not reported |
| 2010 | Median: 27.4 Range: 0–265.9 | <i>Median: 36.2</i> Range: 0–273.5 | Median: 5.3 Range: 0–49.5 | |
| Summerhayes et al. 2012 | Mean (SD) for entire pregnancy: 33.6 (16.0) | Mean (SD) for entire pregnancy: 57.7 (20.5) | Mean for entire pregnancy (SD): 15.8 (4.5) | Mean for entire pregnancy (SD): 6.3 (2.2) |
| | Median: 30.9 Range: 3.4–121.5 | Median: 55.5 Range: 23.2–154.9 | Median: 15.3 Range: 5.7–33.8 | Median: 5.9 Range: 0.7–25.6 |
| Patelarou et al.* 2011 | Mean (SD) for all sites across all years: 0.15 (0.15) | Mean (SD) for all sites across all years: 3.71 (5.75) Range across sites: 0.004–26.0 | Mean (SD) for all sites across all years: 0.19 (0.36) | Mean (SD) for all sites across all years: 0.55 (1.12) |
| Zhou et al. 2010 | Mean: not reported Range of monthly means: 5.99–51.19 | Not reported | Not reported | Not reported |
| Hoffman et al.† ² 2008 | Mean (SD): <u>Site 1</u> 46.7 (13.3) <u>Site 2</u> 13.7 (3.3) | Mean (SD): <u>Site 1</u> 66.4 (15.8) <u>Site 2</u> 63.6 (11.8) | Mean (SD): <u>Site 1</u> 15.1 (4.4) <u>Site 2</u> 21.1 (2.9) | Mean (SD): <u>Site 1</u> 4.4 (2.1) <u>Site 2</u> 23.1 (6.5) |

Abbreviations: BDCM - bromodichloromethane; d - day; CHL - chloroform; DBCM - dibromochloromethane; DBPs - disinfection by-products; EC - enhanced coagulation; IQR - interquartile range; L – liter; Max - maximum; Min - minimum; ND - not detectable; SD - standard deviation; THM - trihalomethane; TTHM - total trihalomethane.

² Hoffman et al. 2008 measured DBPs at two sites. Site 1 consisted predominantly of chlorinated DBPs. Site 2 consisted predominantly of brominated DBPs.

OEHHA August 2016

¹ Mean values for DBPs are presented in **bold**.

| Study | CHL Concentration (µg/L) | TTHM Concentration (µg/L) | BDCM Concentration (µg/L) | DBCM Concentration (µg/L) | |
|---------------------------|---|--|---|---|--|
| Lewis et al.‡ 2007 | Same as for Lewis et al. 2006 | Same as for Lewis et al. 2006 | Same as for Lewis et al. 2006 | Same as for Lewis et al. 2006 | |
| Lewis et al.‡ 2006 | CHL on average: 89% of TTHM (min/max of monthly means ~25/~77) | Interquartile range (IQR) of monthly means: 59 (min 28, max 87) | Range: Not Detectable (ND) to 9 75 th percentile = 6.1 | ND to <1 | |
| Hinckley et al. 2005 | Mean: not reported <u>Tertiles:</u> <10, 10–16, ≥16 | Range of yearly means from 1998–2002: 43.4–56.9 | Mean: not reported <u>Tertiles:</u> <13, 13–18, ≥18 | Mean: not reported <u>Tertiles:</u> <12, 12–16, ≥16 | |
| Porter et al. 2005 | Mean (95% CI): 34.1 (32.5, 35.7) | Mean (95% CI): 53.7 (49.3, 56.0) | Mean (95% CI): 13.4 (12.8, 14.1) | Mean (95% CI): 4.35 (4.01, 4.68) | |
| Toledano et al. 2005 | Mean: not reported Exposure categories: <20, 20–40, >40 | Mean (5 th , 95 th percentiles) by site: <u>Northumbrian</u> : 56.6 (27.0, 81.1) <u>United</u> : 52.0 (19.0, 81.1) <u>Severn Trent:</u> 35.8 (2.8, 72.5) | Mean: not reported Exposure categories: <6, 6–12, >12 | Levels were often below detection limit and too low for meaningful analysis | |
| Dodds et al. 2004 | Mean: not reported <u>Quartiles:</u> 0, 1–49, 50–79, >80 Max: 315 | Mean ³ : Cases: 57 Controls: 55 Max: 318 | Mean: not reported <u>Quartiles:</u> 0, 1–4, 5–9, ≥10 Max: 21 | Not reported | |
| Infante-Rivard 2004 | Tap Mean (SD): Cases: 11.84 (18.19) Controls: 11.58 (16.31) | Tap Mean (SD): Cases: 18.74 (19.76) Controls: 18.26 (18.89) | Tap Mean (SD): Cases: 4.34 (2.94) Controls: 4.24 (3.42) | Tap Mean (SD): Cases: 2.21 (1.95) Controls: 2.08 (2.30) | |
| Wright et al. 2004 | Mean (SD): 31.0 (23.6) 10 th & 90 th percentile: 4, 63 Max: 135 | Mean (SD): 38.2 (27.0) 10 th & 90 th percentile: 8, 74 Max: 163 | Mean (SD): 5.7 (5.1) 10 th & 90 th percentile: 1, 12 Max: 46 | Not reported | |
| Windham et al. 2003 | Mean: not reported Categories: 1 st quartile, 2 nd –3 rd quartile, 4 th quartile (≥17) | Mean: not reported Tertiles: 0–40, >40–60, >60 | Mean: not reported Categories: 1 st quartile, 2 nd –3 rd quartile, 4 th quartile (≥16) | Mean: not reported Categories: 1 st quartile, 2 nd –3 rd quartile, 4 th quartile (≥20) | |
| Dodds and King* * 2001 | <u>Quartiles:</u> <50, 50–74, 75–99, ≥100 | Not reported | <u>Quartiles:</u> <5, 5–9,10–19, ≥20 | Occurred at very low levels, and thus, not analyzed | |

³ In residential water among subjects with chlorinated water supply.

| Study | CHL Concentration | TTHM Concentration | BDCM Concentration | DBCM Concentration | |
|-----------------------|--|--|--|--|--|
| | (μg/L) | (µg/L) | (µg/L) | (µg/L) | |
| King et al.* * | Mean: | Mean: | Mean: | Not reported | |
| 2000 | 64.1 | 71.3 | 6.9 | | |
| Waller et al. 1998 | "high" exposure defined as ≥17 CHL [upper quartile] +≥5 glasses/d | "high" exposure defined as ≥75 TTHM +≥5 glasses/d | "high" exposure defined as ≥18 BDCM [upper quartile] +≥5 glasses/d | "high" exposure defined as ≥31 DBCM [upper quartile] +≥5 glasses/d | |
| Kramer et al. 1992 | Mean (SD): 12.5 (38.7) Median:1 Range: 0–350 | Not reported | Mean: not reported <u>Tertiles:</u> Non-detectable, 1–9, ≥10 | Mean: not reported <u>Tertiles:</u> Non-detectable, 1–3, ≥4 | |

В.

| | C | CHL | | ΉМ | BDCM | | DBCM | |
|------------------------|---|---|---|--|--------------------------------|--------------------------------------|--------------------------------|--------------------------------------|
| Study | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) |
| Botton et al.* 2015 | Median by site ⁴ : Gipuzkoa ~12 Sabadell ~20 Valencia ~0 Crete Not reported | Median by site ⁴ : Gipuzkoa ~0.1 Sabadell ~0.2 Valencia ~0 Crete Not reported | Median by site ⁴ : Gipuzkoa ~20 Sabadell ~120 Valencia ~5 Crete ~0 | Median (IQR) by site: Gipuzkoa ~0.22 (0.14–0.32) Sabadell ~1.6 (1.1–2.1) Valencia ~0.1 (0.05–1.1) Crete ~0.021 (0.0077–0.071) | Not reported | Not reported | Not reported | Not reported |
| Smith et al. 2015 | Mean (SD): 37.8 (3.8) | Mean (SD): 1.61 (1.46) | Mean (SD): 45.6 (4.0) | Mean (SD): 1.86 (1.66) | Mean (SD): 6.6 (0.6) | Mean (SD): 0.20 (0.16) | Mean (SD): 0.9 (0.2) | Mean (SD): 0.03 (0.03) |
| Zeng et al.† † 2014 | Mean: 13.71 Range: 2.68–29.90 | Quartiles: <0.005 0.005–0.011 0.011–0.019 ≥0.019 | Mean: 21.39 Range: 6.38–40.36 | Quartiles: <0.006 0.006–0.012 0.012–0.021 ≥0.021 | Not reported | Not reported | Not reported | Not reported |

⁴ Values were approximated from a figure in the publication.

| | C | CHL | | TTHM | | BDCM | | DBCM | |
|-------------------------------------|--|--|---|--|--|--|--|--|--|
| Study | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | |
| Grazuleviciene et al.‡ ‡ 2013 | Mean (SD): in 3 sites with low THM level - | Median: 0.1424 Range: 0.001–2.109 | Mean (SD): | Range: 0.003–2.448 | Mean (SD): | Range: 0.000–0.436 | Mean (SD): | Range: 0–0.093 | |
| | 0.9 (1.0) in 1 site with high THM level - 17.7 (9.0) | Tertiles: 0.001–0.026 0.026–0.288 0.288–2.109 | 1.3 (1.2) 21.9 (10.9) | Tertiles: 0.031–0.040 0.040–0.356 0.356–2.448 | 0.3 (0.5) 3.6 (2.1) | Tertiles: 0–0.013 0.013–0.051 0.051–0.436 | 0.1 (0.2) 0.5 (0.6) | Tertiles: 0–0.002 0.002–0.006 0.006–0.093 | |
| Costet et al. 2012 | Mean (SD) for all sites: 9.3 (7.0) | Quartiles: <0.068 0.068–<0.133 0.133–<0.237 ≥0.237 | Mean (SD) for all sites: 41.6 (16.1) | Quartiles: <0.351 0.351–<0.578 0.578–<0.940 ≥0.940 | Mean (SD) for all sites: 10.4 (5.4) | Quartiles: <0.083 0.083–<0.141 0.141–<0.226 ≥0.226 | Mean (SD) for all sites: 13.8 (5.5) | Quartiles: <0.118 0.118–<0.188 0.188–<0.267 ≥0.267 | |
| Danileviciute et al.‡ ‡ 2012 | Mean (SD) for all sites: 7.8 (10.2) In 3 sites with low THM level - | Median: 0.1424 Range: 0.0013–2.1328 | Mean (SD) for all sites: 9.8 (12.4) | Median: 0.1733 Range: 0.0025–2.4040 | Mean (SD) for all sites: 1.7 (2.2) | Median: 0.0280 Range: 0.0001–0.34 | Mean (SD) for all sites: 0.3 (0.5) | Median: 0.0026 Range: 0–0.064 | |
| | 0.9 (1.0) In 1 site with high THM level - 17.7 (9.0) | | 1.3 (1.2) 21.9 (10.9) | | 0.3 (0.5) 3.6 (2.1) | | 0.1 (0.2) 0.5 (0.6) | | |
| | Range: 0.9–17.7 | | Range: 1.3–21.9 | | Range: 0.3–3.6 | | Range: 0.1–0.5 | | |

| | CHL | | TTHM | | BDCM | | DBCM | |
|-------------------------------------|---|--|---|--|---|--------------------------------------|--|--|
| Study | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) |
| Levallois et al. 2012 | Mean (SD): Cases: 43.3 (40.7) Controls: 41.1 (39.2) | | Mean (SD): Cases: 49.3 (39.8) Controls: 47.2 (38.3) | | Mean (SD): Cases: 4.7 (3.1) Controls: 4.7 (2.9) | Not reported | Mean (SD): Cases: 1.3 (1.4) Controls: 1.3 (1.4) | Not reported |
| | | Quartiles: <42.24 42.24–80.21 80.22–169.81 >169.81 | | Quartiles: <58.02 58.02–102.44 102.45–195.73 >195.73 | | | | |
| Grazuleviciene et al.‡ ‡ 2011 | Mean (SD) for all sites: 7.8 (10.2) | Range: 0.0013–2.1328 | Mean (SD) for all sites: 9.8 (12.4) | Range: 0.0025–2.4040 | Mean (SD) for all sites: 1.7 (2.2) | Range: 0.0001–0.34 | Mean (SD) for all sites: 0.3 (0.5) | Range: 0–0.064 |
| | In 3 sites with low THM level - 0.9 (1.0) | | 1.3 (1.2) | | 0.3 (0.5) | | 0.1 (0.2) | |
| | In 1 site with high THM level - 17.7 (9.0) | | 21.9 (10.9) | | 3.6 (2.1) | | 0.5 (0.6) | |
| | Range: 0.9–17.7 | | Range: 1.3–21.9 | | Range: 0.3–3.6 | | Range: 0.1–0.5 | |
| Iszatt et al. 2011 | Median: 2.9 | | Median: 23 | | Median: 5.0 | | Median:7 | |
| | Range: 0.0–90 | Range: 0–65 | Range: 0–105 | Range: 0–190 | Range: 0.0–23 | Range: 0–50 | Range: 0–34 | Range: 0–85 |
| | Quartiles: 0.0–0.9 1.0–2.9 3.0–6.9 | Quartiles: 0.0 >0.0–1.4 1.5–4.2 | Quartiles: 0–11 12–23 24–36 | Quartiles: 0.0 >0.0–8.4 8.5–21.0 | Quartiles: 0.0–1.0 1.1–5.0 6–9 | Quartiles: 0.0 >0.0–1.0 2–5 | Quartiles: 0–3 4–7 8–10 | Quartiles: 0.0 >0.0–2.4 2.5–7.1 |
| | 7–90 | 4.3–65.0 | 37–105 | 22–190 | 10–23 | 6–50 | 11–34 | 7.2–85.0 |

| | CHL | | TT | ТТНМ | | СМ | DB | СМ |
|----------------------------|--|--|--|--------------------------------------|---|--------------------------------------|---|--------------------------------------|
| Study | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) | Concentration (µg/L) | Estimated Internal Dose (µg/d) |
| Villanueva et al.* 2011 | Mean: not reported | Mean: not reported Median total | Mean: not reported | Not reported | Mean: not reported | Not reported | Mean: not reported | Not reported |
| | Median by sites⁵: | residential uptake by sites⁵: | Median by sites⁵: | | Median by sites⁵: | | Median by sites⁵: | |
| | Asturias ~26 Gipuzkoa ~9 Sabadell ~20.4 Valencia 0.65 Granada ~4.7 | Asturias ~0.3 Gipuzkoa ~0.1 Sabadell ~0.2 Valencia ~0 Granada ~0 | Asturias ~ 40 Gipuzkoa ~20 Sabadell ~120 Valencia ~5 Granada ~10 | | Asturias ~8 Gipuzkoa ~6 Sabadell ~12 Valencia ~1.1 Granada ~2.5 | | Asturias ~4 Gipuzkoa ~4.4 Sabadell ~24 Valencia ~2 Granada ~2 | |
| Savitz et al.† 2005 | Mean: 23.93 Range of means between sites: 0.24–47.90 | Mean: 25.77 | Mean: 42.62 Range of means between sites: 3.29–67.11 | Mean: 44.69 | Mean: 10.72 Range of means between sites: 1.04–20.31 | Mean: 11.0 | Not reported | Not reported |

⁵ Values approximated from figures.

| | | CHL Upta | ke Factors | | CHL R | eduction |
|--------------------------------------|---|---|---|---|--|--|
| Study | Ingestion | Showering | Bathing | Swimming | Filter Use/ Bottled Water | Thermal Treatment |
| Botton et al.* 2015 | 0.00490196 | 0.001563091 | 0.001320755 | Considered ¹ | 90%/ 100% | Not considered |
| Smith et al. 2015 | 0.00490196 | 0.001563091 | 0.001320755 | 0.002541407 | 90%/ Considered but not included | 92% |
| Zeng et al. †† 2014 | 0.00490196 | 0.001536261 | 0.001320755 | Considered but not included ² | Not considered/ 100% | Boiled tap water 30% coefficient factor |
| Grazuleviciene et al. ‡ ‡ 2013 | 0.00490196 | 0.001536 | 0.001321 | Considered but not included ³ | Considered but not included ⁴ / Not clear | <u>Heating</u> 85–100%⁵ |
| Costet et al. 2012 | 0.00490196 | 0.001563091 | 0.001320755 | 0.002541407 | Not considered/ Considered but not included | Hot beverages 0.3 correction factor |
| Danilevicute et al. ‡ ‡ 2012 | 0.00490196 | 0.001536261 | 0.001320755 | Considered but not included ³ | Not considered/ 100% | <u>Heated water</u> 85–100% ⁵ |
| Levallois et al. 2012 | Multiplied volume ingested from various sources (i.e., hot and cold beverages) x estimated conc in | Based on toxicokinetic model by Haddad et al. (2006) | Based on toxicokinetic model by Haddad et al. (2006) | Considered but not included | 86.8%/ 100% | Boiling 81.6% <u>Hot tap water</u> ⁶ |
| | the ingested water | | | | | <u>Refrigeration</u> 13% |

Table B2. Uptake Factors and Percent Reductions Used in Calculations of Estimated Internal Dose in Human Studies of Chloroform (CHL) Exposure.

Abbreviations: CHL - chloroform; conc - concentration; exp - exposure; L - liter; min - minute; THM - trihalomethane

¹ Personal attendance at indoor and outdoor pools was multiplied by the area THM average, then added together.

² Number of study participants who swam in chlorinated pools was very low (4.0%), therefore swimming was not included in the estimated internal dose estimates.

³ The percentage of participants who attended swimming pools was low (~7%), and it appears that this factor was not included in estimating internal dose.

⁴ The study reported there was no difference in the proportion of women who did and did not use water filters.

⁵ The study cited two references for the reduction in CHL due to heating water. These references are Savitz et al. 2006, which reported a 100% reduction, and Whitaker et al. 2003, which reported an 85% reduction. It is not clear which was used for the CHL estimates.

⁶ Used 160% increase in CHL for hot tap water.

| | | CHL Upta | ake Factors | | CHL R | Reduction |
|--------------------------------------|---|---|--|--|---|---|
| Study | Ingestion | Showering | Bathing | Swimming | Filter Use/ | Thermal |
| Olddy | | | | | Bottled Water | Treatment |
| Grazuleviciene et al. ‡ ‡ 2011 | 0.00490196 | 0.001536261 | 0.001320755 | Considered but not included ³ | Considered but not included ⁴ / 100% | Heated water 85–100% ⁵ |
| lszatt et al. 2011 | 0.00490196 | 0.001506877 | 0.000994222 | 0.0025414077 | Not considered/ Assumed | Not considered |
| | | | | <u>Dishwashing</u> 0.000745 | negligible THM exp | |
| Villanueva et al.* 2011 | 0.00490196 | 0.00153626 | 0.00132075 | 0.00254141 | Home filter 90%/ Considered ⁸ | Not considered |
| Savitz et al. † 2005 | 0.00490 | 0.001536261 | 0.001320755 | Not considered | Faucet filter 100% Pitcher filter | <u>Kettle boiling</u> 100% |
| | | | | | 41% <u>Bottled Water</u> 100% | <u>Microwave boiling</u> 18% |
| Dodds et al. 2004 | Defined as total liters of water consumed | Assumed 5 min shower was equivalent to 1 L of ingested water | Assumed 15 min bath was equivalent to 1 L of ingested water | Not considered | <u>Carbon filter</u> 50%/ 100% | <u>Boiled hot water</u> <u>drinks</u> 70% |

Table B2. Uptake Factors and Percent Reductions Used in Calculations of Estimated Internal Dose in Human Studies of Chloroform (CHL) Exposure (cont'd).

⁷ Swimming was included as a confounder, but was not used in estimating internal dose.

⁸ Because logarithm of zero values in tap water ingestion from bottled water consumers led to invalid transformed variables, these were imputed arbitrarily using half the area-specific lowest value for ingestion.

Table B3. Windows of Exposure Assessed in Human Studies of Chloroform Exposure and Reproductive Outcomes.

| Study | | Exposure Windows (trimester) ¹ | | | | | | | | | | |
|------------------------------------|--|--|--|---------------------|--|-----|---------------------|--|---|--|--|--|
| | PTB | SGA | LBW | VLBW | BW | ŚAB | SB | BD | Other | | | |
| Botton et al.* 2015 | | | | | | | | | Postnatal weight gain at 6 months | | | |
| | | | | | | | | | Entire pregnancy | | | |
| Smith et al. 2015 | | | | | 1 st , 2 nd , 3rd Entire pregnancy | | | | | | | |
| lszatt et al. 2014 | | | Entire pregnancy | Entire pregnancy | | | Entire pregnancy | | | | | |
| Grazuleviciene et al.‡‡ 2013 | | | | | | | | 1 st 1 st month 2 nd month 3 rd month | | | | |
| Rivera-Nuñez and Wright 2013 | 1 st , 2nd | 1 st , 2 nd , 3rd | | | 1 st , 2 nd , 3rd | | | | | | | |
| Costet et al. 2012 | 1st, 2 nd , 3rd | 1 st , 2 nd , 3rd | | | | | | | | | | |
| Danileviciute et al.‡ ‡ 2012 | | 1 st , 2 nd , 3 rd Entire pregnancy | 1 st , 2 nd , 3 rd Entire pregnancy | | | | | | | | | |
| Levallois et al. 2012 | | 3 rd | | | | | | | | | | |
| Summerhayes et al. | | 1 st , 2 nd , 3rd | | | 1 st , 2 nd , 3 rd | | | | | | | |
| 2012 | | Entire Pregnancy | | | Entire pregnancy | | | | | | | |
| Grazuleviciene et al.‡ ‡ | | 1 st , 2 nd , 3 rd | 1 st , 2 nd , 3rd | | 1 st , 2 nd , 3 rd | | | | | | | |
| 2011 | | Entire pregnancy | Entire pregnancy | | Entire pregnancy | | | | | | | |

Abbreviations: BD - birth defects; BW - birth weight; LBW - low birth weight; LMP - last menstrual period; NTD - neural tube defects; PTB - preterm birth; SAB - spontaneous abortion; SB - still birth; SGA - small for gestational age; VLBW - very low birth weight.

¹ For studies that examined more than one window of exposure, the window(s) for which risk estimates are presented in other tables and figures are indicated in **bold**.

Table B3. Windows of Exposure Assessed in Human Studies of Chloroform Exposure and Reproductive Outcomes (con't).

| Study | Exposure Windows (trimester) ¹ | | | | | | | | | | | |
|----------------------------|---|---|---|------|--|-----|----|-----------------|-------|--|--|--|
| - | PTB | SGA | LBW | VLBW | BW | ŚAB | SB | BD | Other | | | |
| lszatt et al. 2011 | | | | | | | | 1 st | | | | |
| Villanueva et al.* 2011 | 1 st , 2 nd , 3rd | 1 st , 2 nd , 3rd | 1 st , 2 nd , 3rd | | 1 st , 2 nd , 3rd | | | | | | | |
| | Entire pregnancy | Entire pregnancy | Entire pregnancy | | Entire pregnancy | | | | | | | |
| Zhou et al. 2010 | | | | | 1 st , 2 nd , 3 rd , 1 st + 2 nd | | | | | | | |
| | | | | | Entire pregnancy | | | | | | | |
| Hoffman et al.† 2008 | | 3 rd | | | 3 rd | | | | | | | |
| Lewis et al.‡ 2007 | 1 st , 2 nd Entire | | | | | | | | | | | |
| | pregnancy | | | | | | | | | | | |
| | 4 weeks before birth | | | | | | | | | | | |
| | 4-week risk sets | | | | | | | | | | | |
| Lewis et al.‡ 2006 | | | 1 st , 2nd , 3 rd | | | | | | | | | |
| | | | Entire pregnancy | | | | | | | | | |
| Hinckley et al. 2005 | <37 weeks gestation | 3 rd | 3 rd | | | | | | | | | |
| Porter et al. 2005 | | 1 st , 2 nd , 3rd | | | | | | | | | | |
| | | Entire pregnancy | | | | | | | | | | |

Table B3. Windows of Exposure Assessed in Human Studies of Chloroform Exposure and Reproductive Outcomes (con't).

| Study | Exposure Windows (trimester) ¹ | | | | | | | | | | |
|--------------------------|---|---|-----------------|-----------------|---|---|--|--|--|--|--|
| - | PTB | SGA | LBW | VLBW | BW | ŚAB | SB | BD | Other | | |
| Savitz et al.† 2005 | 1 st , 2 nd , 3rd | 1 st , 2 nd , 3rd | | | 1 st , 2 nd , 3rd | 9 weeks after last menstrual period (LMP) to 20 weeks after LMP | | | | | |
| | | | | | | 4 weeks prior to LMP to 3 weeks after LMP 4 weeks after LMP to 8 weeks after LMP | | | | | |
| Toledano et al. 2005 | | | 3 rd | 3 rd | | | 3 rd | | | | |
| Dodds et al. 2004 | | | | | | | 1 st + early 2 nd trimester | | | | |
| Infante-Rivard 2004 | | Entire pregnancy | | | | | | | | | |
| Wright et al. 2004 | 3 rd | 3 rd | | | 3 rd | | | | | | |
| Windham et al. 2003 | | | | | | | | | Menstrual cycle function 90 day exposure windows | | |
| Dodds and King** 2001 | | | | | | | | NTD 1 month before conception to 1 month after <u>Cardiovascular</u> anomalies | | | |

Table B3. Windows of Exposure Assessed in Human Studies of Chloroform Exposure and Reproductive Outcomes (con't).

| Study | Exposure Windows (trimester) ¹ | | | | | | | | | | |
|---------------------|---|-----------|-----------|------|-----------|-----------------|-----------|-----------------------------|---------------------|--|--|
| - | PTB | SGA | LBW | VLBW | BW | SAB | SB | BD | Other | | |
| | | | | | | | | 1 st 2 months of | | | |
| | | | | | | | | pregnancy | | | |
| | | | | | | | | Cleft defects | | | |
| | | | | | | | | 1 st 2 months of | | | |
| | | | | | | | | pregnancy | | | |
| | | | | | | | | <u>Chromosomal</u> | | | |
| | | | | | | | | abnormalities | | | |
| | | | | | | | | 3 months | | | |
| | | | | | | | | before | | | |
| | | | | | | | | pregnancy | | | |
| King et al.** 2000 | | | | | | | Entire | | | | |
| | | | | | | | pregnancy | | | | |
| Wennborg et al. | | | | | Entire | Entire | | | | | |
| 2000 | | | | | pregnancy | pregnancy | | | | | |
| Dahl et al. 1999 | | | | | | | | | Fecundability ratio | | |
| | | | | | | | | | 6 months prior to | | |
| | | | | | | | | | pregnancy | | |
| Waller et al. 1998 | | | | | | 1 st | | | | | |
| Kramer et al. | Entire | Entire | Entire | | | | | | | | |
| 1992 | pregnancy | pregnancy | pregnancy | | | | | | | | |

Appendix C. OEHHA (2005) Re-analysis of Data from Two Chloroform Epidemiological Studies: Wennborg et al. (2000) and Infante-Rivard (2004).

On November 4, 2004 the Developmental and Reproductive Toxicant (DART) Identification Committee, the State's qualified experts for reproductive toxicity for Proposition 65, met to consider whether chloroform had been clearly shown through scientifically valid testing according to generally accepted principles to cause reproductive toxicity. The committee voted not to list this chemical as known to cause reproductive toxicity under Proposition 65 for the either developmental, male reproductive or female reproductive toxicity endpoints. However, the Committee did request that the Office of Environmental Health Hazard Assessment (OEHHA) try to obtain additional information regarding re-analyses of findings from two epidemiologic studies, one by Wennborg et al. (2000), and the other by Infante-Rivard (2004). OEHHA contacted the primary authors of these articles and, after discussion of the issues raised by the DART Committee, the authors have provided OEHHA with the results of the requested re-analyses. Below is a description of the specific requests made of the authors and the results from their re-analyses.

Re-analysis from Dr. Wennborg:

As summarized in the draft Hazard Identification Document on Chloroform (OEHHA, 2004: pages 13-14), Dr. Wennborg and coauthors conducted an occupational study of women, which examined exposure to chloroform in association with pregnancy outcomes. The study reported a weak association between women working with chloroform during the time before conception and the occurrence of spontaneous abortion (SAB) (odds ratio = 2.3; 95% confidence interval 0.9 – 5.9). The regression analysis resulting in this finding included adjustment for mother's age and previous SAB. However, as discussed at the DART Committee meeting, it was not clear from the study whether the previous SABs occurred before or during the time when the women were exposed to chloroform. If the women were exposed to chloroform and/or other chemicals at the time the previous SAB occurred, including this variable in the regression analysis could have resulted in over control, which would have biased the results. Therefore, following the direction of the DART Committee, OEHHA requested that Dr. Wennborg either: 1) verify that the SABs occurred before exposure to the chloroform, or 2) rerun the statistical analyses of the data omitting the previous SABs.

Dr. Wennborg responded that previous SABs included SABs that were "previous" in relation to the pregnancy in question. Thus these did include SABs that occurred while the women were occupationally exposed to chemicals. Therefore, she reran the analysis excluding the previous SABs, and reported the following results. The odds ratio was 2.1, with 95% confidence interval 1.1 - 4.0. Thus the odds ratio was about the same (2.1 vs. 2.3), but the 95% confidence interval was smaller (1.1 - 4.0 vs. 0.9 - 5.9), and now statistically significant. Dr. Wennborg noted that the analysis in 2000 was performed with STATA 6.0, and the new analysis with STATA 8.0. STATA is a statistical data analysis program similar to programs such as SAS.

Re-analysis from Dr. Infante-Rivard:

As summarized in the draft Hazard Identification Document on Chloroform (OEHHA, 2004: pages 20-22), Dr. Infante-Rivard conducted a case-control study that examined the association between exposure to chloroform and fetal growth. The study also tested for gene-environment interactions to determine whether effects of chloroform exposure were modified by newborn and genetic variants. In analyzing the effect of exposure to trihalomethanes (THMs) and chloroform, Dr. Infante-Rivard used the 90th percentile as a cutoff, thus considering the top 10th percentile of individuals as exposed. The author concluded that the findings suggest exposure to THMs at the highest levels can affect fetal growth but only in genetically susceptible newborns. The results are not statistically significant for chloroform. However, as discussed at the DART committee meeting, the size of the sample of women in the exposed group was small when the 90th percentile cutoff was used. This may have limited the power of the study to detect an effect, if one were present. Therefore, following the direction of the DART committee, OEHHA requested that Dr. Infante-Rivard reanalyze the data using a less conservative cutoff. Table 1 below shows the results of the analysis conducted using the 90th percentile cutoff, as reported in the study, as well as the reanalysis using the 75th percentile cutoff. These results using the 75th percentile were not statistically significant for either THMs or chloroform.

Dr. Infante-Rivard pointed out that she disagreed with choosing a 75th percentile cutoff since she believed one should choose the cutoff based on where effects are likely. The levels of chloroform exposure in this study were considerably lower, even at the 90th percentile, than those in studies that had reported a statistically significant effect.

Table 1. Adjusted ORs (95% CIs) for exposure to THMs (chloroform and total THMs) in drinking water measured as average level at the tap, according to newborn and maternal polymorphisms in the CYP2E1 and MTHFR genes.

| | | 5% CI) ercentile cutoff | OR (95% CI) Using a 75 th percentile cutoff | | |
|------------------------|-------------------|----------------------------|---|------------------|--|
| Gene | Chloroform | Total THMs | Chloroform | Total THMs | |
| Newborns | | | | | |
| CYP2E1*5 (G1259C) | | | | | |
| Wild type | 0.99 (0.57-1.74) | 0.82 (0.47-1.45) | 0.92 (0.67-1.28) | 0.74 (0.68-1.31) | |
| 1 or 2 variant alleles | 5.62 (0.82-38.39) | 13.20 (1.19-146.72)* | 1.86 (0.63-5.08) | 1.32 (0.68-5.98) | |
| MTHFR C677T | | | | | |
| Wild type | 1.78 (0.82-3.87) | 1.63 (0.72-3.71) | | | |
| 1 or 2 variant alleles | 0.83 (0.38-1.54) | 0.76 (0.38-1.54) | | | |
| Mothers | | | | | |
| CYP2E1*5 (G1259C) | | | | | |
| Wild type | 0.88 (0.50-1.54) | 0.83 (0.48-1.44) | 0.94 (0.68-1.38) | 0.92 (0.66-1.28) | |
| 1 or 2 variant alleles | 4.40 (0.73-26.42) | 6.54 (0.59-71.45) | 1.38 (0.54-3.52) | 1.38 (0.54-3.53) | |
| MTHFR C677T | | | | | |
| Wild type | 1.00 (0.46-2.18) | 0.98 (0.46-2.10) | | | |
| 1 or 2 variant alleles | 1.12 (0.56-2.32) | 0.94 (0.47-1.89) | | | |

* Chi-square (1degree of freedom) for effect modification = 4.87; p = 0.027. Adapted from Infante-Rivard (2004).

Appendix D. Parameters for Literature Searches on the Reproductive Toxicity of Chloroform.

General searches of the scientific literature on the reproductive and developmental toxicity of chloroform were conducted under contract by the University of California at Berkeley (Charleen Kubota, M.L.I.S.). The goal was to identify peer-reviewed open source and proprietary journal articles, print and digital books, reports and gray literature that potentially reported relevant toxicological and epidemiological information on the reproductive and developmental toxicity of the chemical, chloroform. The search sought to identify all literature relevant to the assessment of evidence on male reproductive, female reproductive and developmental neurotoxicity.

Search Process

ChemSpider was searched first to gather chemical names, synonyms, CAS registry numbers, MeSH and Chemical Abstracts Service headings for chlorpyrifos before searching bibliographic databases. The MeSH database was used to identify relevant subject headings for reproductive and developmental toxicology endpoints. MeSH (Medical Subject Headings) terms at the top of hierarchical lists of subject headings are automatically "exploded" in a search to retrieve citations with more specific MeSH terms. For example, the heading "Congenital Abnormalities" includes numerous specific conditions such as spina bifida and congenital heart defects. The broad subject heading "Pregnancy Complications" encompasses multiple conditions or pathological processes associated with pregnancy. Spontaneous abortion and many fetal diseases are listed under this term.

Relevant MeSH subject terms were entered into the PubMed Search Builder to execute a PubMed search.

("*chloroform*" [Mesh] OR 67-66-3 [RN]) AND ("Congenital Abnormalities"[Mesh] OR "Pregnancy Complications"[Mesh] OR "Reproductive Physiological Phenomena"[Mesh] OR "Embryonic and Fetal Development"[MeSH] OR "Receptors, Androgen"[Mesh] OR "Receptors, Estrogen"[Mesh] OR "Endocrine System"[MeSH] OR "Thyroxine"[MeSH])

Additional databases listed below were then searched. Research strategies were tailored according to search features unique to each database. BIOSIS Previews, for example, was searched by entering chloroform and refining the search by applying these facets: toxicology, neural coordination, nervous system, development, behavior, reproduction, population studies, reproductive system, pediatrics, obstetrics and psychiatry. Hand searching of reference lists from relevant articles, book chapters and other sources was done to find articles that were not retrieved through database searches.

Databases

The researcher utilized some or all of the following databases/ search platforms/database vendors:

BIOSIS Previews® (Thomson-Reuters™, Inc.) 1926 - present

CABI: CAB Abstracts® (Thomson-Reuters™, Inc.) 1910 - present

<u>ChemSpider</u> (Royal Society of Chemistry)

MeSH (Medical Subject Headings) (National Library of Medicine)

Developmental and Reproductive Toxicology Database (DART/ETIC) (National Library of Medicine) early 1900s – present

MeSH (Medical Subject Headings) (National Library of Medicine)

EMBASE® (Elsevier) 2012 - present

Environmental Sciences and Pollution Management (Proquest) 1967 - present

PubMed (National Library of Medicine) 1950 - present

National Technical Research Library (NTRL v3.0) (National Technical Information Service) 1900s - present

ReproRisk® System: REPROTEXT® Reproductive Hazard Reference, REPROTOX® Reproductive Hazard Information, Shepard's Catalog of Teratogenic Agents, TERIS Teratogen Information System (RightAnswer® Knowledge Solutions OnSite™ Applications) date coverage varies

Scifinder®: CAS (Chemical Abstracts Service) 1907 - present

TOXLINE (National Library of Medicine TOXNET) 1840s - present

Web of Science[™] (Thomson-Reuters[™], Inc.) 1900 – present

Attachment 1: OEHHA (2004) Evidence of Developmental and Reproductive Toxicity of Chloroform.